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Amyotrophic lateral sclerosis (ALS) is a terminal neurodegenerative disease that affects 
motor neurons causing progressive muscle weakness and respiratory failure. In 2011, the 
presence of a hexanucleotide repeat expansion within chromosome 9 open reading frame 
72(C9ORF72) was identified in ALS patient samples, becoming the major known genetic 
cause for ALS and frontotemporal dementia (FTD). Carriers of this mutation present 
reduced levels of C9ORF72 mRNA, RNA foci produced by the aggregating expansion and 
toxic dipeptides generated through repeat-associated non-ATG translation. These findings 
have led to multiple hypotheses on the pathogenesis of C9ORF72: 1) Haploinsufficiency, 
2) RNA gain-of-function, 3) RAN Translation, and 4) Disrupted nucleocytoplasmic 
trafficking. Due to lack of treatments for this disease, we have pursued an AAV-RNAi 
dependent gene therapy approach, using an artificial microRNA (amiR) packaged in a 
recombinant adeno-associated virus (rAAV). After validating our in vitro results, we 
advanced to in vivo experiments using transgenic mice that recapitulate the major 
histopathological features seen in human ALS/FTD patients. Adult and neonate mice were 
injected through clinically relevant routes and our results indicate that AAV9-mediated 
amiR silencing not only reduced mRNA and protein levels of C9ORF72 but also the 
expansion derived toxic GP dipeptides. Although our amiR is not targeting the expansion 
itself but exon 3, we illustrate here that the evident dipeptide decrease is achievable due to 
the presence of aberrant transcripts in the cytoplasm containing miss-spliced Intron-HRE-
C9ORF72 species. These encouraging results have led to the continued testing of this 
treatment as a therapeutic option for C9ORF72 - ALS patients.  
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In 2011 a newly discovered gene mutation was shown to be the major cause for not only 
(ALS) but also for Frontotemporal dementia (FTD). At the time there were only 2 
publications describing the presence of a hexanucleotide repeat located in the first intron 
of chromosome 9 open reading frame 72 (C9ORF72). Since then ~three thousand papers 
have been published referencing this mutation and the importance of finding a therapeutic 
strategy for the leading genetic cause of ALS and FTD.  
In my thesis I will address a possible therapeutic strategy using recombinant adeno- 
associated virus (rAAV) mediated RNA interference (RNAi) to silence the toxic gene 
products produced by C9ORF72. In Chapter II, I will initially describe ALS and the 
C9ORF72 mutation. I will then summarize in Chapter III, the RNAi pathway and how to 
design artificial microRNAs or shRNAs for delivery to the central nervous system (CNS).  
As a group, we also generated a BAC transgenic mouse model containing the human 
C9ORF72 gene with approximately 500 repeats of the GGGGCC motif. The mice showed 
no overt behavioral phenotype but recapitulated distinctive histopathological features of 
C9ORF72 linked ALS/FTD, including sense and antisense intranuclear RNA foci and poly 
(glycine-proline) dipeptide repeat proteins. In addition to creating this mouse model we 
sought to prove that this model could be a valuable tool in the study of ALS/FTD 
pathobiology and therapeutic testing. In doing so, an AAV mediated artificial microRNA 
(amiR) was designed and tested targeting C9ORF72 in primary cortical cultures obtained 
from this mouse. In Chapter IV, I will not only describe the characterization of the C9BAC 
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mouse model, but also that gene therapy could be used as an approach to attenuate 
expression of the C9BAC transgene and decrease the poly GP dipeptides in vitro. 
Chapter V will encompass the pipeline illustrated in Figure 1.1, for the in vitro screening 
and in vivo validation as well as relevant peripheral and CSF surrogate injection routes for 
therapeutic delivery in mice. 
 
Figure 1.1 Pipeline for microRNA screening and validation 
After a preliminary screening in HEK293T cells, the selected microRNAS are packaged 
into recombinant adeno associated virus (rAAV) serotype 9, which crosses the blood 
brain barrier (BBB). In vitro screening will take place in cortical primary neurons from a 
BAC transgenic ALS mouse model. In vivo proof of concept studies will entail striatal 
injections in adult mice, followed by local and systemic deliveries to neonate mice.  
 
I hypothesized that AAV mediated amiR silencing of C9ORF72 could decrease C9ORF72 
toxic mRNA levels and the corresponding protein. To achieve this several amiRs were 
designed to target all three variants of C9ORF72. Knowing that microRNAs primarily act 
in the cytoplasm as post-transcriptional gene repressors we expected to see an overall 
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decrease of all C9ORF72 gene products, with the exception of the nuclear RNA aggregates 
(foci). After screening, the best amiR candidate was packaged into AAV9 vector for in 
vitro and in vivo delivery to adult and neonatal mice through various injection routes. Here 
I demonstrate that an AAV9 mediated delivery of a H1-amiRC9 against C9ORF72 
effectively leads to a decrease of mRNA, protein and more importantly the most abundant 
dipeptide (GP) in the brain and spinal cords of C9ORF72 BAC transgenic mice. These 
findings suggest that amiRs delivered by AAV9 vector are a potentially viable therapeutic 
strategy for C9 linked ALS/FTD cases. 
In collaboration with a group at the University of Miami we identified key ALS/FTD 
epigenetic factors present in the C9ORF72 BAC mouse model. Similar to what is observed 
in patient populations we found that a subset of C9BAC mice had epigenetic perturbations 
caused by the hexanucleotide repeat, such as DNA histone methylation. These findings 
suggested that epigenetic aberrations in the presence of the expansion may lead to 
repression of the C9ORF72 gene and delay of disease progression. This research will be 
discussed in appendix I. 
In addition to working with ALS as a neurodegenerative disease we also sought to use 
AAV mediated RNAi as an approach to treat other neuronal diseases such as hereditary 
sensory and autonomic neuropathy 1 (HSAN). This disease is the most common 
neuropathy known to affect peripheral sensory nerves, the main mutation linked to HSAN1 
is a lack of function of the SPTLC1 gene. In appendix II, I will describe a summary and 
preliminary data from an in vitro screening of artificial microRNAs targeting the SPTLC1 





C9ORF72 hexanucleotide repeat expansion, the major cause for ALS/FTD 
Introduction 
Amyotrophic lateral sclerosis (ALS), is a lethal neurodegenerative disease that affects 
approximately 2 in every 100,000 persons worldwide [1, 2]. Patients suffering from this 
disease have an average life expectancy of 2-5 years after symptom onset. Over time, 
they develop progressive muscle wasting and shortness of breath, losing their ability to 
move freely or breathe on their own [3]. Although ALS was first described in the early 
1800’s as a motor neuron disease the root cause or prediction of a degeneration pattern 
still remains to be identified. [1,2] Nonetheless, ALS has been further classified as 
sporadic or familial ALS depending on genetic inheritance with only 5% of all cases 
being of known origin. [4-7] 
Recently, two independent groups [8, 9] conducting genomics studies of ALS and 
frontotemporal dementia (FTD) patient samples found an expanded hexanucleotide 
repeat expansion (HRE) of (GGGGCC) located in the non-coding intronic region of 
chromosome 9 open reading frame 72(C9ORF72). These expanded repeats, hundreds to 
thousands compared to healthy variation of 23-30, differ in number depending on the 
tissue; so far, the most substantial repeats are observed in the brain. [8, 9]. To date, 
C9ORF72 HRE accounts for the majority of familial and sporadic ALS (Figure 2.1) as 










Figure 2.1 Familial and Sporadic ALS gene architecture  
The Sporadic ALS pie chart is indicating that most cases are considered unknown with 
10% accounting for C9ORF72 cases. The Familial ALS pie chart shows C9ORF72 as 
the prevalent mutation accounting for 40% of the cases followed by Unknown, SOD1, 
TARDBP, FUS, VCP, Others.  
 
Three main splice variants have been validated by NCBI as the major products of the 
C9ORF72 gene: Variant 1 (NM_145005.5), Variant 2 (NM_018325.3), and Variant 3 
(NM_001256054.1). Variants 1 and 3 containing the expansion are the least abundant, 
contrary to V2, which is the more abundant variant (Figure 2.2). While the function of the 
C9ORF72 protein isoforms remains to be determined they have been linked to 
(differentially expressed in normal and neoplastic cells) DENN proteins which interact 






Figure 2.2. Schematic of the C9ORF72 gene  
 Following the NCBI nomenclature the C9ORF72 gene is 28kb long and has 12 exons. The 
hexanucleotide repeat expansion (HRE) depicted by the red diamond in located in the first 
intron exons 1-2. Two different promoters and alternative splicing give rise to 3 variants, 
V1 is the short isoform that codes a 222 aa protein and variants 2 -3 code for the same 481 
aa protein. Only V1-V3 carry the expansion along with the 80 bp non coding Exon 1a and 
158bp long Exon 1b respectively.  
 
The presence of the HRE causes a series of consequential effects including an overall 
reduction of C9ORF72 mRNA, an accumulation of C9ORF72 sense and antisense 
transcripts resulting in nuclear RNA foci, and the presence of long dipeptide chains 
generated by repeat-associated non-ATG translation (RAN) in the cytoplasm. [11, 14] 
These findings led to three hypotheses on the pathogenesis of C9ORF72: (Figure 2.3): (1) 
Haploinsufficiency, where decreased levels of mRNA lead to insufficient gene product. 
[15-17] (2) RNA gain-of-function, where the expanded RNA foci sequester RNA binding 
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and/or splicing proteins [18] (3) RAN translation of the hexanucleotide expansion, in which 
all reading frames of both a sense and antisense RNA is translated, generating toxic poly-












Figure 2.3 Hypotheses for C9ORF72 disease pathology 
There are 3 major putative mechanisms underlying C9ORF72 (HRE). (1) Involves a loss 
on function of C9ORF72, (2) an RNA gain of function and (3) RAN translation of toxic 
dipeptides. 
 
Glycine Proline (GP) dipeptides are the most abundant since it is translated from both sense 
and antisense reading frames, and Arginine containing dipeptides, Glycine Arginine (GR) 
and Proline Arginine (PR) are the most toxic to the cells when overexpressed in vitro and 
8 
 
in drosophila fly models [12, 14]. A recent (PR) mouse model was used to show that this 
dipeptide was bound to DNA within heterochromatin resulting in cellular aberrations [13]. 
These dipeptides can co-localize with p62 staining yet do not form TDP43 inclusions. A 
series of recent publications have also proposed that C9ORF72 HRE may disrupt 
nucleocytoplasmic transport. [11, 12, 14, 23, 24] While the main cause for motor neuron 
death is still unclear, it may simply be the result of several of these molecular hallmarks 
simultaneously compounding and overwhelming the cell. 
Due to the intricacy of this disease, finding an effective therapeutic strategy has not been 
feasible. Currently, patient treatment is limited to palliative care or two main 
medications approved by the food and drug administration (FDA); Riluzole (Rilutek) 
[25] and Edaravone (Radicava) [26, 27]. Riluzole is a pharmacological agent that blocks 
sodium channels and impedes the release of glutamate from nerve terminals protecting 
neurons from overstimulation, human clinical trials have shown prolonged survival for 
only a few months[25]. Radicava alternatively acts by reducing oxidative stress leading 
to neuronal protection. This treatment requires intravenous administration of the drug 
for 14 days in 28-day cycles for a minimal reduction in disease progression. [26, 27] 
Thus, the need for a new and enhanced therapeutic approach has encouraged the 
scientific community to devise new means to target and safely deliver agents. We 
developed an approach using RNA interference (RNAi) molecules to target C9ORF72 
for post-transcriptional silencing.  
The major concern while developing a therapeutic strategy other than the effectiveness of 
said technology, is finding a way to deliver it safely and to the desired target tissue. 
Specifically, when working with diseases that affect the CNS, the main obstacle is getting 
9 
 
the therapeutic across the blood brain barrier (BBB). This barrier serves as a defense 
mechanism against pathogens and toxins, while allowing certain ions, molecules and cells 
to pass in a controlled manner.[28] Previous attempts for protein replacement therapy 
would not only be thwarted by the presence of the BBB but also by limitations in protein 
half-life, dose and possible toxicity. Although the BBB can be bypassed by direct 
injections, in patients’ however, repetitive brain or intrathecal injections can lead to a 
higher risk of contracting cerebral infections. Reagents such as nanoparticles or antisense 
oligos can deliver or express a therapeutic agent however toxicity and recurrent injections 
to deliver said therapeutics over time can become overwhelmeing and dangerous for 
patients.[29] [30] [31] The use of recombinant adeno-associated vectors (rAAV) as tools 
to mediate transgene delivery has overcome these hurtles and become the safest and most 
reliable path to obtain sustained expression of a transgene in mice, non-human primates 
and in clinical trial patients.  
Recombinant adeno-associated virus (rAAV) as a vehicle for therapeutic delivery 
Initially wild type (WT) AAV was found as a contaminant of adenovirus (Ad) cultures. 
This single stranded 4.7kb DNA virus contains two genes (rep) replication and (cap) 
capsid. Rep genes produce four proteins, two involved in genome replication (78-68) and 
two involved in genome packaging (52-40). Cap genes produce 3 proteins VP1-VP2-VP3 
at a 1:1:10 ratio, these proteins are involved in capsid production and generating an 
icosahedral structure.In addition to the assembly activating protein (AAP) gene, coded 
within cap has also been linked to vector construction. These genes are flanked by 125 nt 
palindromic sequences called inverted terminal repeats (ITRs ) which are crucial for 
genome replication and packaging [32].  
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As a member of the Parvovirinae family it is non-pathogenic and replication deficient, 
requiring the aid of a helper virus such as Adenovirus(AD), Herpes simples virus (HSV) 
type I,II, Baculovirus, Cytomegalovirus or Pseudorabies in order to replicate. Other non 
common paths involve making the virus susceptible by using agents such as Ultraviolet 
irradiation (UV), cycloheximide, hydroxyurea, topoisomerase inhibitors and chemical 
carcinogens. [30] However for the purpose of packaging rAAV as a therapeutic vehicle 
addition of a helper virus along with a plasmid containing the rep and cap genes, is the 
standard approach also known as triple tranfection. [33-35] 
 To use AAV for gene delivery the plasmid is modified to retain only the wild type ITRs 
and the rep and cap gene are replaced with the transgene of interest [36]. The packaging 
capacity is ~4.7 kb of single stranded DNA for which expression can be detected three to 
four weeks post delivery. The delay in expression results from the time needed to generate 
the complentary strand [37]. This can be bypassed by packaging double straned or self 
complementary DNA ~2.3kb where gene expression can be detected two weeks post 
injection. This is a limiting factor for genes too large to be packaged within AAV, however 
new strategies have evolved, using shorter promoters or truncated versions of the 
transgenes in order to fit the transgene in the vector. Other studies involve trans-splicing 
AAV vectors by using the recombination capabilities of the ITRs. A desired ~9kb transgene 
cassette can be split between two vectors, each containing the appropriate donor and 
acceptor sites and can be re-combined to create a full message once inside the cell [38].  
Because the AAV capsid will determine the cell tropism, multiple capsids have been 
discovered, modified or generated to improve cell tropism, infectivity and specificity. This 
vast library of vectors is available for researchers to test the more adequate capsid for each 
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therapeutic purpose. [28]. For my thesis work we have chosen to use rAAV9. This capsid 
crosses the BBB and transduces a wide neuronal population including astrocytes, and 
motor neurons in the brain and spinal cord of rodents and non-human primates[39-46] An 
additional benefit of using rAAV9 as a delivery tool for the CNS, is that motor neurons are 
non-dividing cells, so once the cells are transduced they will sustain transgene expression 
indefinitely. Keeping in mind that although rAAV9 will transduce cell populations in the 
CNS it will also leak systemically and transduce the liver, heart, muscle. Luckily there are 
ways to use tissue specific promoters to restrict this moving forward. [28, 47] 
 A common concern when treating diseases where the targeted cells will continue to 
replicate is loss of rAAV expression overtime. Since rAAV remains episomal it will not 
replicate along with the host cell. Depending on the turnover rate of the cells, rAAV will 
go through a dillution effect which will then lead to a decrease of overall transgene 
expression. Whoever as long as a significant population of cells continue to express the 
transgene of interest, the expression levels produced may be sufficient to maintain normal 
cell function for an extended period of time. [42, 48, 49]  
Another concern when using rAAV as a vehicle is generating an immune response towards 
either the capsid or to transgene within it. Because AAVs are common within the human 
population the presence of neutralizing antibodies (nab) is a complication which can be 
managed to a degree using immunosupressors [50]. However pre-screening of possible 
gene therapy candidates can provide information inregards to the presence of neutralizing 
antibodies against specific serotypes. In which case using a different serotype may be the 
simplest solution [50].  
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Understanding the biology of AAV, the immunological response to rAAV and finding 
ways to improve rAAV capsids, production and their purification is a continued goal that 






Design of shRNA and microRNA for delivery to the Central Nervous System 
Introduction  
There are many well-known human neurodegenerative diseases, such as Parkinson’s, 
Alzheimer’s and Huntington’s, that specifically affect neurons [51]. Neuronal cells, unlike 
other cells in the body are non-regenerating; therefore if they suffer damage they may 
deteriorate and die without being replaced [52]. Neuronal loss can lead to many symptoms 
of neurologic disease such as ataxia (uncoordinated movements) and/or dementia (loss of 
mental health and higher thought processing) [51-56]. Every year the number of patients 
diagnosed with one of these illnesses increases [57, 58]. Currently there is an increased 
interest in neuroscience research a lot of which is focused in pursuit of a treatment that will 
slow the progression and/or cure these diseases. To this end many approaches are 
constantly being developed. The discovery of RNA interference (RNAi) as well as the use 
of viral vectors as mediators for delivery has given gene therapy the possibility to treat 
diseases caused by a toxic gain of function, such as Huntington’s and ALS [59]. 
The RNAi mechanism entails the transcription of sequence specific small RNAs that bind 
in a complementary manner to their target messenger RNA (mRNA) forming double strand 
RNA (dsRNA). The cells innate defense response to dsRNA is to induce its degradation 
[60]. This response evolved to regulate gene expression or as protection against exogenous, 
single stranded DNA seen, for example, from viruses [61, 62]. 
RNAi was first observed in plants in 1990, followed by its description in the nematode 
Caenorhabditis elegans in 1998 by Craig Mello and Andrew Fire [63]. Small RNAs such 
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as short hairpin RNAs (shRNAs) and micro RNAs (miRNAs) enter the RNAi pathway and 
act as post-transcriptional gene regulators [59, 60, 63]. Researchers have designed artificial 
short hairpin RNAs (shRNAs) and micro RNAs (miRNAs) to target specific gene 
sequences.  
Engineered miRNAs are designed based on the endogenous miRNA biogenesis. They are 
commonly transcribed from genes by RNA polymerase II (pol II) or less frequently by 
RNA polymerase III (pol III). Pol II promoters transcribe precursors for small RNAs, 
mRNA, snRNA and microRNAs. Pol III are strong promoters that not only synthesize 
small RNAs but are also transcribing housekeeping genes that are expressed abundantly 
throughout different cell types.[64]  
After being transcribed, miRNAs transcripts are capped at the 5’ end, and polyadenylated 
at the 3’ end. This structure is termed primary miRNA (pri-miRNA). Pri-miRNAs will then 
be recognized by the protein/enzyme complex DGCR8/Drosha and further cleaved to 
precursor miRNAs (pre-miRNAs)[65]. Pre-miRNA hairpins are then structurally 
recognized by the nuclear receptor Exportin-5, which will guide it to the cytoplasm [65]. 
In the cytoplasm the RNase III enzyme Dicer serves as a molecular ruler that will recognize 
dsRNA and cleave a specified distance from the 3’end overhang[66], or 5’ end phosphate 
group[67] resulting in a 22-nucleotide miRNA: miRNA duplex[66]. This duplex is made 
up of a guide strand, which will enter the RNA- induced silencing complex (RISC), and a 
passenger strand, which will be degraded. Once in the RISC complex the guide strand will 
bind to its target mRNA. If the guide strand, is perfectly complementary to the target 
sequence the result will be cleavage by the catalytic component of RISC, argonaut 2 
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(AGO2)[59, 65, 68]. However, if there is only partial complementarity at the seed sequence 
(2-8 nt) with the target sequence the result will be translational repression.  
Short hairpin RNAs are commonly transcribed from pol III promoters (e.g. U6 or H1) 
however, pol II and cell specific promoters can be an alternative option though scarcely 
used [69]. Unlike miRNAs they enter the RNAi pathway as hairpins skipping cleavage by 
Drosha and being shuttled through Exportin-5 to the cytoplasm where they follow the same 
miRNA Dicer- RISC route. A diagram of the RNAi pathway can be found in (Borel. 2013) 
[59]. Although these molecules are designed to only bind to their target, there may be 
instances where there are off target effects. Given that miRNAs can regulate translation by 
just binding at the seed sequence it’s difficult to repress all off-target effects [70]. However, 
the engagement of the slicer activity from AGO2 relies on more extensive base pairing as 
mentioned above, the off-target effects for this can be more easily controlled. Several 
bioinformatics tools and websites exist that will allow the user to query their sequence to 
find theoretical targets to minimize the off-target effects. [71] 
A debatable issue regarding shRNAs driven by strong pol III promoters has been cell 
toxicity caused by overload of the RNAi machinery. Saturation occurs when artificial 
molecules and endogenous microRNAs compete to enter this pathway and exit it through 
Exportin-5 [59, 72]. Researchers have compared toxicity levels between miRNAs driven 
by pol III promoters and shRNAs; they found that although miRNAs have an extra 
saturable step in the nucleus in addition to the cytoplasmic, they cause less toxicity than 
shRNAs. Results by Maczuga, P., et al. (2012) also show that although using a pol II 
(CMV) promoter lead to reduced toxicity compared to pol III driven shRNAs, the overall 
effectiveness of miRNAs was more consistent than that of shRNAs [73].  
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 Additionally, vector-derived genes can transcribe artificial miRNAs by either pol II or pol 
III; allowing researchers to use pol II tissue specific promoters. These factors have 
encouraged investigators to opt for the use of miRNAs for long-term expression and 
silencing rather than using shRNAs for therapeutic purposes.  
In this chapter detailed instructions for the proper design of miRNA and an shRNA will be 
discussed in addition to guidance on how to design an in vitro screen prior to packaging 
these constructs in either recombinant Adeno Associated Viruses (rAAV) or lenti-virus for 
an in vivo delivery. The main goal is to design molecules with the potential of being 
delivered to the CNS for therapeutic purposes.  
Methods 
Selection of RNA target sites and design of miRNA or shRNA 
First, one selects the target sequence to be silenced. Both miRNAs and shRNAs can be 
designed to be species specific, or to target a region conserved across various species. In 
addition, these molecules can also be tailored to target a single variant or multiple variants 
produce by a gene. The sequences can be obtained at the National Center for Biotechnology 
Information (NCBI) http://www.ncbi.nlm.nih.gov/refseq/.  
With the aid of an RNA folding software [74] , which computes an algorithm for base pair 
probabilities, thermodynamics and circular RNA folding; the structure of the target 
sequence can be analyzed. The prediction software will allow the visualization of the 
secondary structure of the target sequence and all looped areas of single stranded RNA that 




microRNA design  
The 22-nucleotide sequence from the loops identified can be selected and copied into a 
microsoft word document. Within each sequence the 5’ end should contain an A or a U as 
the first base of the microRNA, this will improve thermodynamic stability, and allow for 
enhanced AGO2 loading.[75]. The following 19-21 nucleotides selected should be unique 
to the intended target. To verify this, the BLAST database from NCBI (http://blast.be-
md.ncbi.nlm.nih.gov/Blast.cgi) can be used as a tool to ensure there are no mistargeting 
effects. 
 Another feature to consider is the GC content of the selected sequence, the preferential 
range should lie between 20-70%. An example of a target sequence is shown in (Figure 
3.1) this sequence has a GC content of 57.1%. The GC calculation can be done manually 
by counting the number of G’s, C’s and dividing by the total number of nucleotides in the 
sequence. Or online calculators are available on the web https://molbiol-
tools.ca/DNA_composition.htm 
 The addition of a basal UG motif immediately after the stem-loop at position 14 can also 
be added to the microRNA design, it has been shown to enhance Dicer binding [75]. At 




Figure 3.1: An example of a microRNA designed against the human housekeeping 
gene GAPDH NM_002046.5 (NCBI) 
 
Both flanks and loop have been modified and adapted from human miR155. A) Indicates 
the folding structure of GAPDH obtained from the software, zoomed into the loop to be 
targeted. B) Starting from the 5’ end the microRNA contains flank sequences, which will 
form part of the structure and cleavage sites recognized by Drosha. The 5’ flank is followed 
by the 22-nucleotide sequence that contains a seed sequences from nucleotides 2-8, and a 
mismatched loop. The antisense sequence is the reverse compliment of the sense sequence 
with nucleotides from positions 10-11 deleted to form an unpaired bulge. The sequence has 
a +G modification that should be added if cloning into a plasmid with a U6 promoter, and 




shRNA Design  
After identifying and selecting the 22-nucleotide target sequence the following 19-
nucleotides comprise a loop structure adapted from an endogenous microRNA (human 
miR155 in this case). After the loop the reverse complement of the 22 nucleotides will be 
added to form a hairpin structure. The conserved loop structure will contain the cleavage 
sites needed for Dicer to cleave it and leave a dsRNA duplex. Adding a multiple cloning 
site to the construct design is a useful tool, when cloning into different expression cassettes. 
Selection of a pol III U6 or H1 promoter would be at the discretion of the designer. 
Nonetheless if a U6 promoter is selected an additional +1-G must be added at the 3’ end of 






























Figure 3.2: An example of an shRNA designed to target the human housekeeping gene 
GAPDH NM_002046.5 (NCBI) 
The loop has been modified and adapted from hsa-miR155. In panel A) starting from the 
5’ end is a restriction site for cloning; followed by the sense 22-nucleotide sequence, then 
a 19-nucleotide loop that contains the 2nt- 3’overhang site for Dicer cleavage, and finally 
the antisense 22-nucleotide sequences with bases in positions 10-11 deleted to form a 
bulge. The bottom strand is the reverse complementarity of the top strand. In panel B) is 
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Backbone design  
Either endogenous miR155 or miR30 are commonly used as backbones to design the 
artificial microRNA and shRNA. For the microRNA design both the 3’ and 5’ flanks, as 
well as the loop region are adapted from the endogenous miRNA of choice (Figure 3.1). 
For the shRNA design only the loop region is adapted as the backbone (Figure 3.2). The 
5’ and 3’ flank sequences of 50-100nts, from the endogenous microRNA of choice should 
contain the structural cleavage areas for the Drosha-DGCR8 machinery to bind. Drosha 
will sit 40nt upstream and downstream of the pre-miRNA hairpin, these flanking sequences 
complement each other and leave single stranded areas at the base of the stem loop that the 
microprocessor will recognize as substrate. Refer to [68, 76-78]. In addition to the flanks a 
loop from a naturally occurring microRNA should be selected. Dicer will recognize the 
hairpin shaped pre-mRNA. Refer to (Gu et al., 2012) [79] on specific details for loop design 
and (Lewis et al., 2003 , and Siolas et al., 2003) for problems concerning improper Dicer 
cleavage [80, 81].  
 
Introduction of the 20-22-nucleotide sequence into the backbone 
Immediately after 5’ flank sequence, the 20-22-nucleotide sequence that is perfectly 
complementary to the target sequence can be added, this stretch of nucleotides will also 
contain the seed located in positions 2-8. A common problem when designing is not finding 
a 21-22-nucleotide single stranded sequence. In that case the seed sequence should be 
enough, although the specificity and efficiency might vary. Prediction programs other than 
the mentioned above, can be used and might result in alternative secondary structures. After 
the 22 nucleotides, the loop sequence adapted from the naturally occurring microRNA can 
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be added followed by the reverse complement of the 22 nucleotides modified by having a 
deletion in positions 10-11 creating a bulge. The presence of the bulge will allow for the 
sense strand to be preferentially loaded into AGO2. The whole sequence described above 
can then reverse complemented to create the bottom strand 3’-5’. 
 If a pol III promoter such as U6 is being used addition of a +1 G at the 3’end of the U6 
promoter sequence is needed, before the 5’flank sequence of the miRNA. [82] After the 3’ 
flank sequence the pol III terminator formed by 4-6 T’s (TTTTTT) and the restriction site 
of choice for cloning should be the last components added to the design. This stretch of T’s 
will create an overhang at the 3’end necessary for Dicer recognition [82]. Stretches of 
AAAA or TTTTT’s, should be generally avoided for these are common terminator sites 
for pol III promoters.  
 When designing the experiment proper controls should include a microRNA targeting an 
unrelated non essential sequence or gene . A scramble for proof of concept and to control 
for saturation of the RNAi machinery, promoter or reporter toxicity. An example of U6 




























Figure 3.3: An example of the entry plasmid used for cloning a microRNA/ shRNA  
 
A) U6 entry plasmid contains a U6 promoter followed by either the miR155 endogenous 
flanks or the shRNA directly. AN additional Chicken beta actin (CB-A) promoter driving 
the expression of a reporter gene (GFP) can be added. B) CB entry plasmid contains a CB 





Cloning of the miRNA or shRNA 
Oligonucleotides must be reconstituted with nuclease-free water to 100-μMolar 
concentration. The oligo annealing reaction will then take place in a beaker with boiling 
water at 95oC, each eppendorf 1.5ml tube containing the annealing reaction (Table 3.1) will be 
kept at 95oC for 5 minutes, then the heat will be shut off and the beaker will be allowed to cool to 
room temperature. Oligos can then be stored at -20 oC indefinetly.  
 
Table 3.1. Annealing reaction  
Component Volume 
5’-3’ oligo 2 μl 
3’-5’ oligo 2 μl 
Annealing buffer (IDT) 196 μl 
 
The plasmid containing the promoter of choice, reporter etc. must be verified prior to 
starting any cloning experiments. The plasmid should be digested with the enzyme selected 
for cloning to confirm the presence of the expected cut site and size of the band. the 
annealed oligonucleotides and the vector should be run side by side in a 1% agarose gel to 
observe and quantify the relative abundance of each to ensure a 1:1 ratio to then perform 
an adequate ligation. The ligation mixture described in (Table 3.2) can be left at 160C 






Table 3.2. Ligation reaction 
Reagent Volume 
Vector 1 μl 
Insert 1 μl 
Quick T4 DNA ligase 1 μl 
Buffer  2 μl 
Nuclease-free water  15 μl 
Volume reaction 20 μl 
 
The transformation protocol should be followed as instructed by the manufacturers. For 
our intented purposes we used SURE2 super-competent cells. The transformations were 
plated and incubated overnight at 370C. The next day, multiple colonies were selencted and 
grown in 5ml tubes containing terrific broth media and the antibiotic used for selection at 
370C, shaking. Cultures should no be grown for more than 13 hours . A 2ml aliquot of 
bacterial growth media was taken to extract the plasmid DNA using a commerical miniprep 
kit. And the leftover was stored in a 50:50 ratio solution of glycerol for -800C long term 
storage. Based on the designed restriction site digests of the DNA should allow for clear 
distinction of the vector and the insert when run in a 1% agarose gel.  
Once the correct clones have been verified, they should be sent to be sequence verified to 
confirm the insert (miRNA/shRNA) is properly cloned into the plasmid. Once the 
sequencing results are received the sequences can be compared and aligned to a cloning 
map. Software such as snapgene or clonemanager should be purchased for ease of plasmid 




Screening of miRNA or shRNA 
 An adequeate cell line shown to have detectable levels of expression of your gene of 
interest should be selected for the screening process. This cell line should also be amenable 
to tranfections and easy to maintain such as human embryonic kidney cells (HEK293) 
which are commonly used for these purposes. A transfection optimization prior to the 
experiment is recommended, where different tranfection reagents, volumes, media 
changes, plasmid concentrations and incubation times can be adjusted. Reagents for 
transient tranfections such as Lipofectamine2000 or Jet Prime are the more frequently used. 
An additional way to assess the tranfection efficiency and verify the presence of the 
transgene includes the use of reporter genes such as Green fluorescent protein (GFP). These 
can either be cloned into the same construct with the miRNA/ShRNA or can be co-
transfected at a 1:1 ratio. Twenty four to seventy two hours post transfection the cells can 
be collected for RNA extraction. The experimental design should include the proper 
controls: 1) A miRNA, that targets an unrelated sequence, which will control for saturation 
of the RNAi machinery and as a a guide for normalization. The use of a scrambled miRNA 
sequence is also very common however we discourage it since it may lead to uncknown 
misstargeting. 2) A control plasmid with only the selected promoter and reporter (i.e: 
CMV-GFP) to control for the reporter gene expression and possible toxicity. 3) A sham 
transfection, where all transfection components are added except for DNA. 4) And an un-
transfected well, to control for cell growth, viability and contamination. To collect cells, 
cell media is removed and washed with 1x PBS solution, followed by Trizol reagent 




 Silencing analysis by RT-qPCR or Western blot. 
Following an RNA extraction, complementary DNA should be made using the RNA to 
cDNA kit from Qiagen with the reagents in (Table 3.3). The reaction will be incubated at 
370C for 60 minutes, then stopped by heating at 950C for 5 minutes and held at 40C or 
stored at -200C indefinitely. Primers and probes can be designed or made to order for the 
gene of interest. 
Table 3.3 cDNA reaction 
Component Component Volume /Reaction (μl) 
 + RT reaction -RT control 
2X RT Buffer 10 10 
20X Enzyme Mix 1 - 
RNA sample 2μg- up to 9μl 2μg- up to 9μl 
Nuclease-free H2O Bring to 20 μl Bring to 20 μl 
Total Per Reaction 20 20 
 
cDNA should be diluted in a 1:10 ratio with sterile water or serial dilutions should be run 
to assess the adequate concetration needed for an efficient qPCR. Additional controls for 
the qPCR include assessing the expression levels of a housekeeping gene such as GAPDH 
or HPRT which will then be used as references for relative expression quantification via 
the delta delta CT method [83]. If antibodies against the gene of interest are available a 
western blot may be used to measure the level of protein knockdown using Actin as loading 




In vivo validation of miRNA and shRNA 
 To test the selected constructs in vivo, the artificial miRNAs/shRNAs can be packaged in 
either recombinant adeno associated virus (rAAV) or lentivirus. Something to be 
considered for the in vivo work is the nature of the constructs, if they are designed to be 
species specific to human sequences, then a transgenic model or human derived cell lines 
may be needed. Nonetheless,both miRNAs/shRNAs designed against human sequences 
might cross-react with other species if the target sequence or the seed is conserved. 
Summary 
 The discovery of RNA interference (RNAi) has enabled scientist to design new therapeutic 
approaches based on specific gene silencing rather than the canonical gene therapy through 
gene augmentation. Two types of molecules can be used for viral vector-mediated gene 
silencing: short hairpin RNAs (shRNAs), and artificial microRNAs (miRNAs), that can 
enter the RNAi pathway. Although both shRNAs and miRNAs can be used to silence 
genes, they enter the RNAi pathway at different points. Unlike shRNAs, miRNAs require 
an additional cleavage step inside the nucleus before being exported to the cytoplasm. 
These molecules can then be incorporated into the RNA-induced silencing complex (RISC) 
which utilizes sequence complementarity to recognize target mRNAs and activate either 
translational repression, in the case of partial complementarity, or induce mRNA cleavage 
in the case of complete complementarity. Elevated amounts of shRNAs, which are 
commonly driven by strong polymerase III promoters, can cause saturation of the 
endogenous RNAi machinery due to competition between endogenous and artificial 
molecules. Switching to a DNA polymerase II promoter is an alternative to reduce shRNA 
production thereby reducing toxicity. Even though the molecules are designed to target 
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specific mRNAs there may be off-target effects due to non-specific binding that must be 
accounted for during the design process. If the microRNA is designed to target a mouse 
gene any off target effects can be further evaluated to ensure no essential gene is affected 
as a result of the therapeutic. We have shown here, how to properly design these artificial 
molecules so they can be used as a tool for modifying gene expression not only to target 
the CNS but also a wide variety of diseases. The AAV capsid can also be selected based 

















Hexanucleotide Expansion Reproduces RNA Foci and Dipeptide Repeat Proteins 
but Not Neurodegeneration in BAC Transgenic Mice 
Introduction 
Model systems that recapitulate the pathobiology of the mutant C9ORF72 gene are 
particularly helpful in understanding how such mutations cause neurodegeneration in vivo. 
Several invertebrate [84, 85], vertebrate [86] and patient-derived cell models [87-90] of 
C9ORF72 motor neuron pathology have been reported. While each of these models have 
been instructive, it can be argued that a more informative model will permit studies of the 
C9ORF72 expanded GGGGCC repeats in the context of stable expression in an intact 
mammalian nervous system. For that reason, we generated a novel transgenic mouse 
carrying an expanded form of the human C9ORF72 gene with approximately 500 
GGGGCC motifs.  
We sought to assess if the model created would recapitulate the major molecular and motor 
hallmarks of the disease. If so, could this transgenic mouse be used as a model system to 
study the mechanism by which the hexanucleotide expansion causes toxicity or be an aid 








BAC transgenic mice express the human mutant C9ORF72 gene. 
We generated a line of SJL/B6 transgenic mice using a 153.2kb bacterial artificial 
chromosome containing exons 1 through 6 of the human C9ORF72 with about 500 
GGGGCC repeat motifs, including approximately 140.5kb of upstream sequence (Figure 
4.1A). Hemizygous C9BAC mice were viable, producing progeny at expected Mendelian 
frequencies. Southern blot analysis of genomic DNA from these animals detected two 
distinct bands corresponding to about 500 and 300 GGGGCC repeat motifs, which were 
intergenerational, and tissue type stable (Figure 4.1B, C). Using a human specific probe 
for all variants (Vall), C9ORF72 mRNA transcripts were detected in the C9BAC mice in 
all tissues examined. The truncated human C9ORF72 gene generates three transcript 
variants; V1 and V3 carry the repeat expansion (Figure 4.1 D). Human specific probes 
targeting human C9ORF72 V1, V2 and V3 mRNAs detected all three transcripts in the 
C9BAC mice at expression levels comparable to their abundances in human frontal cortex 
having used the same RNA concentration input (Figure 4.1 E). Moreover, the total level 
of the transgenic human transcripts was roughly comparable to that of the endogenous 
mouse C9ORF72 ortholog transcripts, and to levels of expression of human control and 


































Figure 4.1: Construct design, expansion size and expression profile for the C9ORF72 
BAC transgene and phenotyping of C9BAC mice.  
(A) Schematic of the bacterial artificial chromosome fragment used for generating the 
C9BAC mice. The 153.2kb construct contains (as shown from left to right) 140.5kb of 
human genomic DNA upstream of C9ORF72, the human C9ORF72 promoter region, and 
exons 1 to partial exon 6 with a (GGGGCC)500 repeat motif in C9ORF72 intron 1. The 
black bar indicates the target region for the Southern blotting probe used in B. (B) Southern 
blot of genomic DNA extracted from various tissues digested with HindIII, SacI, and TaqI 
and probed with a 5’-DIG-(GGGGCC)5-DIG-3’ DNA probe. Two bands of ~4.4kb and 
~6.0kb, are stable in size after 6 generations representing expansions of 300 and 500 
repeats. The arrowhead indicates a non-specific band. No variation in expansion size was 
seen among tissues as assessed in liver, brain, spinal cord, skin, muscle and ovary. C) 
Southern blot of genomic DNA extracted from liver, digested with HindIII, SacI, and TaqI 
and probed with a 5’-DIG-(GGGGCC)5-DIG-3’ DNA probe. Two bands of ~4.4kb and 





respectively. Arrowhead indicates a non-specific band. (D) Schematic showing potential 
RNA transcript generated from the C9ORF72 gene fragment used to generate the C9BAC 
mice. Three splice variant isoforms can be produced from the gene fragment, with V1 and 
V3 containing the hexanucleotide expansion. Nomenclature is based on NCBI reference 
sequences. For each isoform, the upper image shows unspliced pre-, while the lower image 
at the right is the spliced mRNA. The red bar denotes the presence of the southern blot 
probe used for determining expansion size. Blue bars show location of isoform specific 
TaqMan probes. Green bar shows location of TaqMan probe designed to recognize all 
isoforms (Vall). (E) ddPCR analysis of expression of all human C9ORF72 variants (Vall), 
and variants V1, V2 and V3 and the mouse C9ORF72 ortholog in human frontal cortex 
tissues from non-neurological disease control, c9ALS/FTD and SOD fALS patients, and 
whole brain homogenate from C9BAC and Ntg mice (meanSEM, n=4, Kruskal-Wallis 
test, Mann-Whitney U-test, * p<0.05, ND = not detectable). (F) ddPCR analysis of 
expression of all isoforms.  
 
Survival, motor and cognitive systems are normal in mice bearing the mutant 
C9ORF72 gene.  
A cohort of F1 generation male C9BAC mice was aged for phenotypic characterization 
and analysis of survival. At all ages, the C9BAC and control mice remained healthy. They 
trended towards a non-significantly elevated weight compared to Ntg littermates (Figure 
4.2A) and lived beyond two years. Survival in the C9BAC and Ntg littermates was 
indistinguishable (Figure 4.2B).  
We first tested for behavioral and histological abnormalities within the motor system of 
the C9BAC mouse. Overall, the C9BAC mice showed no significant motor deficits by 
rotarod performance and grip strength testing (Figure 4.2 C, D). No difference was 
observed in motor or sensory spinal nerve root axon number and morphology (Figure 4.2 
E), nor was increased denervation of neuromuscular junctions seen in 24-month C9BAC 
mice (Figure 4.2 F). Motor unit number estimation (MUNE) recording in the hind limbs 
of 24-month C9BAC mice detected no changes in MUNE score, motor unit size or 
35 
 
compound motor action potential, although there was a trend towards a modestly increased 
denervation score, as gauged by electromyography (Figure 4.2 G). We also assessed 
several pathological features in the motor cortex and spinal cord that are common features 
of ALS. No significant changes were seen in activation of microgliosis or astrogliosis 
(Figure 4.2 H). Cytoplasmic mislocalization and aggregation of TDP-43, both identified 
in the majority of ALS patients [91, 92], were not detected in the motor cortex of our 
C9BAC mice (Figure 4.2 I, J). To assess activation of programmed cell death within the 
spinal cord, we observed levels of cleaved capase-3 by Western blotting; levels in C9BAC 
and Ntg mice did not differ significantly. Because studies have demonstrated cortical 
hyperexcitability in patients and cell lines with C9ORF72-ALS hexanucleotide expansions 
[93], we next asked whether cortical neurons of neonatal C9BAC mice showed altered 
electrophysiological characteristics. We detected no changes in the electrophysiological 
properties of either pyramidal tract-type or intratelencephalically projecting neurons in L5 






















































Figure 4.2 Aged C9Bac mice show no gross motor phenotypic abnormalities  
A) C9BAC mice and Ntg littermates show no differences in weight from 3-24 months of 
age (mean±SEM, 2 -way ANOVA, Bonferroni’s multiple comparison, Ntg n-17, 
C9BACn=15) B) Kaplan-Meier curve representing lifespan showing no significant 
difference in survival of C9BAC mice compared to Ntg littermates (Ntg n=17, C9BAC 
n=16, Mandel-Cox Log Rank, P=0.971). C) The performance of the C9BAC mice on a 5-
minute accelerating rotarod task did not differ significantly from Ntg controls (mean±SEM, 
2 -way ANOVA, Bonferroni’s multiple comparison, Ntg n-17, C9BACn=15) D) The grip 
force of forelimb only and all limbs from 3-24- months of age showed no difference in 








Ntg n-17, C9BACn=15) . (E) Toluidine blue stained semi-thin section of L5 ventral (upper 
panels) and dorsal (lower panels) nerve roots of 24-month old C9BAC mice and age-
matched Ntg mice. Age-related alterations in axon and Schwann cell morphology were 
observed in motor fibers in both Ntg and C9BAC mice, while sensory fibers appeared 
normal. A plot of the numbers of myelinated motor axons in L5 ventral nerve roots as a 
function of axon diameter (µm) revealed no significant change in size distribution in 24-
month old C9BAC mice compared to Ntg controls (mean±SEM, Ntg n=3, C9BAC n=4, 2 
-way ANOVA, Bonferroni’s multiple comparison) (F) Immunofluorescent staining 
(Green=synaptophysin, beta-III-tubulin, Red=alpha-bungarotoxin-alexa555) and 
quantification of neuromuscular junctions in the gastrocnemius muscle of 24-month old 
C9BAC mice revealed no significant change in innervation (mean±SEM, Ntg n=4, 699 
NMJ assessed, C9BAC n=4, 675 NMJs assessed; 2 -way ANOVA) (G) Physiological 
studies reveal showed no significant change in motor unit number estimations (MUNE) 
motor unit’s size or compound motor action potential, though a modest increase in 
electromyogram score was observed (mean±SEM, Ntg n=3, C9BAC n=4 unpaired t-test). 
(H) Immunostaining of motor cortex from 24-month old C9BAC mice revealed no 
pronounced increase in number of GFAP-labeled activated astrocytes or Iba1-labeled 
microglia, (I) nor was TDP-43 found to mislocalize in these neurons. (J) Quantitative 
western blotting revealed no difference in levels of GFAP, Iba1, TDP-43 or p62 in the 
spinal cord of age matched Ntg and C9BAC mice (mean±SEM, n=3, Kruskal-Wallis test 
(K) the top panels are representative voltage traces recorded from pyramidal tract (PT) type 
neurons in layer 5 of motor cortex from Ntg and C9BAC mice evoked by 40-120 and 200 
pA current steps as indicated. (mean±SEM, Ntg=23 cells, 7 mice; C9BAC: 15 cells, 5 mice; 
P>0.4, 2-way ANOVA, Bonferroni corrected for multiple comparisons). And the lower 
panels are intratelencephalic (IT)-type neurons in later 5 of motor cortex. (mean±SEM, 
Ntg=19 cells, 7 mice; C9BAC: 13 cells, 5 mice; P>0.6, 2-way ANOVA, Bonferroni 
corrected for multiple comparisons) (L) A corresponding summary graph for the current 
spike frequency relationship for transgenic and control neurons. Scale bars E=20µm, F-H-
I= 50µm  
 
We next surveyed pathological findings that are common in FTD. No activation of gliosis 
was detected in the prefrontal cortex (PFC) or hippocampus (Figure 4.3 A-B) Changes in 
social interaction behavior have been described in rodent models of FTD [94, 95], however 
we found no change in social behavior of adult C9BAC in response an intruder mouse 
response assay. (Figure 4.3 C). Quantitative studies of Golgi preparations revealed no 
change in dendritic spine density of PFC layer 2-3 pyramidal neuron apical dendrites in 
aged C9BAC mice (Figure 4.3 D). Finally, altered gene expression profiles have been 
shown in c9ALS/FTD patient derived cell lines [88-90] and tissues [96]. To determine 
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whether a specific C9ORF72 RNA profile can be defined in our C9BAC transgenic mice, 
we sequenced total RNA extracted from the frontal cortex of six-month old C9BAC mice 
and littermate controls. Statistical analysis of differentially expressed genes did not reveal 
any change between the two groups, including several genes identified as differentially 





Figure 4.3: Aged C9BAC mice do not recapitulate FTD-like pathology nor show 
changes in cortical neuron electrophysiology. 
(A) Immunostaining for markers of astrogliosis (GFAP) and microgliosis(iba1) in (A) 
prefrontal cortex and (B) hippocampus of 24-month old Ntg or C9BAC (C)During a 5-
minute test period, the interaction times of 18-24 month olf Ntg or C9BAC mice with a 
juvenile male mouse were not different (mean±SEM, unpaired t-test, Ntg n=7, C9BAC 
n=9) (D) Golgi staining and quantification of dendritic spine density of layer 2-3 pyramidal 
neuron apical dendrites found no difference between 18- month old C9BAC and Ntg mice 
(mean±SEM, Mann-Whitney U- test, n=3 animals per genotype, 3-12dendrites per brain, 
total length of dendrite sampled: Ntg=1943.5 µm, C9BAC=1266.1 µm). (E) Heatmap 
showing the Euclidean distance between sample conditions and replicates (frontal cortex, 
6month old, n=5 C9BAC and n=3 Ntg) as calculated from the regularized log 
transformation of the gene expression counts. Based on these values, no distinct 
hierarchical clustering was observed, indicating that the overall gene expression patterns 
of C9BAC and Ntg mice were similar. (F) Differentially expressed genes (DEG). MA-
plot of log2 fold changes from the C9BAC over the mean of normalized counts. No DEG 
were identified using DESeq2 negative-binomial Wald test. (G) Table of genes of interest 
from (Donnelly, et al.,2013, Sareen et al., 2013) selected from the DESeq2 dataset showing 
adjusted p-value. (H) ddPCR quantification of NEDD4L, DPP6, KCNQ3 and CBLN4 from 
the RNA library used for RNAseq analysis (mean± SEM, Mann-Whitney U -test) Scale 
bars A=100µm, B=200µm, D=2µm  
 
 
C9BAC mice recapitulate histopathological features of human C9ORF72 ALS-FTD. 
At autopsy, brains from c9ALS/FTD patients show several histopathological 
characteristics that are not detected in other forms of familial and sporadic ALS or FTD: 
(i) sense transcript nuclear and occasional cytoplasmic RNA foci, (ii) antisense transcript 
nuclear RNA foci and (iii) the generation of DPR proteins through RAN translation of the 
sense and antisense transcripts.  
We used fluorescence in situ hybridization (FISH) to detect C9ORF72 sense and antisense 
foci in the brain and spinal cords of C9BAC mice (Figure 4.4). Intranuclear, sense foci 
were detected at 3 months of age (data not shown) and by 10 and 24 months were abundant 
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throughout the CNS, including motor cortex and spinal cord (Figure 4.4A), present in both 
neurons (Figure 4.4 B, C) and glia (Figure 4.4 D). Antisense foci were also detected in 
10- and 24-month old mice (Figure 4.4 A) but were sparser throughout the brain than 
sense-foci. Quantification of numbers of sense foci in nuclei of the cortical external 
pyramidal layer (Figure 4.4 E) and spinal motor neurons (Figure 4.4 F) revealed that the 
majority of foci-positive nuclei contain one to five detectable sense foci, though in some 
cases greater than 20 foci were seen in individual nuclei. A trend towards a reduced number 
of nuclei containing foci was seen between 10 and 24-months, reaching statistical 
significance in the motor cortex external pyramidal layer, but not spinal cord motor 
neurons.  
Because both sense and antisense C9ORF72 transcripts were present in the C9BAC mice, 
we next sought evidence of RAN translation products, using a sandwich immunoassay for 
the detection of poly (Glycine-Proline) poly (GP), which is synthesized from both sense 
and antisense transcripts. Tissues from 4- and 24-month old Ntg and C9BAC mice, and 
frontal cortex from six c9ALS case, were homogenized in buffer containing 2% SDS, with 
the detergent soluble fraction analyzed for poly (GP) content. At 4 months of age, poly 
(GP) was detected throughout the brain of C9BAC mice, with levels highest in the 
cerebellum, the spinal cord, sciatic nerve and liver (Figure 4.4 G). Though the mean 
concentration of poly (GP) levels in 4-month mice was lower than that observed in c9ALS 
frontal cortex, the 4-month C9BAC mean did fall within range of the lowest samples in the 
patient group (Figure 4.4 G). All tissues from 24-month old C9BAC mice showed a 
significant reduction in SDS-soluble poly (GP) levels. One hypothesis for the observed 
decline in soluble poly (GP) is that the DPR proteins show an age-dependent propensity to 
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form insoluble species. Immunostaining of brain tissues from 10- and 24-month old 
C9BAC mice revealed the presence of small perinuclear inclusion bodies stained for poly 
(GP) (Figure 4.4 H). Such inclusions were detected throughout the brain, including cortex, 
cerebellum and striatum, and were more frequently observed in the brains of 24-month 
mice, suggesting a heightened deposition of insoluble poly (GP) species.  
  
Figure 4.4: C9BAC mice recapitulate the histopathological hallmarks of C9ORF72 
ALS and FTD patients. 
 (A) Fluorescence in situ hybridization (FISH) using Cy3-tagged DNA probes against 
sense and anti-sense abnormally expanded C9ORF72 transcripts (Red = probe, Blue = 
DAPI nuclear stain). The C9ORF72 repeat containing sense or anti-sense transcripts form 
intranuclear RNA inclusions, or foci, throughout the brain, including motor cortex internal 
pyramidal layer and internal granular layer, and lumbar motor neurons of 24-month old 
C9BAC mice. FISH coupled with cell type specific immunostaining revealed sense 
transcript foci in neurofilament heavy positive neurons (B), choline acetyl transferase 
(ChAT) positive pyramidal neurons (C) and GFAP positive astrocytes (D). The number of 
sense transcript foci per nucleus in 10-month and 24-month old C9BAC mice in (E) motor 
cortex internal pyramidal layer and (F) lumbar motor neuron nuclei (Cortex: 10-month, 
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n=3, 821 nuclei; 24-month, n=3, 845 nuclei: Spinal cord: 10-month, n=3, 124 nuclei; 24-
month, n=3, 100 nuclei: mean±SEM, 2-way ANOVA, Bonferroni multiple comparison * 
p<0.05, ** p<0.001). (G) Quantification of soluble poly (GP) proteins in various regions 
of the CNS and liver of 4- and 24-month old C9BAC mice and frontal cortex of C9ALS 
cases by immunoassay (mean±SEM, C9BAC groups n=3, c9ALS n=6, two-way ANOVA, 
Bonferroni’s multiple comparison, * p<0.05, *** p<0.001). (H) Immunostaining for poly 
(GP) proteins in cortex of C9BAC mice. Staining revealed the presence of small 
perinuclear inclusion bodies throughout the brain at 10-months of age, with a pronounced 
elevation in the number observed in 24-month old mice. Such inclusions were not observed 
in age-matched Ntg mice. Scale bars A - D = 10 µm, H = 20 µm. 
 
We established primary cortical neuron cultures from C9BAC and non-transgenic 
littermate embryos. At 10 days in vitro (DIV) both nuclear foci containing sense or 
antisense C9ORF72 hexanucleotide expansion transcripts (Figure 4.5 A) and poly (GP) 
RAN-translation products could be detected (Figure 4.5B). We next tested whether 
neurons from C9BAC mice are hypersensitive to cellular stress. In a previous study, 
neurons differentiated from induced pluripotent stem cells (iPSCs) derived from FTD 
patients showed an increased sensitivity to cell death induced by inhibition of autophagy 
in vitro [87]. We treated 15 DIV primary cortical neuron cultures derived from individual 
embryos with two inhibitors of autophagy (Figure 4.5C), chloroquine and 3-
methyladenine. Both compounds increased cell death to the same degree in the C9BAC 
and Ntg neurons, as determined by an LDH assay.  
Silencing C9ORF72 transcripts and poly (DP) production in vitro  
Though lacking cognitive or motor deficits, the C9BAC mouse robustly recapitulates the 
molecular pathology of c9ALS/FTD, with readily quantifiable expression of all three 
C9ORF72 transcripts, RNA foci and at least one of the poly (DP) RAN-translation 
products. Both read-outs rely on the expression of the C9ORF72 gene transcripts. We have 
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therefore tested a gene therapy approach to silence expression of the C9ORF72 transgene 
in our C9BAC mice. We generated recombinant adeno-associated virus (rAAV) serotype 
9 expressing an artificial microRNA (miRC9) targeting exon three of human C9ORF72 
preceded by an eGFP reporter, under the transcriptional control of the CB-promoter and 
CMV-enhancer (rAAV-GFP-miRC9). For control groups, a vector expressing only the 
eGFP reporter was used (rAAV-GFP). We carried out two sets of experiments in DIV4 
primary cortical neuron cultures (Figure 4.6 D, E, F). In the first (Exp 1), individual 
cultures were generated from separate C9BAC hemizygous embryos from the same litter 
of C9BAC mice; in the second (Exp 2), all transgenic embryos from a C9BAC litter were 
pooled to generate a mixed population of cortical neurons from multiple transgenic 
embryos. In both experiments, transgene transcripts and poly (GP) were reduced by 
expression of the GFP control vector alone, in conjunction with some cell death; to account 
for this non-specific silencing, all silencing outcomes are normalized to this GFP control. 
In all experiments we consistently observed further depletion of C9ORF72 products in 
groups expressing the microRNA. Relative to the rAAV-GFP group, C9ORF72 mRNA 
transcript (Figure 4.5D) expression in individual embryo cultures (Exp 1) was decreased 
by 35% by rAAV-GFP-miRC9 (n=4, one-way ANOVA, Bonferroni’s multiple 
comparison, p<0.05), and 24% in the pooled embryo cultures in Exp 2 (not statistically 
significant; n=3, one-way ANOVA, Bonferroni’s multiple comparison). We detected 
mature miRNA only in the rAAV-GFP-miRC9 treated cultures and found that the percent 
silencing was proportional to levels of the expressed miRNA (Figure 4.5E). In two cultures 
derived from individual embryos (Exp 1), rAAV-GFP-miRC9 reduced levels of poly (GP) 
by ~60% (Fig. 3F). In mixed cultures (Exp 2), poly (GP) was reduced by 73% relative to 
45 
 
GFP. Though not significant by one-way ANOVA (n=3, Bonferroni multiple comparison 
test), we note that in Exp 2 statistical testing of the rAAV-GFP vs rAAV-GFP-miRC9 
(independent of the untreated group) detected a significant decrease in poly (GP) levels 




Figure 4.5: Silencing of C9ORF72 in C9BAC mice and primary cortical neurons. 
(A) Sense and antisense foci are detected in cultured cortical neurons of C9BAC embryos 
at 10 days in vitro (DIV). These foci were not visible following RNase treatment and were 
not detected in Ntg neurons, or by probes targeting the myotonic dystrophy associated type-
1 (CTG)n or type-2 (CCTG)n expansions (DM1 and DM2 respectively, scale bar = 5 µm). 
(B). Concentration of poly (GP) in cultured cortical neurons derived from individual 
C9BAC or Ntg littermate embryos measured by ELISA (mean±SEM, Ntg n=2, C9BAC 
n=6, unpaired t-test). (C) No significant differences were detected in the response of 
cultured cortical neurons derived from individual C9BAC and Ntg embryos to the 
autophagy inhibitors chloroquine or 3-methyladenine (two independed experiments, 
individual embryos cultured; C9BAC n=6, Ntg n=5, mean±SEM, 2-way ANOVA, 
Bonferroni’s multiple comparison, * p<0.05). (D) ddPCR analysis of all transcripts of 
C9ORF72 (Vall) relative to HPRT in two independent experiments (Exp. 1. individual 
embryos n=4, mean±SEM, one-way ANOVA, Bonferroni’s multiple comparison test, * 
p<0.05, *** p<0.001; Exp. 2. mixed embryo culture, n=3, one-way ANOVA, Bonferroni’s 
multiple comparison test *** p<0.001). (E) Levels of the mature microRNA product 
(normalized to snoRNA135) of rAAV-GFP-miRC9 trended toward correlation with 
percent silencing of C9ORF72 relative to rAAV-GFP from Exp. 1 (black) and Exp. 2 
(blue). (F) Levels of poly(GP) quantified by ELISA from primary cortical neuron cultured 
derived from two independent experiments (Exp. 1. individual embryos n=2, mean±SEM, 
one-way ANOVA; Exp. 2. mixed embryo culture, n=3, one-way ANOVA, Bonferroni’s 
multiple comparison test, ** p<0.01).  
 
Discussion 
We report here a novel line of transgenic mice that harbor a portion of the human C9ORF72 
gene with an expanded GGGGCC repeat motif. Though the mice do not develop an overt 
motor phenotype, they recapitulate distinctive histopathological features seen in 
c9ALS/FTD patients, including both sense and antisense intranuclear RNA foci and the 
presence of RAN-translated DPR proteins. These data indicate that the 300-500 GGGGCC 
repeat motifs are sufficient for the generation and deposition of abnormal tracts of RNA 
and DPR proteins but not to induce neurodegeneration. Why this is the case remains 
unclear. Possibly the pathology, seen quite clearly at the molecular level, is not sufficient 
to compromise motor neuron viability within the lifespan of the mice. Alternatively, some 
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other aspect of the model may be required to induce motor pathology. For example, if the 
pathology in humans entails sequestration of critical RNA binding proteins by intranuclear 
RNA aggregates, it is possible that these proteins are more abundant in the mouse, and thus 
less prone to be titrated to insufficiency in the RNA foci. Alternatively, it is possible that 
the DPR proteins are better tolerated in some manner in the mouse.  
Two aspects of the histological findings in these mice are intriguing. First, there were 
distinctly more cells containing sense foci than anti-sense RNA foci. This is broadly 
analogous to data from human cortex [97]. It is also conceivable that the relative paucity 
of anti-sense RNA foci reflects the structure of the human BAC in our mice, which contains 
the full 5’ expanse of the C9ORF72 locus but only extends through exons 1-6 and thus 
might lack 3’ regulatory regions necessary for generating anti-sense foci. Also, of interest 
in the C9BAC mice were age-dependent changes in the abundance of RNA foci and the 
levels of soluble RAN-translated poly (GP) proteins. Our data indicate that the numbers of 
intranuclear foci composed of C9ORF72 RNA sense transcripts declined between 10 and 
24 months, possibly reflecting an age-dependent increase in clearance of these foci, 
reduced expression of the offending transcripts with age, or loss of foci-containing cells.  
There were also age-related shifts in the properties of poly (GP) DPR proteins. In 4-month 
C9BAC mice, SDS-soluble poly (GP) species were present at a concentration comparable 
to levels detected in frontal cortex of some c9ALS patients. Soluble poly (GP) levels in 24-
month C9BAC mice were lower, a change that coincided with an increased presence of 




Finally, we note that although the C9BAC mouse does not develop a discernible abnormal 
behavioral phenotype, the histopathological and transcript variant expression profile 
matches well with that of c9ALS/FTD patients. In successful experiments in vivo and in 
vitro [88-90], the C9ORF72 expression has been reduced following treatment with 
antisense oligonucleotides (ASO). In the present study we have conducted a proof-of-
principle experiment to test whether a synthetic microRNA (miR) targeting exon 3 of 
C9ORF72 delivered by recombinant adeno-associated virus (rAAV) might offer an 
alternative therapeutic strategy. With this intervention, primary cortical neuron cultures 
from the C9BAC transgenic mice demonstrated a consistent trend towards reduced 
expression of C9ORF72 transcripts and decreased production of the poly (GP) DPR. These 
studies suggest that this strategy (AAV-mediated delivery of a synthetic miR) merits 
further investigation and that these C9BAC mice will be useful for assessing therapies that 
silence transcription or RAN translation across the expanded GGGGCC repeats or 
otherwise inhibit the formation of RNA foci and DPR proteins. Combined with accurate 
analytical techniques to quantify levels of aberrant RNA transcripts, RNA foci and DPR 
proteins, the C9BAC mouse will be of considerable use for investigating the 
pathophysiology of C9ORF72-mediated neurodegeneration and much needed therapeutic 
approaches. 
Methods 
Generation of C9ORF72 transgenic mice  
A BAC library was generated from a familial FTD/ALS patient from a C9ORF72-linked 
ALS/FTD pedigree. Transgenic animals were produced using a BAC carrying a 153.2kb 
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genomic DNA fragment including 140.5kb upstream of C9ORF72, exons 1 to exon 6 of 
the C9ORF72 gene, including part of the 3'UTR of the short isoform V1 and ~500 
GGGGCC motifs between exons 1 and 2. Mice were maintained on an SJL/B6 background. 
Circular construct injections generated 3 out of 49 positive animals; one (C9BAC) resulted 
in germline transmission. Presence of the C9BAC transgene was detected using forward 
primers 5’ TTAATT TCC TAC CCC TGC CC 3’ and reverse primers 5’ AGG CCT TGA 
CAA ATG TAG CC 3’, amplifying a 250bp fragment. F1 males used for longitudinal 
survival and behavior testing were housed individually The University of Massachusetts 
Medical School Institutional Animal Care and Use Committee approved all experiments 
involving animals.  
Motor behavior testing  
Motor function was assessed in F1 male C9BAC mice and non-transgenic (Ntg) littermates  
monthly from 3- to 24-months of age using rotarod (Med-Associates Inc., USA). Mice 
were tested three times on a 5-minute, 4-40rpm accelerating rotarod task with latency to 
fall for each individual test recorded. The mean score for each animal was used for 
statistical analysis. Limb grip strength was recorded using a digital force gauge (Mark-10, 
USA) fitted with a metal grid. Mice were placed on the grid, allowing either all paws to 
grip or forepaws only, followed by being gently pulled horizontal to the apparatus until 
grip was released. Each animal was tested 5 times for fore- or all limb grip, with peak 
strength for each recorded for statistical analysis. Data from longitudinal behavior testing 




Intruder testing  
To assess social interaction behavior, an unfamiliar 6-week-old, juvenile C57Bl6/J wild 
type mouse was introduced into the home cage of an individually housed 18-22-month-old 
male C9BAC or Ntg mouse. Direct physical interaction by the home cage male with the 
juvenile was recorded over a 5-minute period.  
 Electrophysiological recordings: Motor Unit Number Estimate  
Electrophysiological recordings were as described [3]. Motor conduction studies and motor 
unit number estimate (MUNE) were performed using a portable electrodiagnostic system 
(Cardinal Synergy). For the motor nerve conduction studies, the lowpass filter was set at 
30 HZ, and the high-pass filter was set at 10 kHZ. The nerve was stimulated with single 
square-wave pulses of 0.1-ms duration. Supramaximal responses were gradually generated, 
and maximal responses were obtained with stimulus currents <20 mA (most often <10 
mA). The distal latency, distal and proximal compound motor action potential (CMAP) 
amplitudes, distal and proximal CMAP durations (measured from onset of initial negative 
deflection to initial return to baseline), and conduction velocity were determined for each 
nerve studied. For the MUNE recordings, the incremental technique was used [4-6]. For 
electromyography potentials were recorded from several sites of the hindlimb muscles with 
a concentric needle electrode (30G) [7].  
 Electrophysiological recordings: Whole-cell cortical neuron recordings  
Brain slice preparation for electrophysiological recordings. After anesthetizing mice with 
isoflurane, brains were rapidly removed and chilled in an ice-cold sucrose solution 
containing 76mM NaCl, 25mM NaHCO3, 25mM glucose, 75mM sucrose, 2.5mM KCl, 
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1.25mM NaH2PO4, 0.5mM CaCl2, and 7mM MgSO4; pH 7.3. Acute brain slices (300 
µm) were prepared (VT1200s, Leica) tilted anteriorally 15° in the coronal plane. Slices 
were then incubated in warm (32-35°C) sucrose solution for 30 minutes and then 
transferred to warm (32-34°C) artificial cerebrospinal fluid (aCSF) composed of 125mM 
NaCl, 26mM NaHCO3, 2.5mM KCl, 1.25mM NaH2PO4, 1mM MgSO4-7H2O, 20mM D-
(+)-glucose, 2mM CaCl2-2H2O, 0.4mM ascorbic acid, 2mM pyruvic acid, and 4mM L-
(+)-lactic acid; pH 7.3, 315 mOsm. All solutions were continuously bubbled with 95% 
O2/5% CO2. Slices were transferred to a submersion chamber on an upright microscope 
(Zeiss AxioExaminer, 5x and 40x objectives lenses, 0.16 and 1.015 NA respectively) and 
continuously superfused (2-4 ml/min) with warm oxygenated aCSF (32-34°C). Neurons 
were visualized with a digital camera (Sensicam QE, Cooke) using transmitted light with 
infrared differential interference contrast optics. PT-type neurons were distinguished by 
their large, pyramidal shaped cell bodies and thick apical dendrite. IT-type neurons were 
identified by their small oval shaped cell bodies and a thinner apical dendrite. The identity 
of each cell was further confirmed by analyzing its intrinsic membrane properties including 
sag amplitude, input resistance, and response to current injections as these are significantly 
different between the two types (Table 4.1). Glass recording electrodes (2-4 MΩ) were 
filled with internal solution containing 2.7mM KCl, 120mM KMeSO4, 9mM HEPES, 
0.18mM EGTA, 4mM MgATP, 0.3mM NaGTP, 20mM phosphocreatine (Na), pH 7.3, 295 
mOsm with 0.25% biocytin. Whole-cell patch clamp recordings were obtained using a 
Multiclamp 700B amplifier (Molecular Devices) and digitized using an ITC-18 
(Instrutech) controlled by custom software written in Igor Pro (Wavemetrics). All signals 
were low-pass filtered at 10 kHz and sampled at 20-100 kHz. The access resistance 
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averaged 9.6 ± 0.7 MΩ. Cells with an Ra of 30 MΩ or more were eliminated from the 
analysis. The Ra was not compensated during recordings. To measure intrinsic excitability, 
cells were recorded in the presence of the synaptic blockers: NBQX (AMPA receptor 
antagonist, 5 µM), CPP (NMDA receptor antagonist, 5 µM), and SR95531 (GABAA 
receptor antagonist, 10 µM, all from Tocris). The resting membrane potential (RMP) was 
measured after whole-cell configuration was achieved. Neurons exhibiting an RMP greater 
than -60 mV were excluded from the analysis. The input resistance was determined by 
measuring the voltage change in response to hyperpolarizing current steps and the 
amplitude of the sag response was calculated as the difference in minimum potential at the 
early phase of a hyperpolarizing current step and the steady-state potential at the end of the 
1 s step. The current-spike frequency relationship was measured with depolarizing current 
steps (1 s) applied in 40 pA increments. The rheobase was measured similarly using 2 pA 
increments. Action potential properties were measured from single spikes evoked by 
rheobase current injections. The amplitude of the afterhyperpolarizations (AHP) was 
measured from the spike threshold to the minimum membrane potential during the AHP.  
 All data analyses were performed in Igor Pro (Wavemetrics), Excel (Microsoft), and 
Origin (OriginLab). The Mann-Whitney test was used to compare the rheobase, input 
resistance, RMP, sag amplitude, and spike properties recorded from control and C9BAC 
mice. A 2-way ANOVA with Bonferroni correction was used to test statistical differences 
in the current-frequency relationships between groups.  
 Electrophysiological characteristics were tested in the presence of blockers of 
glutamatergic and GABAergic synaptic transmission (NBQX, 5 µM, AMPA receptor 
antagonist; CPP, 5 µM, NMDA receptor antagonist; and SR95531, 10 µM, GABAA 
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receptor antagonist). We found no significant differences in the resting membrane 
potential, input resistance, sag amplitude, or action potential properties between control 
and C9BAC neurons for PT- or IT-type neurons. To compare the intrinsic excitability of 
neurons we evoked action potentials with a series of depolarizing current steps. We found 
that neither neuron type showed a significant difference in the rheobase or the current-spike 
frequency relationship between control and mutant neurons. 
Table 4.1. Electrophysiological properties of layer V neurons in cortical slice cultures 




Primary cortical culture and drug susceptibility analysis  
Cortical neurons were harvested and cultured from individual E15 embryos generated from 
C9BAC x WT crosses. For Experiment 2 of the knock down experiment, all transgenic 
embryos from a litter were maintained in Hibernate media (Thermo-Fischer) at 4C for 
approximately 5 hours whilst genotypes were established and were subsequently pooled 
and cultured. Cells from individual embryos were seeded onto poly-L-ornithine coated 
plates or cc2 coated chamber slides at 50,000/cm2. Neurons were maintained in neurobasal 
media supplemented with Glutamax, B27, and pen/strep (all from Invitrogen) with one half 
of the media replaced every 3-4 days. To inhibit glial cell proliferation, the anti-mitotic 
AraC (1 µM, Sigma) was added at DIV3 to the cultures used for assessment of neuronal 
susceptibility to cytotoxic insult. Susceptibility of DIV15 neurons to 24 hr treatment with 
chloroquine (CQ) and 3-methyladenine (3-MA) (all from Sigma) at the indicated doses 
was assessed by lactate dehydrogenase release assay (Promega).  
 For treatment with silencing vectors, cells were plated in 6-well dishes at 50,000/cm2 and 
fed every fourth day. At day in vitro four, 18µl of rAAV-GFP (titre = 1.7 E13 viral particles 
/ml) or rAAV-GFP-miRC9 (titre = 1.2 E13 vp/ml) were added to 1.5 ml of media and the 
cultures were maintained for a further 6-days. For protein analysis, cells were scrapped 
from the well, washed with PBS and pelleted. For quantification of C9ORF72 transcripts, 
total RNA was collected using Trizol as per the manufacturer’s instructions.  
RT-qPCR  
Frozen tissue samples were homogenized in a gentleMACS Dissociator (Miltenyi Biotec, 
USA) before total RNA extraction with Trizol (Life Technologies). Reverse transcription 
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to cDNA was performed using random hexamers and MultiScribe reverse transcriptase 
(High capacity RNAto-cDNA Kit, Life Technologies). Real time quantitative PCR was 
performed on an Applied biosystems StepOnePlus Real-Time PCR system using the Fast 
TaqMan Advanced master mix following the manufacturer instructions. A commercial 
mouse HPRT assay (Life Technologies, Mm01545399_m1) was used as an endogenous 
control. Data was analyzed using the Delta Delta CT method. Probes used to detect each 
variant are as follows: Vall commercial assay (Life Technologies Hs00376619_m1), probe 
AGAATATGGATGCATAAGGAAAGAC; V1 commercial assay (Life Technologies 
Hs00331877_m1), probe AGATGACGCTTGATATCTCCGGAGC (Life Technologies 
assay, # Hs00331877_m1); V2 forward primer AGGCGGTGGCGAGTGGATA, reverse 
primer TTGGAGCCCAAATGTGCCTTA, probe CGACTCTTTGCCCACCG; V3 
forward primer GCGGGGTCTAGCAAGAGCAG, reverse primer 
TTGGAGCCCAAATGTGCCTTA, probe CCACCGCCATCTC. Position of probes is 
shown in Figure 4.1D 
Droplet Digital PCR (ddPCR) 
To assess the absolute concentration of transcripts, droplet digital PCR (ddPCR Bio-rad) 
was performed on both mouse samples and human frontal cortex samples from 
c9ALS/FTD (age, 61.3±4.5 years; sex, 3 male, 1 female), SOD1 fALS (age, 46.8±3.5 
years; sex, 3 male, 1 female), and non-neurological disease control patients (age, 62.8±7.2 
years; sex, 2 male, 2 female). Mouse brain tissue was obtained from 2-month-old C9BAC 
transgenic mice (n=4) and wild type littermate controls (n=4). Total RNA was extracted 
by homogenization in Trizol (Life Technologies, USA) in a gentleMACS Dissociator 
(Miltenyi Biotec). cDNA was synthesized from 2µg/µl RNA using High-Capacity RNA-
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to-cDNA Kit (Life Technologies, USA). For reactions, cDNA was diluted 1:5 in nuclease 
free water. 20µl reactions solution were prepared for each sample, containing ddPCR 
Supermix for Probes (Bio-Rad, USA), 2µl of diluted cDNA, 1µl of each primer and 1µl 
C9ORF72 variant specific FAM-labeled probes. 20µl samples and 70µl of ddPCR-oil was 
loaded into a DG8 cartridge (Bio-Rad, USA) and droplet generated using the QX100 
droplet generator (Bio-Rad, USA). PCR was then run using 40µl of the sample droplet 
solution on a standard thermocycler (Eppendorf, USA), and absolute quantification 
calculated using the QX100 ddPCR reader (Bio-Rad, USA). Primers and probes used to 
detect each variant are as follows: C9ORF72 all variants (Vall) forward primer 
ATCCTTCGAAATGCAGAGAG, Vall reverse primer 
TGAAGTGGGAGGTAGAAACT, Vall probe CTGGAATGGGGATCGCAGCACA; 
C9ORF72 variant 1 (NM_145005.6) commercial assay, probe 
AGATGACGCTTGATATCTCCGGAGC (Life Technologies assay, # Hs00331877_m1); 
C9ORF72 variant 2 (NM_018325.4) forward primer AGGCGGTGGCGAGTGGATA, 
reverse primer TTGGAGCCCAAATGTGCCTTA, probe CGACTCTTTGCCCACCG; 
C9ORF72 variant 3 (NM_001256054.2) forward primer 
GCGGGGTCTAGCAAGAGCAG, reverse primer TTGGAGCCCAAATGTGCCTTA, 
probe CCACCGCCATCTC. Position of probes is shown in Figure S1A. Endogenous 
mouse C9ORF72 (Rik_3110043O21, NM_001081343.1) commercial assay, probe 
GCAGCGGCGAGTGGCTATTGCAAGC (Life Technologies Mm01216837_m1). 
Probes for detection of RNAseq candidate genes were Biorad PrimePCR ddPCR 
Expression Probe Assays: Cbln4, Mouse dMmuCPE5122216 DDPCR GEX FAM ASSAY 
500R; Dpp6, Mouse dMmuCPE5105460 DDPCR GEX FAM ASSAY 500R; Kcnq3, 
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Mouse dMmuCPE5117670 DDPCR GEX FAM ASSAY 500R; Nedd4l, Mouse 
dMmuCPE5124352 DDPCR GEX FAM ASSAY 500R; Hprt, Mouse dMmuCPE5095493. 
For detection of the mature microRNA product of rAAV-GFP-miRC9, RNA was diluted 
to 10ng/µl and the Taqman microRNA reverse transcription kit (Life Technologies assay 
#4366597) was used to generate cDNA. A custom Taqman small RNA assay was designed 
to detect the mature microRNA product of rAAV-GFP-miRC9 (probe 
ATAGCACCACTCTCTGCATT, Life Technologies). Control RNA snoRNA135 was 
detected using a commercially available probe (Life Techonolgies # 4427975).  
Western Blotting  
Tissue samples were lysed in RIPA buffer containing Complete Protease Inhibitor Tablets 
(Roche, USA) using a Dounce homogenizer followed by sonication on ice. Samples were 
centrifuged for 10 min at 14,000×g at 4˚C and the supernatant collected. Total protein 
concentration was quantified using the BCA Protein Assay kit (Thermo, USA). Five 
micrograms of protein lysate were run on Novex 12% Tris-Glycine gels (Life 
Technologies, (USA) using Tris-Glycine SDS running buffer (Invitrogen, USA). Proteins 
were transferred to nitrocellulose membranes using an i-Blot transfer device (Invitrogen, 
USA). Membranes were blocked for 1 hour at room temperature with Odyssey Blocking 
Buffer (LiCor, USA) before being probed overnight with primary antibodies. IR labeled 
secondary antibodies (LiCor, USA) were applied, and blots visualized using the Odyssey 
Infrared imaging system (LiCor, USA).  
 Poly (GP) immunoassay  
An immunoassay for poly (GP) dipeptides was performed as published [36]. Tissues were 
homogenized in 10% (w/v) buffer containing 50 mM Tris–HCl, pH 7.4, 300 mM NaCl, 
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1% Triton X-100, 5 mM EDTA, as well as protease (EMD Millipore, USA) and 
phosphatase inhibitors (Sigma-Aldrich, USA). Sodium dodecyl sulfate was then added to 
a portion of homogenate at a final concentration of 2% and samples were vortexed, re-
homogenized and sonicated. After sonication, samples were centrifuged at 16,000 x g for 
20 min and supernatants collected. The protein concentration of lysates was determined by 
BCA assay (Thermo Scientific, USA). Poly (GP) levels in lysates were measured using a 
previously described sandwich immunoassay that utilizes Meso Scale Discovery (MSD) 
electrochemiluminescence detection technology [9]. Lysates were diluted in Tris-buffered 
saline (TBS) and tested using 35µg of protein per well in duplicate wells. Serial dilutions 
of recombinant (GP)8 in TBS were used to prepare the standard curve. Response values 
corresponding to the intensity of emitted light upon electrochemical stimulation of the 
assay plate using the MSD QUICKPLEX SQ120 were acquired and background corrected 
using the average response from lysates obtained from non-transgenic mice prior to 
interpolation of poly (GP) levels using the standard curve.  
Antibodies  
Primary antibodies: Goat anti-beta Actin (Abcam, USA), Rabbit anti-Actin (Sigma, USA), 
Rabbit anti-GFAP (IHC 1:500 Abcam, USA), Rabbit anti-Beta-III-tubulin (IHC 1:1000, 
Covance, USA), rabbit anti-ChAT (IHC 1:100, Abcam, USA), rabbit anti-cleaved caspase-
3 (AB3623, Millipore, (USA), Rabbit anti-IBA1 (IHC 1:1000, WAKO, Japan), mouse anti-
NF200 (IHC 1:100, clone SMI32 Abcam, USA), Guinea Pig anti-P62 (Progen, Germany), 
Rabbit anti-Synaptophysin (IHC 1:5,Life Technologies, USA), Rabbit anti-TDP43 (IHC 
1:500 Proteintech, USA), Rabbit anti-TDP43 N-terminus (IHC 1:500, kind gift from 
Zuoshang Xu) [8]. Secondary antibodies: Donkey antiRabbit Alexa Fluor-488 (IHC 
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1:1000, Life Technologies, USA), Donkey anti-Mouse Alexa Fluor488 (IHC 1:1000, Life 
Technologies, USA), Biotinylated Goat anti-Rabbit (IHC 1:1000, Vector Labs, USA), 
Biotinylated Horse anti-Mouse (IHC 1:1000, Vector Labs, USA). Stated dilutions are for 
immunohistochemistry or immunofluorescent staining. For western blotting all antibodies 
were used at the manufacturers recommended dilution. 
Human tissues 
Frozen frontal cortex tissues analyzed for poly (GP) via ELISA assay were obtained from 
the Brain Bank for Neurodegenerative Disorders at Mayo Clinic in Jacksonville, Florida, 
which operates under protocols approved by the Mayo Clinic Institutional Review Board, 
in accordance with Health Insurance Portability and Accountability Act guidelines. Frozen 
frontal cortex tissues for ddPCR were obtained from the UCLA Human Brain and Spinal 
Fluid Resource center and University of Massachusetts and were collected under protocols 
approved by the UMMS Institutional Review Board. 
MicroRNA design and cloning  
 A 22-nucleotide artificial miRNA (targeting sequence AATGCAGAGAGTGGTGCTATA) in exon 
3 of the C9ORF72 gene was designed and cloned into the miR-155 backbone. This 
synthetic miR was cloned into the 3’UTR of a GFP encoding AAV proviral plasmid under 
the control of the chicken beta actin (CB) promoter with a CMV enhancer. The plasmid 
was used to package pseudotyped rAAV9 vectors. Plasmids and vectors can be requested 





RNA fluorescence in situ hybridization (FISH)  
Cryosections (20µm) were fixed in 4% PFA for 20 min, followed by five 20 min washes 
in DEPC-treated PBS containing 0.1% Tween-20. Sections were permeabilized with 0.5% 
Triton X100 before pre-hybridization for 1 hour at 55C in 2x saline sodium citrate (SSC) 
containing 0.1% Tween-20, 50% of dextran sulfate, 50µg/ml heparin, 1mg/ml heat-
denatured salmon sperm and 40% formamide. For hybridization, samples were incubated 
overnight at 55°C in pre-hybridization buffer containing a 1:500 dilution of 1µM DNA 
probe (Sense: (GGCCCC)4, Antisense: (GGGGCC)4, DM1 (GAC)6, DM2 (GGAC)6) 5’ 
end Cy3 labeled. After hybridization the samples were washed in a pre-warmed mix 1:1 of 
hybridization buffer and 2XSSC for 30 min at 55°C. Followed by 2 washes in pre-warmed 
2XSSC for 30 min at 55°C, 2 washes with 0.2XSSC for 30 min at 55°C, and 2 washes in 
1XPBS+ 0.1% Tween-20 for 30 min, at room temperature. Sections were stained with 
DAPI (1:10,000) for 5 min, and autofluorescence quenched by incubation in 0.5% Sudan 
Black in 70% ethanol for 7 min. Glass coverslips were mounted using Lab Vision 
PermaFluor (Thermo Scientific Shandon, USA)  
For FISH coupled with fluorescent immunohistochemistry, after probe hybridization and 
washes, sections were blocked by incubation with 10% serum donkey-serum in PBS with 
0.4% TritonX100 for 1hr, followed by incubation with primary antibodies diluted in 
blocking solution overnight at 4°C. After PBS washes, sections were incubated with an 
Alexa Fluor-488 conjugated secondary antibodies diluted 1:1000 in PBS for 1hr at room 
temperature. Autofluorescence was blocked by submersion in 0.5% Sudan black B in 70% 
ethanol for 7 mins, followed by staining of nuclei by incubation in DAPI (1:10,000). Glass 
coverslips were applied using ImmuMount (Thermo Scientific Shandon, USA). For 
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quantification of motor cortex external pyramidal layer nuclei 8-10 10µm z-stack images 
were collected from three sections per animal. Lumbar spinal motor neurons were 
identified by large nuclei, with 20-40 nuclei assessed from 8 sections per animal. The 
number of foci per nucleus was counted using ImageJ, with each nucleus categorized as 
containing 0 foci, 1-5 foci, 6-10 foci or >10.  
Immunohistochemistry  
For DAB immunohistochemistry, 8µm paraffin sections of 4% paraformaldehyde or 
formalin fixed sagittal brain or coronal spinal cord were dewaxed in xylene and brought to 
water through a graded alcohol series. Endogenous peroxidase activity was quenched by 
incubation in a solution of 3% H2O2 in 10% methanol for 20mins at 4oC. Non-specific 
antibody binding was blocked by incubation with 10% serum goat-serum in PBS with 0.4% 
TritonX-100 for 1hr. Primary antibodies were diluted in blocking solution and sections 
incubated overnight at 4oC. Following washing, biotinylated secondary antibodies diluted 
in PBS were applied for 1hr at room temperature. After washing sections were incubated 
with an avatin-HRP solution (Vector labs, USA) for 30 mins. Peroxidase labeling was 
visualized with chromogen solution 3, 3’diaminobenzidine (Sigma-Aldrich, USA). 
Sections were counterstained with hemotoxylin, dehydrated and a glass coverslip applied 
using DPX. For fluorescent immunohistochemistry, Alexa Fluor-488 or -546 conjugated 
secondary antibodies diluted in PBS for 1hr at room temperature. Autofluorescence was 
blocked by submersion in 0.5% Sudan black B in 70% ethanol for 7 mins, followed by 
staining of nuclei by incubation in DAPI (1:10,000). Glass coverslips were applied using 
ImmuMount (Thermo Scientific Shandon, USA).  
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Immunohistochemistry for poly (GP)  
For immunostaining of poly (GP) dipeptide repeats, eight micron-thick sagittal slices of 
mouse hemibrain were cut from formalin-fixed, paraffin-embedded blocks and mounted 
on glass slides. After drying, slides were deparaffinized and rehydrated in xylene and 
alcohol washes before being steamed for 30 min in 1X Tris–EDTA (pH 9) buffer solution 
for antigen retrieval. All slides were processed on a Dako Autostainer with the Dako 
EnVision™+ system and 3'3diaminobenzidine chromogen. After staining with anti-GP 
serum (1:10,000) [10], slides were counterstained with Lerner hematoxylin and 
coverslipped with Cytoseal permanent mounting media.  
Immunostaining for neuromuscular junctions  
Mice were perfused first with a PBS prewash for 2mins followed by 4% PFA in PBS for 
5mins. Gastrocnemius muscles were dissected and post-fixed overnight in 1.5% PFA at 
4oC. Muscles were washed in PBS, incubated in 25% sucrose in PBS overnight at 4oC and 
embedded longitudinally in OCT (Thermo Scientific Shandon, USA). 35µm cryosections 
were collected, mounted on glass slides and stored at -80°C until use. Frozen sections were 
air dried for 30mins and washed with PBS, followed by blocking in 10% goat-serum in 
10% tritonX100 for 3hrs. Sections were incubated for 24hrs at 4°C in a primary antibody 
solution containing a cocktail of rabbit anti-synaptophysin (1:5, Invitrogen) and rabbit anti-
Neuronal Class III BetaTubulin (1:1000, Covance, USA) diluted in blocking solution. 
Following washing sections were incubated in PBS containing secondary antibodies Alexa 
Fluor-488 conjugated donkey antiRabbit (1:500) and Alexa Fluor-555 conjugated alpha-
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bungarotoxin (1:500) overnight at 4°C. Sections were washed, counterstained with DAPI 
and coverslips mounted using Immumount (Thermo Scientific Shandon, USA).  
 For quantification, 15µm z-stacks were collected at 40x magnification from two non-
adjacent section of gastrocnemius muscle. Approximately 150-200 NMJs were assessed 
per animal. NMJs were categorized as; innervated, with complete overlap of green and red 
signal; partial, with incomplete overlap of green and red signals; denervated, with no 
overlap of green and red signals.  
Semi-thin sectioning, toluidine blue staining and axon quantification Mice were fixed by 
perfusion with 4% PFA in PBS and L5 ventral nerve roots dissected. Following overnight 
fixation in 2.5% gluteraldehyde in 0.1M cacodylate buffer nerves were washed and further 
post-fixed in 1% osmium tetroxide for 1hr. Samples were dehydrated through a graded 
ethanol series into propylene oxide, followed by overnight infiltration in 1:1 solution of 
propylene oxide and SPI-Pon 812 resin mixture. Following 3hrs of incubation in SPI Pon 
812 resin samples were polymerized at 68°C for 4 days. Nerves were trimmed, reoriented 
and 0.6µm semi-thin sections collected. Semi-thin sections were mounted on glass slides, 
followed incubation in toluidine blue on a hot plate for 30 seconds. Following washing, 
sections were dried, and a coverslip mounted using DPX. Sections were imaged and axon 
number and diameter quantified using ImageJ.  
Dendritic spine analysis  
Brains from 18-month-old C9BAC and Ntg littermate controls (n=3 per genotype) were 
prepared for Golgi staining using the FD Rapid GolgiStain Kit (FD NeuroTechnologies 
Inc, USA) as per the manufacturer’s instructions. Brains were embedded in low gelling 
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temperature agarose (Boston BioProducts, USA) and 100µm coronal sections were 
collected using a Leica VT1000 S vibratome (Leica Microsystems Inc, USA). Apical 
dendrites of layer 2-3 pyramidal neurons were imaged at 60x magnification with 1.5x 
optical zoom in the prefrontal cortex (3-12 per brain). Number of spines was counted along 
a recorded length of dendrite (total length of dendrite sampled: Ntg = 1943.5µm, C9BAC 
= 1266.1µm). Density of spines per dendrite was calculated by dividing the number of 
spines by the length of dendrite sampled.  
 RNAseq  
Total RNA was extracted from dissected frontal cortex of six months old C9BAC and their 
Ntg littermate controls by Trizol (Life Technologies). 4µg of high-quality total RNA was 
treated with RiboZero magnetic beads (Epicentre) to remove most of the ribosomal RNA 
(rRNA). rRNA depleted total RNA was then treated with Turbo DNAse 1 (Ambion) for 30 
min at 37°C to remove possible contamination from genomic DNA. Resulting RNA was 
purified with RNA clean and Concentrator 5 (Zymo Research), removing RNA fragments 
shorter than 200 nt and tRNA. Strand-specific libraries were then prepared as described 
[11]. Validation of cDNA libraries fragment size was performed using an Agilent 
Technologies 2100 Bioanalyzer. Four barcoded samples were pooled in a single lane and 
sequenced as 100nt paired-end reads on an Illumina HiSeq 2000 instrument. RNA seq 
generated greater than 34 million clean reads for each sample. Using TopHAT 2, at least 
75% of this total clean read mapped at a single location of the mouse reference genome 
(mm10) for each replicate sample. RNA seq reads were then aligned to mouse reference 
transcripts and their abundance was estimated using RSEM software workflow (RSEM 
parameters: --bowtie-e 70 --bowtie-n 200 --forward-prob 0) [12]. Normalization and 
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differential expression gene analysis was performed with DEseq2 software package, based 
on the negative binomial model on R/bioconductor statistical framework [13]. RNAseq 






Artificial microRNA silences C9ORF72 variants and 
 decreases toxic dipeptides in vivo 
Introduction  
Amyotrophic lateral sclerosis (ALS), is a lethal neurodegenerative disease that affects 
approximately 2 in every 100,000 persons worldwide [1]. Patients suffering from this 
disease have an average life expectancy of 2-5 years after symptom onset. They develop 
progressive muscle wasting and shortness of breath, ultimately losing their ability to 
move freely or breathe on their own [3]. Although ALS was first described in the early 
1800’s as a motor neuron disease, the root cause or prediction of a degeneration pattern 
still remains to be identified. [1,2]  
Recently two independent groups [8, 9] conducting genomics studies of samples from 
patients diagnosed with ALS and frontotemporal dementia (FTD), found an expanded 
hexanucleotide repeat expansion (HRE) of (GGGGCC) located in the intronic region of 
chromosome 9 open reading frame 72 (C9ORF72). These expanded repeats, ranging 
from 23-30 repeats in healthy individuals to hundreds or thousands in ALS patients, vary 
in number depending on the tissue. So far, the most extensive number of repeats are 
observed in the brain. [8, 9]. To date, C9ORF72 HRE accounts for the majority of 
familial (FALS) and (FTD) cases with known origin [8, 9].  
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Three main splice variants have been annotated by NCBI as the major products of the 
C9ORF72 gene: Variant 1 (NM_145005.5), Variant 2 (NM_018325.3), and Variant 3 
(NM_001256054.1). Variants 1 and 3 containing the expansion are the least abundant, in 
contrast to V2, which is the more abundant variant. While the function of the C9ORF72 
protein isoforms remains to be determined, they have been linked to endosomal trafficking 
and nucleocytoplasmic transport [11-13]. 
The presence of the HRE causes a series of consequential effects including an overall 
reduction of C9ORF72 mRNA, an accumulation of C9ORF72 sense and antisense 
transcripts resulting in nuclear RNA foci, and the presence of long dipeptide chains 
generated by repeat-associated non-ATG translation (RAN) in the cytoplasm. [11, 14] 
These findings led to three hypotheses on the pathogenesis of C9ORF72: (1) 
Haploinsufficiency, where decreased levels of mRNA lead to insufficient gene product 
[15-17]; (2) RNA gain-of-function, where the expanded RNA foci sequester RNA binding 
and/or splicing proteins [18]; and (3) RAN translation of the hexanucleotide expansion, in 
which all reading frames of both a sense and antisense RNA is translated, generating toxic 
poly-dipeptide protein inclusions [19-22]. Glycine Proline (GP) dipeptides are the most 
abundant because they are translated from both sense and antisense reading frames, and 
the Arginine-containing dipeptides, Glycine Arginine (GR) and Proline Arginine (PR), are 
the most toxic to the cells when overexpressed in vitro and in drosophila fly models [12, 
14]. A recent mouse model designed to overexpress the poly (PR) dipeptide was used to 
show that this sole dipeptide was bound to DNA within heterochromatin, resulting in 
cellular aberrations [13]. In addition, a series of recent publications have proposed that the 
presence of the expansion may disrupt nucleocytoplasmic transport [11, 12, 14, 23, 24], as 
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well cause epigenetic aberrations that result in age-dependent gene repression seen in both 
patients and a BAC transgenic model [98]. While the main cause for motor neuron death 
is still unclear, it may simply be the result of several of these molecular hallmarks 
simultaneously compounding and overwhelming the cell.  
Because the majority of ALS cases are sporadic and only ten percent are familial, finding 
an effective therapeutic strategy has been challenging. As previously mentioned in 
CHAPTER II, mainly two FDA approved medications are accessible, providing minor 
benefits to qualified patients [26, 27]. Thus, the need for a more effective and sustained 
therapeutic approach. We developed an approach using RNA interference (RNAi) 
molecules to target C9ORF72 for post-transcriptional silencing using recombinant 
adeno associated vectors (AAV) as a means for delivery.  
We hypothesize that AAV artificial microRNA (amiR) mediated silencing of C9ORF72 
would decrease mRNA, protein and the cytoplasmic misspliced C9ORF72 resulting in the 
reduction of toxic dipeptides. Several amiRs were designed to target all three variants of 
C9ORF72, knowing that microRNAs acting in the cytoplasm as post-transcriptional gene 
repressors will most likely not affect the nuclear RNA aggregates (foci). After screening, 
the best amiR candidate was packaged into an AAV9 vector for in vitro and in vivo delivery 
to neonate and adult mice through various injection routes. We demonstrate that AAV9 
mediated delivery of amiR against C9ORF72 effectively leads to a decrease of mRNA, 
protein, and more importantly, the most abundant dipeptide (GP) in the brain and spinal 
cords of C9ORF72 BAC112 transgenic mice [99]. Moreover, these findings offer a 





Newly designed artificial microRNAs target C9ORF72 variants for silencing  
Because the C9ORF72-HRE is the major mutation linked to ALS, targeting it for silencing 
is a practical approach to ameliorate the molecular hallmarks caused by the HRE. To this 
end, we designed four different artificial microRNAs (amiRs) that perfectly match areas 
within the C9ORF72 gene. The constructs were cloned into two different plasmids. The 
first with a (Pol II) Chicken B-Actin promoter, and the second with a stronger (Pol III) H1 
promoter, both containing enhanced Green Fluorescent Protein (eGFP) and ITR flanks 
(Figure 5.1A) 
The target location for each amiR is depicted in Figure 5.1B and Table 5.1 lists the amiR 
sequences. The amiRs were screened in HEK293T cells, and mRNA levels for each variant 
were evaluated by quantitative Droplet Digital PCR (ddPCR). The results were graphed as 
ratios of each variant to human endogenous HPRT levels and normalized to the GFP 
control (Figure 5.1C). After the selection process of amiRC9 and based on published data 
from Pfister, 2017 [100], we anticipated that the weaker CB promoter would not be strong 
enough for in vivo experiments in a mouse model with multiple copies of the transgene. To 
overcome this obstacle, we moved forward to the in vivo experiments using only the H1-
amiRC9 construct packaged in AAV9. 
H1-amiRC9 silences C9ORF72 in vitro  
Prior to validating our candidate in vivo, we first sought to assess silencing actiity of the 
packaged AAV9-H1-amiRC9 in primary cortical cultures from the C9ORF72-BAC112 
mouse model [99, 101]. Cells were dissected and plated as previously described [102]. Two 
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independent cultures were transduced with GFP control vector, a PBS-mock control, and 
the H1-amiRC9 vector at day in vitro four (DIV4) at a MOI of 50,000 vector particles and 
collected at DIV10, the transduction efficiency was visually assessed by GFP fluorescence 
of ~70% (Figure 5.1D). Total RNA extraction followed by ddPCR quantification indicated 
a significant decrease for each C9ORF72 mRNA variant (Figure 5.1E).  
To confirm that C9ORF72 silencing was the result of post transcriptional regulation of 
gene expression by amiRC9, we designed a custom microRNA assay to quantify the mature 
form of amiRC9 levels by ddPCR. (Figure 5.1F) As expected, only treated samples had 
detectable levels of amiRC9. In addition to detecting amiRC9, we wanted to compare the 
expression levels to other endogenous miRs. Henceforth, we assayed for the presence of 
microRNA128a, a miR shown to be highly expressed in the brain [103, 104] as a guide for 
comparison. Results show that in treated samples the levels of miR128a are 19-25 times 
higher than the levels of amiRC9. Nonetheless, the high levels of miR128a detected 
provide insight that although amiRC9 levels are lower they have a significant biological 
effect and are most likely not saturating the RNAi pathway. 
In CHAPTER IV we had similarly used AAV mediated amiRC9 driven by a Pol II CB 
promoter, in primary cultures from the BAC we were characterizing. We showed that 
amiRC9 decreased C9ORF72 mRNA and the most abundant poly GP depeptide [102]. To 
determine if we could attain a similar reduction in a second mouse model (BAC112) 
containting a non-truncated version of the gene, we repeated said experiment and 
quantified the GP levels in treated and control samples. Notably, an ELISA assay showed 
the GP dipeptides were significantly lower compared to controls (Figure 5.1G), thereby 
further validating previous results from our group [102].  
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While microRNAs primarily act in the cytoplasm [80, 105, 106], we suspected based on a 
some publications [107-109], that they could be shuttled back into the nucleus and decrease 
the number of RNA foci[23]. To test this, we used fluorescent in situ hybridization (FISH) 
to detect sense foci. Multiple 4-well chamber slides were scored for foci number per 
nucleus (Figure 5.1H). Quantification revealed no significant differences in foci presence 






Figure 5.1: Artificial microRNA plasmid constructs, HEK293T screening, microRNA 
silencing validation in cortical primary cultures from BAC112 transgenic model  
(A) Schematic of the artificial microRNA plasmid constructs: The first plasmid was used 
for preliminary screening in HEK293T and the second for further experiments in vivo 1.) 
Chicken beta actin promoter driving enhanced Green Fluorescent Protein (eGFP) and the 
artificial microRNA, followed by a PolyA tail and flanked by inverted terminal repeats 
(ITRs). 2.) H1 promoter driving the expression of the artificial microRNA followed by a 
CBA promoter driving eGFP a PolyA tail and flanking ITRs. (B) Target location of each 
artificial microRNA: amiRs labeled by the nucleotide target position in regard to each 
variant. (C) Screening of microRNAs in human HEK293T cell line.: HEK293T cells were 
transfected with 4 artificial microRNA plasmids driven by CBA promoter 1.) Digital PCR 
analysis of expression of each individual variant V1, V2, V3 as well an assay detecting all 
variants jointly Vall, normalized to Human HPRT and in reference to GFP control. Top 
silencing amiRC9 marked with a black arrow (mean ±SEM, n=3, biological replicates, 
Student-T test (p ≥0.05 not significant; p* 0.01-0.05; p** 0.001-0.01; p*** 0.0001-0.001; 
p****<0.0001). (D) Primary culture timeline: Male homozygous mice were crossed with 
Wild Type female C57/BL6 mice. Cortical neurons were dissected from multiple embryos 
at embryonic day 15, pooled and plated at 50,000cells/cm2. Infected with each vector at 
day in vitro 4 (DIV4) at a MOI of 50,000 AAV, in 3-5 technical replicates per condition 
and collected at (DIV10). (E) Digital PCR analysis of expression of each individual variant 
V1, V2, V3 as well an assay detecting all variants jointly Vall, normalized to mouse HPRT 
and in reference to GFP control. amiRC9 effectively decreases each variant by~50% in 2 
independent experiments with 3-4 technical replicates each. (mean ±SEM, n=2, biological 
replicates, Student-T test (p* 0.01-0.05; p** 0.001-0.01; p*** 0.0001-0.001; 
p****<0.0001) (F) Detection of mature amiRC9 product, ratio to small nuclear RNA135. 
(Mean ±SEM), and compared to endogenous microRNA128a, this miR is highly expressed 
in the brain. (G) Concentration of poly (GP) measured by Elisa in mixed cortical neurons 
from the same 2 biological experiments in (E) consistent decrease in treated samples (Mean 
±SEM, n=2, biological experiments, Student-T test (p** 0.001-0.01; p*** 0.0001-0.001) 
(H) Fluorescent in situ hybridization quantification for the sense foci in 4 well chamber 
slides from the second set of primary cultures (Exp2). The graph shows quantification of 
2-3 chambers with ~300 cells counted. Grouped into cells with 1-10 foci, 11-40 or greater 









Striatal brain injections silence C9ORF72 variants in vivo  
Since the discovery of C9ORF72, a variety of transgenic mouse models were generated by 
multiple groups [13, 99, 101, 102, 110] with each model differing with respect to mouse 
background, expansion size, transgene insertion site, copy number and C9ORF72 
expression levels. These mouse models mostly recapitulate the human molecular hallmarks 
of RNA foci and toxic dipeptides of C9ORF72-linked ALS, but do not recapitulate the loss 
of motor function. Moving forward with the in vivo studies, we used the non-truncated 
transgenic mouse model BAC112 from O’Rourke [99], available at Jackson Laboratories. 
This mouse model, with a C57BL/6 background and containing the full-length human 
C9ORF72 gene and an expansion that ranges from 100-1,000 repeats, recapitulates the 
pathological aspects of the disease-producing abundant RNA foci and poly-dipeptides. 
Heterozygous mice have ~16-20 copies of the transgene and homozygous ~38-40 copies 
[101] (Figure 5.2 A) 
To determine in vivo efficacy of the vector, we first delivered our AAV9-H1-amiRC9 
vector into adult heterozygous mice via tail vein injection. Two weeks post injection, liver 
tissue was collected and analyzed for mRNA silencing by ddPCR (Figure 5.2 B). After 
confirming the vector’s effectiveness, we next delivered our vector to the striatum of adult 
homozygous mice. Striatal injections are a comparatively easy method to inject a large 
volume to a broad area in the brain.  
Homozygous 4-month-old mice were gender and copy-number matched, and separated 
into three injection groups (PBS-mock, AAV9-CB-GFP-control, and AAV9-H1-amiRC9). 
We performed bilateral striatal injections, delivering 5 µl of vector per side for a final dose 
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of 5E10 GC/ml per mouse (Figure 5.2 C). Mice were culled 16 weeks post injection, PBS-
perfused, and dissected. Two-millimeter punches were taken from each hemisphere for 
RNA and protein extraction. In accordance with our primary culture experiments, we found 
significant silencing of each C9ORF72 mRNA variant by 50% when compared to GFP-
control and PBS mock (Figure 5.2 D). This was consistent with significant levels of the 
mature form of amiRC9 in treated samples only (Figure 5.2 E).  
To quantify the protein levels of C9ORF72, we used what was advertised as a human 
specific antibody. However, we were still able to detect the mouse C9ORF72 ortholog, 
which was not detected in knockout control brain samples. To control for this non- species-
specific detection, we ran 3 (WT) C57BL/6 brain samples side by side with our controls 
and treated samples. Densitometry was used to quantify protein levels and the average of 
the WT samples were subtracted as background. Results showed protein levels of the long 
isoform (481 aa~ 51kDa) (Figure 5.2 F, G) were significantly decreased by more than 
80%.  
Unlike previously described AAV based therapeutic strategies [35, 49], RNase-H based 
therapeutic strategies for C9ORF72 linked ALS, involve decreasing the toxic 
C9ORF72 dipeptides, here we tested whether an RNAi based approach could engage RAN 
translation-RNA templates and achieve sustained dipeptide reduction. To quantify 
the toxic dipeptide levels, we ran an immunoassay designed to detect the most 
abundant dipeptide poly GP. After a single striatal AAV injection of H1-amiRC9 at a dose 
of 5E10 GC/ml we detected ~50% reduction of poly GP dipeptides in all treated mice 






Figure 5.2: AAV9 mediated artificial microRNA silences in the striatum: Adult 
bilateral striatal injections in BAC112 transgenic model 
(A) DNA from ear tissue was used for ddPCR analysis of copy number variation for all 
animals injected. Samples normalized to either EiF2C1 or RPP30 reference gene for 
diploid genome. Homozygote and Heterozygote controls at ~40 and ~20 CNV 
correspondingly. (B) Adult heterozygous mice were injected via tail vein injection with 
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200µl of vector at a dose of 5E11vg/ml. Mice were collected 2 weeks post injection, RNA 
from the liver tissue was extracted and ddPCR showed a significant decrease of Vall 
of~40%. Samples were normalized to mouse HPRT and in reference to GFP control. (mean 
±SEM, mice n=3 PBS, n=3 H1-amiRC9) Student-T test (p** 0.001-0.01) (C) Striatal Brain 
image from an injected mouse depicting the coordinates; medial- lateral +/- 2mm, dorsal –
ventral -2.5mm, anterior-posterior +1mm. Arrow depicts ~2mm punch location. (D) 
Starting from a 2mm punch dissected from the striatum we ran ddPCR analysis of 
expression of each individual variant V1, V2, V3 as well an assay detecting all variants 
jointly Vall, normalized to mouse HPRT and in reference to GFP control. Approximately 
~50% silencing is observed in H1-amiRC9 treated mice. (mean ±SEM, mice n=4 CB-GFP, 
n=7 PBS, n=7 H1-amiRC9), (p* 0.01-0.05; p** 0.001-0.01; p*** 0.0001-0.001; 
p****<0.0001) (E) Detection of mature H1-amiRC9 product, ratio to small nuclear 
RNA135. (Mean ±SEM), and compared to endogenous microRNA128a, this miR is highly 
expressed in the brain. (F) Western Blot image for the long isoform of C9ORF72, 55kDA 
protein, normalized to Actin ~42kDA. From left to right KO mouse samples used as a 
negative control, n= 3 C57 WT mouse controls, n=3 PBS and GFP controls and n=4 H1-
amiRC9 treated mice. There is a clear decrease of signal in mice treated with H1-amiRC9. 
(G) Densitometry quantification of western blot in F); n=3 Wild type mice were used to 
average and subtract as background signal. Significant silencing is detected compared to 
untreated controls. Student-T test (p** 0.001-0.01) (H) Concentration of poly (GP) from 
corresponding groups were measured by Elisa, a similar ~50% decrease in the treated H1-
amiRC9 group (Mean ±SEM, Brain punch corresponding to the opposite side of all mice 
for each group described in A), (p** 0.001-0.01; p****<0.0001) 
 
 
CSF based delivery outperform peripheral based delivery for transduction of the 
frontal lobe of the brain   
In order to deliver this therapy to patients, multiple delivery options need to be considered 
to obtain a thorough distribution of the vector to all target sites. The main goal in treating 
ALS is to reach the brain and central nervous system (CNS). However, when using mouse 
models to test vector delivery and distribution certain procedures such as intrathecal 
injections, which in patients is a common delivery route, are considered challenging due to 
the small size of the animals. To overcome this, we tested both an intracerebroventricular 
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(ICV) injection as surrogate for efficient cerebrospinal fluid (CSF) delivery and a 
peripheral facial intravenous (IV) injection in neonate mice.  
An ICV delivery is a local injection to the cerebral lateral ventricles. The result predicted 
is sustained silencing of C9ORF72 in the frontal lobe of the brain, close to the injection 
site. Heterozygous P1 pups were injected bilaterally [43] with 2µl of vector (Figure 5.3 A) 
AAV9-CB-GFP~ 8.5E12 GC/ml; AAV9-H1-amiRC9 ~ 5E12 GC/ml and a PBS control. 
Animals were culled 16 weeks post injection, when PBS-perfused, and whole brain and 
spinal cords were extracted. Frontal lobes were dissected and fresh frozen for RNA 
extraction. We assessed knockdown for each variant as described above. As expected, there 
was significant silencing in the treated samples (Figure 5.3 B). We validated the presence 
of the mature H1- amiRC9 in all injected animals and quantitated levels via ddPCR (Figure 
5.3 C). We also detected a decrease in toxic poly GP dipeptides by ELISA (Figure 5.3 D). 
FISH was used to assay for sense RNA foci in layer V of the frontal cortex; total 
quantification showed no significant differences in size or number of foci between treated 
and control brains. Tranduction efficiency in the frontal lobe was ~60% by visual 










Figure 5.3: Neonatal Intracerebroventricular ICV injections silence C9ORF72 
mRNA and dipeptides but not RNA foci in the frontal lobe of the brain  
(A) Neonate ICV Injection site. (B) Neonate pups were injected bilaterally with 2µl of 
vector at ~1E13GC/ml. Mice were collected 16 weeks post injection. Total RNA from 
Frontal lobe tissue was used for Digital PCR analysis of expression of each individual 
variant V1, V2, V3 as well an assay detecting all variants jointly Vall, normalized to mouse 
HPRT and in reference to GFP control. Mice treated with H1 promoter had significant 
silencing (mean ±SEM, mice n=8 CB-GFP, n=6 PBS, n=4 H1-amiRC9), Student-T test 
Student-T test (p ≥0.05 not significant; p* 0.01-0.05; p** 0.001-0.01; p*** 0.0001-0.001; 
p****<0.0001) (C) Detection of mature H1-amiRC9 product, ratio to small nuclear 
RNA135. (Mean ±SEM) and compared to endogenous microRNA128a. (D) Concentration 
of poly (GP) from corresponding groups measured by Elisa showed no significant decrease 
when compared to GFP, although there is a slight decrease in the H1 treated group. 
Significant silencing is detected when compared to PBS controls. Student-T test (p ≥0.05 
not significant; p* 0.01-0.05) (E) Fluorescent in situ hybridization confirms the presence 
of sense foci in frontal lobe Layer V of treated and control mice. RNA foci were not 
detected following RNAse treatment or in non-Transgenic controls. (F) Quantification of 
RNA foci in the frontal lobe layer V, showed no significant differences between treated 
and untreated groups. The graph shows quantification of an average of 3 mice per group, 











Facial (IV) injections slightly outperform (ICV) injections for delivering therapeutic 
to the spinal cord  
Because ALS affects both upper (brain) and lower (spinal cord) motor neurons, we next 
sought to seek the best surrogate delivery route for our therapeutic in mice. We compared 
both a systemic and a local route for their ability to spread to the frontal lobe and the spinal 
cord, an important consideration for clinical settings. P1 pups were injected with 50µl of 
vector at a dose of 2E11GC/ml (Figure 5.4 A). We used the same vectors as previously 
mentioned. At 16 weeks post injection, tissue collection was followed in the same manner 
as for ICV samples. We extracted RNA from the frontal lobe and assessed silencing for 
each variant. Though there was a decrease in C9ORF72 mRNA and detectable levels of 
the mature H1-amirRC9, there were no statistically significant differences between treated 
and control groups (Figure 5.4 B, C) Frontal lobe samples from both routes were processed 




















Figure 5.4: AAV9 mediated artificial microRNA silencing in the brain of facial vein 
injected mice.  
(A) Injection site depicted in neonate temporal vein. (B) Neonate pups were injected 50µl 
of each vector at 2E11vp/ml into the temporal vein. Mice were collected 16 weeks post 
injection. Total RNA from Frontal lobe tissue was used for ddPCR analysis of expression 
of each individual variant V1, V2, V3 as well an assay detecting all variants jointly Vall, 
normalized to mouse HPRT and in reference to GFP control. There was no significant 
silencing (mean ±SEM, mice n=4 CB-GFP, n=5 PBS, n=7 H1-amiRC9), Student-T test 
Student-T test (p ≥0.05 not significant) (C) Detection of mature amiRC9 product, ratio to 
small nuclear RNA135. (Mean ±SEM) and compared to endogenous microRNA128a. 
 
 
Nonetheless, a systemic delivery was expected to be more efficacious at silencing mRNA 
in the spinal cord [40]. To verify this, we next compared our two delivery methods to 
determine which most efficiently silenced C9ORF72 in the spinal cord. By using a laser 
capture microdissection (LCM) microscope, we specifically captured motor neurons within 
the ventral horn of cervical cord sections. We then quantified both the mRNA levels of the 
C9ORF72 variants, and the presence of the mature H1-amiRC9. Indeed, a facial vein 
delivery knocked down C9ORF72 by ~50% (Figure 5.5 A, B), which is slightly more 
efficient compared to an ICV delivery, where we detected a 30-35% decrease (Figure 5.5 





























Figure 5.5: Comparison between a systemic and CSF based delivery of therapeutic 
for spinal cord silencing 
(A) Total RNA from laser-captured motor neurons from the cervical portion of the cord 
showed significant silencing between treated groups for all the variants jointly. Samples 
were normalized to mouse HPRT and in reference to GFP control. (mean ±SEM, mice n=4 
CB-GFP, n=4 PBS, n=6 H1-amiRC9) Student-T test (p** 0.001-0.01; p*** 0.0001-0.001; 
p****<0.0001) (B) Detection of mature H1-amiRC9 product in LCM cervical cords from 
temporal vein injections, ratio to small nuclear RNA135. (Mean ±SEM) and compared to 
endogenous microRNA128a. (C) ICV injected mice were described in Figure 5.3. Total 
RNA from laser-captured motor neurons from the cervical portion of the cord showed 
significant silencing between treated groups for all the variants jointly. Samples were 
normalized to mouse HPRT and in reference to GFP control. (mean ±SEM, mice n=4 CB-
GFP, n=4 PBS, n=6 H1-amiRC9), Student-T test (p** 0.001-0.01; p*** 0.0001-0.001; 
p****<0.0001). (D) Detection of mature H1-amiRC9 product in LCM cervical cords from 













H1-amiRC9 targets misspliced transcript that produces the cytoplasmic toxic 
dipeptides  
Although we were able to detect silencing of C9ORF72 mRNA, protein and dipeptide, we 
sought to confirm the mechanism by which our H1-amiRC9 can decrease the toxic 
dipeptides. To this end, we used RNA in situ hybridization (RNAscope) on cervical cord 
sections from the facial vein injected group and designed two probes: the first targeting the 
intronic area just before the HRE (intron target) and the second targeting joint exons 3-6 
(exon target) (Figure 5.6 A). We predicted the presence of the intron and exon targets in 
both nuclear and cytoplasmic compartments. Under the assumption that the intron-HRE is 
retained within the misspliced transcript, we also expected to see these colocalize. In 
addition, we correctly anticipated a decrease of both targets in the cytoplasm of treated 
cervical cord samples compared to controls.  
Henceforth, ventral horn motor neurons were imaged as Z-stacks and each puncta detected 
was quantified as an RNA target. Representative images in (Figure 5.6 B) illustrate the 3 
different treated groups: mock, control and H1-amiRC9. The first column shows DAPI 
staining for the nucleus of the cell followed by the exon target in red, the intron target in 
green, and the overlay in yellow. Dotted areas on the top right corners emphasize magnified 
cytoplasmic regions containing colocalized targets. We scored for total exon targets, 
cytoplasmic intron targets, and colocalized targets (Figure 5.6 C). Treatment with AAV9-
amiRC9 resulted in a decrease of ~40% total exon targets, ~60% cytoplasmic intron targets 
and ~50% of colocalized targets. We also identified the presence of cytoplasmic intron 
targets that did not colocalize with the exon target. Although we cannot assume this the 
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expansion lariat, we suspect this is likely the unaccompanied intron-HRE transcript, which 








Figure 5.6: RNA in situ hibridazation staining and quantification of intronic and 
exonic RNA targets 
(A) Representation of RNAish target location for Exon and Intron probes. (B) Cervical 
cord sections were cut at 7µm and stained with RNAish. Each row contains representative 
images from controls (GFP, PBS) and treated animals (AAV9-H1-amiRC9). Motor 
neurons were identified based on morphology, and position within the ventral horn. Slides 
were incubated with multiplex probes detecting C9ORF72 intron1 (Cy3- Green), 
C9ORF72 exons2-6 (Cy5-red). The nuclei are stained with DAPI. The final panel shows 
the co-localization of all channels and the merge in yellow. Quantification of each target 
RNA for independent channels shown in panel. The treated samples are distinguishable 
from controls, they show a significant decrease in RNA target signal for each channel. 
Scale bars indicate 100 µm (C) Quantification of RNA targets in motors neurons in the 
ventral horn of cervical cords. Total exon target quantification, cytoplasmic intron target 
and co-localization of both targets. (Mean ±SEM) Student-T test Student-T test (p** 0.001-




Recent publications from our group and others have shown that an AAV-mediated amiRs 
approach can be used to target neuro-muscular diseases such as Huntington’s and ALS 
where the key factor is efficient transduction of the brain and spinal cord, as well as 
sustained silencing of said target [43, 46, 100, 102, 111-113]. Because the C9ORF72-HRE 
mutation accounts for most FALS and FTD, it is a prime target for therapy. Hence, we 
sought to use RNAi gene therapy to silence this gene and decrease its toxic products. 
To achieve this, we designed multiple amiRs targeting exon regions within the C9ORF72 
gene. After screening in HEK293T cells, we selected the top silencing candidate and further 
validated its efficiency in primary cortical cultures and in vivo in a C9ORF72 transgenic 
mouse model.  
The transgenic model used throughout our experiments overexpresses C9ORF72 by 
carrying multiple (18-20) tandem copies of the transgene. In a clinical setting, however, 
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most patients carry a single copy of the C9ORF72-HRE mutation, and only a few rare cases 
have been diagnosed as homozygous. Mindful of these differences, we set out to 
demonstrate that our therapeutic strategy could silence C9ORF72 and its toxic counterparts 
in a safe and sustainable way.  
The in vitro primary culture experiments confirmed the efficiency of rAAV9-H1-amiRC9 
at transducing cortical neurons shown by eGFP expression, the proper processing of the 
mature H1-amiRC9, and the reduction of C9ORF72 mRNA and dipeptide levels. In order 
to assess the RNA foci presence in the nucleus, we used (FISH) to probe for the sense RNA 
aggregates. Quantification of these showed no significant differences compared to the 
untreated control. Although recent evidence shows that some microRNAs can shuttle back 
into the nucleus’s for silencing [14, 107-109], that does not seem to be the case for H1-
amiRC9 based on our foci quantification, Nonetheless, analysis of nuclear and cytoplasm 
fragments to assess whether H1-amiRC9 is present and silencing in the nucleus remains to 
be addressed. It would offer additional useful information regarding the silencing ability 
of this specific amiR.  
As a proof of concept, we aimed to test the efficiency of our H1-amiRC9 in vivo, by 
performing stereotaxic striatal injections in adult mice, where we delivered a high dose of 
vector to a broad area of the brain. Although we can detect transduction thru eGFP 
expression 3-4 weeks after injection, we decided to age the mice 16 weeks post injection 
to allow for the accumulated or de novo GP dipeptides to be decreased by H1-amiRC9. We 
confirmed proper distribution of the vector into the striatum by eGFP expression, where 
medium spiny neurons compose most of the neuronal population transduced. All the assays 
showed a significant silencing of ~50% of C9ORF72 mRNA, ~80% of protein and~50% 
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poly GP dipeptides, thereby supporting the notion that a local delivery to adult mice of 
AAV9-mediated H1-amiRC9 results in knockdown of C9ORF72 and its products. 
A relevant aspect of this research entailed comparing two different alternative delivery 
approaches in neonate mice: a local delivery with ICV injections, and a systemic delivery 
through the temporal (facial) vein. The intent was to learn which route is more efficient at 
silencing C9ORF72 in the frontal lobe of the brain and in the spinal cord, and to determine 
if silencing at an early stage of life before the toxic dipeptide proteins accumulate yields 
higher silencing results. Since C9ORF72 BAC112 produces detectable GP dipeptides by 2 
months of age, we decided to age the mice from both ICV and facial experiments for 4 
months post treatment, assuming an extra 2 months would be a good starting point to assay 
for GP decrease.  
We first analyzed silencing in the frontal lobe. In the ICV-injected group. a significant 
reduction of C9ORF72 variants and a slight decrease of the GP dipeptides in the treated 
group were detected. The facially-injected group, however, showed a non-significant 
mRNA and GP decrease (Figure 5.4). We detected low levels of silencing in the brain after 
a facial delivery, we assume this is due to a dilution factor explained by the nature of the 
delivery route which ensures the vector would spread systemically throughout the whole 
body, including crossing the weak BBB forming at P1 in the brain. The ICV route, in 
contrast, is a local injection closer to the frontal lobe.  
Using the same ICV-injected brain sections, we sought to confirm the primary culture data 
and quantify foci aggregates in vivo in Layer V of the Frontal Lobe. Further supporting our 
previous results, the in vivo data showed no significant differences between the treated and 
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control animals. The only disparity observed between primary cultures and brain sections 
were the number of sense foci per nucleus. Foci were more abundant in primary cortical 
cultures ranging from 1-40 than the 1-10 in layer V.  
Focusing on the cervical portion of the spinal cord, we used laser capture microdissection 
to collect motor neurons from the ventral horn of both ICV and temporal (facial) vein 
injected mice. Since high levels of eGFP expression were visible upon dissection, GFP 
negative neurons were not excluded for LCM to avoid compromising the RNA integrity 
and limited sample needed for proper quantification.Both routes showed significant 
silencing compared to controls; however, the facial vein route had 10-20% greater mRNA 
silencing effect. 
Comparison across the different in vitro and in vivo experiments revealed a consistent 
silencing threshold of only 50% C9ORF72 mRNA, ~70% protein, and Poly GP dipeptide 
decrease. Assuming 100% of cells are transduced and the majority of silencing is post-
transcriptional, we hypothesized that ~50% leftover of C9ORF72 mRNA should localize 
primarily to the nucleus where it cannot be targeted by H1-amiRC9. Similarly, with regard 
to dipeptide silencing, we examined the idea that missplicing results in a cytoplasmic 
species containing the both the intron-HRE, and the intron-HRE attached to correctly 
spliced exons 3-6. Only this intron-HRE-exon species allows for cytoplasmic H1-amiRC9 
targeting.  
These localization questions were addressed using in situ hybridization and specific probes 
targeting either the intron or the joint exons 3-6. We detected the exon RNA target in both 
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cellular compartments at a ~ ratio of 40 nuclear to 60 cytoplasmic. Quantification of the 
exon target showed it to be significantly reduced in the cytoplasm of treated mice only.  
One would expect intron containing mRNA to be nuclear or perinuclear, yet their presence 
in the cytoplasm suggests missplicing is occurring. Lastly, the rare co-localized exon-intron 
transcript was significantly decreased in the cytoplasm of treated mice, hence the abnormal 
transcript containing intron-HRE-exon is available for H1-amiRC9 targeting. The 
cytoplasmic intron-HRE species that does not co-localize with the exon target may be the 
source for GP production that we are detecting and are unable to decrease. Our work, along 
with other publications [114, 115], reiterate the presence of the retained intron-HRE as well 
as a pseudo-start site (CUG) upstream of the intron, driving the translation of the C9ORF72 
(HRE) [116]. The status of the expansion however, remains to be studied, and we cannot 
exclude the possibility of the HRE remaining within a lariat or as an unaccompanied intron-
HRE transcript, If the latter is occurring it would be interesting to study how this transcript 
avoids degradation.  
A summary of the mechanism by which our therapeutic approach is acting is proposed in 
(Figure 5.6) The first portion depicts the C9ORF72 gene and the three different variants it 
produces, with variants 1 and 3 less abundant and carrying the (HRE), represented by the 
red diamond within the first intron. Splicing then removes the intron sequence and unifies 
the exons to form a mature mRNA, and each variant is translated to produce two proteins, 
a short 221 aa. (~24kDA) and a longer 481 aa. (~55 kDA). However, when missplicing 
occurs, variants 1 and 3 retain the intron beside the expansion, and the expansion is by 
some means exported to the cytoplasm. The presence of the expanded repeat in the 
cytoplasm allows for repeat associated non-ATG translation (RAN); resulting in the 
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production of toxic poly-dipeptides from six different reading frames, GP sense/antisense, 
GA, GR, PA, and PR [117]. The second portion depicts rAAV9-mediated delivery of H1-
amiRC9, where the primary microRNA (pri-miR) enters the RNAi silencing pathway and 
it is exported to the cytoplasm to be further cleaved and enter the RISC complex, where it 
binds in perfect complementarity to the target mRNA. Since H1-amiRC9 targets exon 3, 












Figure 5.7: C9ORF72 suggested mechanism  
(1) The C9ORF72 gene produces three different variants, variants 1 and 3 carry the 
hexanucleotide repeat expansion, depicted by the red diamond within the first intron. (2) 
When proper splicing takes place, each variant will follow the canonical translation and 
produce two proteins a short 221 aa. (~24kDA) and a long 481 aa. (~55 kDA) (3) When 
unconventional splicing is occurring, Variants 1 and 3 retain the intron along with the 
hexanucleotide expansion. The presence of the expansion in the cytoplasm allows for 
repeat associated non-ATG translation (RAN). Producing toxic poly-dipeptides. GP, GA, 
PR, PA, GR. (4) After rAAV9 mediated delivery of H1-amiRC9, the primary microRNA 
enters the RNAi silencing pathway. It is first trimmed by the microprocessor complex 
Drosha, and then exported to the cytoplasm to be further cleaved by Dicer. The mature 
microRNA will enter the RISC complex and bind in perfect complementarity to the target 
mRNA for cleavage. Since H1-amiRC9 specifically targets Exon 3, both properly spliced 
and intron retaining C9ORF72 mRNA transcripts will be targeted for silencing, leading to 
in vitro and in vivo of ~ 50% of the C9ORF72 mRNA, protein and GP Dipeptides.  
 
Even though we have shown that there is intron retention of the HRE, the mechanism by 
which C9ORF72 - HRE causes ALS remains a conundrum. While the formation of RNA 
foci is usually linked to sequestering of RNA-binding proteins that create a gain of function 
disease, this has not been shown to be the definitive source. Hence the cause of neuronal 
death could be an accumulation of all the toxic products from C9ORF72-HRE. A 
comparison where either the RNA foci or the dipeptides are individually silenced would 
provide greater clarity. Using AAV9-mediated H1-amiRC9 to silence C9 mRNA and 
dipeptides is a useful tool to address this problem.  
Another similar approach involves amiRs designed to either target the expansion carrying 
variants 1-3, or the intron-HRE for both sense and antisense strands. These approaches 
would also be clinically advantageous, since variants V1-V3 represent a small fraction of 
total C9ORF72 mRNA (sparing the abundant normal transcript V2). In addition, targeting 
the intron itself would lead to a decrease of all HRE-bearing transcripts and preserve 
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C9ORF72 mRNA. A group in the Netherlands recently published encouraging data using 
different amiR scaffolds, and AAV5 as a delivery vehicle [23, 118], supporting the use of 
AAV-mediated amiR silencing as a safe and reliable approach for the treatment of ALS. 
Prior to moving forward with these therapeutics, testing in a mouse model that recapitulates 
not only the molecular but also the motor deficits seen in ALS is advised. If there is 
sufficient rescue of the motor deficit, then testing should advance to non-human primates. 
Our group has performed similar studies using AAV-mediated amiR for SOD1, which is 
the second most common mutation in ALS, yielding extended survival in the SOD1-G93 
mouse model [111] as well as in non-human primates [112]. 
Other available strategies to target C9ORF72 involve using antisense oligonucleotides 
(ASOs). ASO treatment in C9-ALS motor neurons derived from iPSCs reduce foci 
formation as well as gene expression alterations [90] [119]. Jiang et al. showed in their 
mouse model that they can not only reduce foci but also toxic dipeptides and overt 
behavioral aspects [89, 99, 110]. Though ASOs have certain delivery and long-term 
expression setbacks, they have been widely used to target gene silencing and have begun 
to move into the clinical setting for trials for multiple CNS diseases (SMN2, Huntington’s, 
ALS-SOD1) [29]. 
While an AAV9- H1-amiRC9-mediated approach may not reach the nuclear foci, the main 
therapeutic advantage in this instance is that neurons are non-dividing cells, so a single 
dose can decrease C9ORF72 gene products, especially the toxic GP dipeptide; hence it can 
diminish overall cell toxicity which may be sufficient to prevent motor neuron death. 
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In addition to determining a safe vehicle for a therapeutic, the delivery route, dose, and 
timing is crucial for gene therapy. For sporadic ALS, if diagnosed at an early stage, it can 
provide protection and perhaps decelerate the progression of the disease. In Familial ALS, 
it can be considered a pre-treatment for carriers and ameliorate the symptoms caused by 
this disease.  
Methods 
MicroRNA design and cloning  
A 22-nucleotide artificial miRNA against exon 3 of the C9ORF72 gene was designed and 
cloned into the miR-155 backbone. The artificial miR was cloned into 2 entry plasmids. 
The first was in the 3’UTR of a GFP encoding AAV proviral plasmid under the control of 
the chicken beta actin (CB) promoter with a CMV enhancer. The second was in a plasmid 
containing H1 promoter driving the miR a CMV enhancer followed by a CB promoter 
diving the expression of GFP. Both were used to package into rAAV9 vectors.  
Table 5.1: microRNA Target sequences  
amiR 
 
Oligo Sequence Target 
Exon 
amiR123 Top strand: 5'- TGCTGTTTGGAGCCCAAATGTGCCTTGTTTTGGCCACTGACTGACAAGGCACATGGGCTCCAAA -3' 
Bottom strand: 5'- CCTGTTTGGAGCCCATGTGCCTTGTCAGTCAGTGGCCAAAACAAGGCACATTTGGGCTCCAAAC -3' 
3 
amiRC9 Top strand: 5'- TGCTGTATAGCACCACTCTCTGCTAAGTTTTGGCCACTGACTGACTTAGCAGAGTGGTGCTATA -3' 
Bottom strand: 5'- CCTGTATAGCACCACTCTGCTAAGTCAGTCAGTGGCCAAAACTTAGCAGAGAGTGGTGCTATAC -3' 
3 
amiR228  Top strand: 5'- TGCTGTTTACATCTATAGCACCACTCGTTTTGGCCACTGACTGACGAGTGGTGATAGATGTAAA -3' 
Bottom strand 5'- CCTGTTTACATCTATCACCACTCGTCAGTCAGTGGCCAAAACGAGTGGTGCTATAGATGTAAAC -3' 
3 
amiR496 Top strand: 5'- TGCTGAATACTCTGACCCTGATCTTCGTTTTGGCCACTGACTGACGAAGATCAGTCAGAGTATT -3' 
Bottom strand: 5'- CCTGAATACTCTGACTGATCTTCGTCAGTCAGTGGCCAAAACGAAGATCAGGGTCAGAGTATTC -3' 
4-5 
 
In vitro plasmid screening in HEK293T 
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HEK293T cells were seeded (1.2 E5 cell/ml) in a 24 well plate, maintained with DMEM 
media (11995-073; Gibco), 10% Fetal Bovine Serum FBS (F-0926 Sigma-Aldrich) and 1% 
Penicillin- Streptomycin (30-001-CI; Corning). Twenty-four hours after the cells were 
transfected using jetPRIME Reagent (Polyplus) and 1µg of each plasmid DNA (CB-GFP, 
CB-GFP-amiRs) (Table 5.1). Forty-eight hours post-transfection, GFP expression was 
visually assessed; cells were rinsed with PBS and collected using Trizol Reagent (Gibco 
BRL, Life Technologies, NY, and USA) for RNA isolation. Complementary DNA (cDNA) 
was generated using (High capacity RNA-to-cDNA Kit, Life Technologies). cDNA was 
diluted to 20ng/µl and a master mix was prepared for ddPCR. 
Droplet Digital PCR (ddPCR) was run as a 20µl reaction containing ddPCR Supermix for 
Probes (no dUTP) (Bio-Rad, Gladesville, NSW, Australia), 1µl of diluted cDNA, 1µl of 
each primer/probe (20x), human HPRT with a HEX label was used as an endogenous 
control, and C9ORF72 assays with FAM labels that detect each variant (Table.5. 2) . The 
20µl sample, along with 70µl of ddPCR-oil was loaded into a DG8 cartridge and covered 
with a gasket according to manufacturer’s instructions; the cartridge was then placed in a 
QX100 droplet generator. Into a 96 well PCR plate 40µl of sample were transferred and 
then placed in a PCR thermocycler (Eppendorf, North Ryde, NSW, and Australia). The 
plate was then placed in the QX100 ddPCR reader (Bio-Rad, Gladesville, NSW, Australia) 
for absolute quantification. Ratios were obtained by dividing absolute values from each 
variant to human HPRT. Samples were normalized in respect to GFP controls. GraphPad 







Table 5.2: Primer and Probes  
Probe  Location Sequence 
 Gene Expression   
V1 Life Technologies GEX: Hs00331877_m1 1a-3 AGATGACGCTTGATATCTCCGGAGC 
V2 Life Technologies GEX: Custom 2-3 Fwd: AGGCGGTGGCGAGTGGATA 
Rev: TTGGAGCCCAAATGTGCCTTA 
Probe: CGACTCTTTGCCCACCG 
V3 Life Technologies GEX: Custom 1b-3 Fwd: GCGGGGTCTAGCAAGAGCAG 
Rev: TTGGAGCCCAAATGTGCCTTA 
Probe: CCACCGCCATCTC 
Vall Life Technologies GEX: HS00376619 3 AGAATATGGATGCATAAGGAAAGAC 
HPRT hum: Bio-Rad GEX: qHsaCIP0030549  Chromosome location X:133627547-133632465 
HPRT mus: Bio-Rad GEX: 
qMmuCEP0054164 
 Chromosome location X:53021117-53021221 
 Copy Number Variation   
C9ORF72 genomic CNV: Custom 4 -intron Fwd: AAGGCACAGAGAGAATGGAAG 
REV: AGGCTTATTCGTATGTCTCCAAG 
Probe: AGGTTGATGGCTACATTTGTCAAGGC 




Copy number variation (CNV)  
C9ORF72 BAC 112 mouse brains were fresh frozen and cut in a sagittal section to extract 
DNA. The tissue was lysed overnight at 550C, RNAse treated and eluted following 
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manufacturer’s instructions (Gentra Puregene Tissue Kit, Qiagen). The DNA was diluted 
to 20ng/µl and 2µl were added to the ddPCR master mix along with 1µl of each primer 
/probe (Genomic C9ORF72 and mouse EIF2C1 or RPP30 diploid genome). Droplets were 
generated followed by PCR and absolute quantification. CNV is determined by dividing 
the absolute value of C9ORF72 by the absolute value of mEIF2C1 divided by 2 for diploid 
genome (Table 5.2). GraphPad Prism Program was used to graph the values. Homozygote 
mice have a CNV of 38-40, and heterozygote mice 18-20.  
Mouse cortical cells 
All murine experiments were conducted at UMASS medical school following strict 
protocols approved by the Institutional review board. Homozygotes BAC112 mice JAX 
Stock# 023099 were crossed with Female WT C57BL/6 mice to generate heterozygous 
embryos. Cortical cells were dissected at embryonic day 15 and pooled from multiple 
embryos. Mouse cortical cells were seeded at 50,000 cells/cm2 in six well plates treated 
with poly-lysine (P4707; Sigma-Aldrich) and four well chamber slides (154917; Thermo 
Scientific). Cells were maintained with Neurobasal media (21103049; Invitrogen), 
Glutamax (35050-061; Invitrogen), 2% Penicillin- Streptomycin (15110122; Invitrogen), 
B27 supplement (17504-001; Invitrogen).  
At day, in vitro four (DIV4) cells were infected with vectors (rAAV9-CB-GFP; rAAV9-
H1-amiRC9-CB-GFP) at MOI of 50,000. At DIV10, cells were rinsed with PBS and 
collected for RNA or Protein isolation. For total RNA extraction samples were collected 
in Trizol reagent (Gibco, Life Technologies), the aqueous phase was added to a Zymo 
column for RNA purification following the Zymo Direct-zol (Zymo research R2050) 
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extraction protocol. cDNA was made using High-Capacity RNA-to-cDNA Kit, Life 
Technologies). cDNA was diluted to 20ng/µl and a master mix was prepared for Digital 
PCR. Ratios were obtained by dividing absolute values from each variant to mouse HPRT. 
Samples were normalized in respect to GFP controls. GraphPad Prizm Program was used 
to graph and run Student- T test statistical. 
Mature H1-amiRC9 detection  
In order to detect the mature H1-amiRC9 product of rAAV9-H1-amiRC9-CB-GFP, the 
RNA extracted from cells or tissue was further diluted to 10ng/µl. We generated 
complementary DNA using the TaqMan microRNA reverse transcription kit (4366597; 
Life Technologies). We used a custom TaqMan small RNA assay that detects the mature 
artificial microRNAC9 (Table 5.3) and used small nuclear RNA 135 as an endogenous 
control. For comparing the expression levels expressed by our amiRC9 with an endogenous 
microRNA. We used miR128a (Table 5.3) shown to be highly expressed in the brain.  
Table 5.3: microRNA assays 
Probe Assay ID Sequence 
amiRC9: Life Technology custom ATAGCACCACTCTCTGCATT 





Bilateral Striatal injections: 
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Heterozygous BAC112 mice were age 4-6mo, gender and CNV matched into three groups. 
(PBS, rAAV9-CB-GFP, rAAV9-H1-amiRC9-CB-GFP). Mice were anesthetized with an 
intraperitoneal injection with a cocktail of Ketamine (100mg/kg), Xylazine (10mg/kg). 
Mice were positioned in a stereotaxic frame following (Stoica, Lorelei et al. “AAV-
Mediated Gene Transfer to the Mouse CNS.” Current protocols in microbiology 0 14 
(2013): Unit14D.5. PMC. Web. 20 Apr. 2018.). Sterile disposable scalpels (Dynarex # 
4111) were used to cut through the skin. Following Stereotaxic Atlas coordinates for the 
striatum the skull was drilled at positions (AP+1, ML+-2, DV-2.5). The mice were injected 
at a.5nl/ml flow a volume of 5 µl per side. At a final dose of 5E10 GC/ml per mouse. Mice 
were collected 16 weeks post injections. The animals were PBS perfused and the brain 
dissected. Brains were placed in an acrylic 1MM mouse Matrix (CP68-1175-1 SouthPoint 
surgical supply) and sections 2-6 were taken. A GFP positive 3mm punch encompassing 
the injection site was taken and used for either RNA or protein. The samples were fresh 
frozen in liquid nitrogen and stored in a -80 freezer for tissue processing.  
ICV injections in Neonates 
Postnatal day 1 pups were separated from their mother and individually anesthetized with 
isoflurane and placed in a heated pad. Prior to the injection’s special adaptors RN 
Compression fitting 1mm Catalog # 55750-01, were used to attach to the Hamilton Syringe 
10µl, gastight model: 1701 RN, and Micro-capillary FHC: Borosil 1.0 mm OD x 0.5mm 
ID/Fiber (100mm, 250 pack) were pulled in a Sutter Instrument: P-97 Flaming/Brown 
Micropipette puller. The pup was injected with 2µl of vector, into the lateral ventricle of 
each hemisphere, 2mm from the transverse sinus and 1mm to either side of the superior 
sagittal sinus, to a depth of 2 mm. It was then placed in a heating pad until it regained 
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consciousness. The pups were then rubbed against the bedding and placed back with the 
mother. Multiple litters were injected with the vectors: AAV9-CB-GFP~ 8.5E12 GC/ml; 
AAV9-CB-GFP-amiRC9~ 1E13 GC/ml; AAV9-H1-amiRC9-CB-GFP~ 5E12 GC/ml. 
Animals were aged and culled 16 weeks post injection. Following a 3-minute PBS 
perfusion, the whole brain and spinal cord were extracted, and the frontal lobe was 
dissected. The left side was fresh frozen, and the right side was embedded in OCT for cryo-
sectioning and staining.  
Temporal vein injections in Neonates  
Postnatal day 1 pups were separated from their mother and individually anesthetized with 
isoflurane and placed in a heated pad. A Hamilton Syringe 10µl, gastight model: 1701 RN 
was used to inject 50µl of vector at a dose of 2E11GC/ml. We used the same vectors as 
previously mentioned for the ICV treatment. After injection the pups were rubbed against 
their bedding to prevent rejection from their mother and placed back in the cage. Mice were 
culled 16 weeks post injection following the same collection procedure as for the ICV 
samples.  
 Western Blot 
Samples were lysed in RIPA buffer and a complete inhibitor tablet (Roche), at 4˚C and the 
supernatant collected. Then, 5µg of protein lysate was run on Novex 12% Tris-Glycine 
gels (Life Technologies, USA) using Tris-Glycine SDS running buffer (Invitrogen, USA). 
Protein was transferred to nitrocellulose membranes using an i-Blot transfer device 
(Invitrogen, USA). Membranes were blocked for 1 hour at room temperature with Odyssey 
Blocking Buffer (LiCor, USA) before being probed overnight with primary antibodies 
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(SiGMA ABN 1644-1645). IR labeled secondary antibodies were applied, and blots 
visualized, and the band intensity was quantified using the Odyssey Infrared imaging 
system (LiCor, USA).  
Poly (GP) ELISA  
Samples were lysed in RIPA buffer and a complete inhibitor tablet (Roche), using lysing 
Matrix D Beads (MP Bio). 3x 3min 30HZS in a Tissuelyser II (Qiagen 85300), samples 
were placed in a new Eppendorf 1.5ml tube and sonicated. After sonication, samples were 
centrifuged at 16,000 x g for 20 min and supernatants collected. The protein concentration 
of lysates was determined by BCA assay (Thermo Scientific, USA). Poly (GP) levels in 
lysates were measured using a previously described sandwich immunoassay that utilizes 
Meso Scale Discovery (MSD) electrochemiluminescence detection technology [29]. 
Lysates were diluted in Tris-buffered saline (TBS) and tested using 35µg of protein per 
well in duplicate wells. Serial dilutions of recombinant (GP)8 in TBS were used to prepare 
the standard curve. Response values corresponding to the intensity of emitted light upon 
electrochemical stimulation of the assay plate using the MSD QUICKPLEX SQ120 were 
acquired and background corrected using the average response from lysates obtained from 
non-transgenic mice prior to interpolation of poly (GP) levels using the standard curve.  
Fluorescent in situ hybridization  
Cryosections of 20µm were serially collected (1/20) through the motor cortex and Cervical 
spinal cord. Sections were fixed in 4% PFA for 20 min, followed by five 20 min washes in 
DEPC-treated PBS containing 0.1% Tween and 50μg/ml of Heparin. Sections were pre-
hybridized for 1 hour at 550C in 2x Sodium citrate (SSC) containing 0.1% Tween 20, 50% 
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of dextran sulfate, water, 50μg/ml heparin, 1mg/ml heat-denatured salmon sperm and 40% 
deionized sulfate. For hybridization, samples were incubated overnight at 550C in pre-
hybridization buffer containing a 1:500 dilution of 1μM DNA probe (Sense: GGGGCC4) 
with a Cy3 label. After hybridization, the samples were washed in a pre-warmed mix 1:1 
of hybridization buffer and 2XSSC for 30 mins at 550C. Followed by 2 washes in pre-
warmed 2XSSC for 30 mins at 550C, 2 washes with 0.2XSSC for 30 min at 550C, and 2 
washes in 1XPBS+ 0.1%Tween +50μg/ml Heparin for 30 min, at room temperature. 
Sections were stained with DAPI (1:10,000) for 5 min, and auto fluorescence quenched by 
incubation in 0.5% Sudan Black in 70% ethanol for 5 min. Glass coverslips were mounted 
using Lab Vision™ PermaFluor™ Aqueous Mounting Medium (Thermo Scientific 
Shandon, USA) 
For quantification of frontal lobe layer V neurons nuclei 10- 15µm z-stack images were 
collected from three sections per animal. 100-200 nuclei assessed from 3 sections per 
animal. The number of foci per nucleus was counted manually, with each nucleus 
categorized as containing 0 foci, 1-5 foci, 6-10 foci or >10.  
Laser Capture microdissection of motor neurons and RNA isolation 
Fresh frozen cervical cords were cryo-sectioned at 7µm of thickness. Using the Arcturus 
XT laser capture microdissection system. Slides were stained with histogene kit, fixed and 
dehydrated with 70-95-100% Ethanol followed by Xylenes. Approximately ~200 ventral 
horn Motor neurons per cap were collected and a total of 3 caps per animal. The samples 
were then processed for RNA using the PicoPure RNA extraction kit following 
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manufactures instructions and sent to a bio-analyzer for RNA concentration and quality. 
RNA from 2 out of 3 caps were individually run on ddPCR for quantification.  
 
 
RNAscope Fluorescent Multiplex Assay 
Cervical cords were embedded in OCT, frozen and 7µm cryosections were placed in 
plus/plus slides for staining. Sections were fixed in 10% NBF for 1 hour, followed by two 
washes in 1X PBS and four 5 min washes in ethanol (50%, 70%, 100%, and 100%) at room 
temperature. The fixed sections were covered with 5 drops of Protease IV for 30 min at 
room temperature followed by two washes in 1X PBS prior to proceeding to the RNAscope 
Fluorescent Multiplex Assay protocol. Probes were warmed for 10 min at 400C, cooled to 
room temperature, and a 1:50 C2:C1 and C3:C1 hybridization mixture was prepared. 
Approximately 180µl of hybridizing probe mixture was used to cover the sections 
completely and incubated for 2 hours at 400C. Two 2 min washes in 1X Wash Buffer (2.94 
L distilled water to 1 Bottle (60mL) RNAscope Wash Buffer Reagents) with minor 
agitation preceded all of the Fluorescent Multiplex Detection Reagent additions. 
Approximately 180µl of each of the fluorescent detection reagents was added to completely 
cover all sections within the hydrophobic barrier prior to incubation in the HybEZ™ Oven 
at 400C. A 30 min incubation was used for Amp 1-Fl, 15 min for Amp 2-Fl, 30 min for 
Amp 3-Fl, and 15 min for Amp 4-Fl-Alt C. Sections were counterstained with Dapi for 30 
sec at room temperature and glass coverslips were mounted using Prolong Gold Antifade 
Mountant and stored in 4ºC. 
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RNAscope Imaging and Quantification 
All images were taken using a Leica DM5500 B microscope with a Leica DFC365 FX 
camera. A total magnification of 100.8X (63X oil lens * 1.6X camera) was used to generate 
the images, while using the acquisition settings (Table 5.4) for the various probes. A 
maximum projection of z-stacks with a range of 1-3µm was used for quantification. 
Table 5.4 Fluorescent Microscope Acquisition and Filter Settings (AMP 4 Alt-C-FL) 
Probe 
Channel  
Excitation[nm] Emission[nm] Filter 
Set 
Exposure[ms] Gain Intensity 
C1 Atto 550 nm 580 ± 10nm Cy3 645.00 3.2 5.0 
C2 Atto 647 nm 690 ± 10nm Cy5 466.00 3.2 5.0 
 358 nm 461 nm DAPI 36.00 1.2 3.0 
 ~488 nm ~509 nm EGFP 300.00 3.0 4.0 
 
Approximately 15 images were taken from three different cervical spinal cord sections for 
each animal, each with at least one motor neuron present. The quantification of intron, 
exon, and co-localized targets was conducted manually for motor neurons in the ventral 
horn. Cervical spinal motor neurons were identified by location, morphology, and larger 
nuclei. All RNA targets were characterized with respect to size (Table 5.4) as measured 
by the scale bar annotation tool in Leica Application Suite X (LAS X). Intron RNA targets 
were additionally classified as inside or outside of the nucleus by the presence of puncta 
within the DAPI signal. Co-localization of intron and exon puncta was determined using 
the z-stack and spectral color change as observed by light color properties of the RGB 
additive color model. RNA targets corresponding to an overlap of GFP signal were 








ALS is a fatal neurodegenerative disease, for which only 5-10% of familial cases could 
benefit from genetic screening. For most cases the irreversible effects of neuronal death 
become evident when the patient first shows signs of weakness, with either a bulbar onset, 
affecting primarily the facial muscles, speech and swallowing reflex, or a non-bulbar form 
affecting the extremities, neither following a specific degeneration pattern. The goal is to 
employ the therapeutic developed here as an early intervention to slow or halt the disease 
progression and improve the patient’s quality of life.  
For C9ORF72 linked ALS however, haploinsuffiency, gain of function, RAN translation 
and nucleocytoplasmic transport seem to be key mechanisms by which C9ORF72 -HRE is 
causing toxicity. Although the main issue seems to be the expansion itself, we and others 
have shown that targeting other areas within the gene can also lead to decreased 
cytotoxicity [23, 89, 90, 99, 118-121]. Due to the lack of a model that recapitulates all of 
the ALS hallmarks in which to test this approach, our group generated a human C9ORF72 
BAC transgenic model. For unknown reasons we[121] and others[99, 122] were unable to 
generate a model with both motor and molecular phenotype seen in ALS/FTD patients 
[101]. With the exception of a later model generated by Liu, Y. J. et al, 2016 [122] for 
which a small percentage of females and at a later time point males , develop the motor 
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and molecular C9ORF72-ALS phenotype. To date no one has elucidated why this and not 
the other models recapitulated the motor deficits.  
After characterizing the C9BAC mouse model we sought to test the artificial microRNAs 
targeting C9ORF72 in primary cortical cultures and demonstrated a statistically significant 
decrease of C9ORF72 mRNA variants and GP dipeptides in the treated samples when 
compared to controls. We then decided to further validate the artificial microRNA in a 
different mouse model produced by O’Rourke et al,[99], to confirm that the decrease was 
not just specific to our mouse model. In this model we tested our therapeutic reagent using 
both adult and neonate mice and multiple dosing routes. We were able to show different 
levels of C9ORF72 mRNA, protein and dipeptide silencing in the frontal lobe of the brain 
and in the spinal cord depending on the delivery route. More importantly, we have 
identified a new transcript produced by missplicing of the intron bearing the HRE. This 
new cytoplasmic species is accessible for amiR targeting leading to the decreased dipeptide 
levels. Based on this preclinical screening, in vivo work in non-human primates to test 
safety and toxicity of AAV mediated H1-amiRC9 is currently underway.  
Although we have yet to understand the complete mechanism of action for C9ORF72. An 
ideal approach would entail using AAV to deliver two artificial microRNAs targeting both 
the sense and antisense intron bearing the-HRE. This approach would decrease the levels 
of only the intron- HRE transcripts sparing the correctly spliced C9ORF72. 
Moreover, recent studies using RNAse-H based technology have shown antisense 
oligonucleotides (ASOS) targeting both exonic and intronic C9ORF72 nuclear RNAs can 
decrease mRNA, foci and dipeptides with the only caveat of having to be continuously re 
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delivered depending on the ASO’s chemistry and half-life. Another concern with this 
therapeutic strategy envolves the risk of repeated injections for delivery of the ASO. Until 
the chemistry allows for longer, sustained persistance of ASOs, this therapeutic can be 
successful but at a health risk to the patient. Even so, the efficiency and lack of toxicity 
seen in animal models have lead to the commencement of clinical trials using ASOs for 
SOD1-ALS and SMN2 for SMA [29, 123] among others. Both AAV and ASO approaches 
have shown significant therapeutic advantages, with differences which may or may not 
vary from patient to patient. Nonetheless, historical data from AAV clinical trials [36, 49, 
124, 125] have shown that this approach if successful could be a permanent cure for 
C9ORF72 linked ALS patients. 
In addition to demonstrating that an AAV mediated RNAi approach is a sound and 
powerful tool to target ALS, I have also provided a methodology and approach to targeting 
other diseases with similar mechanisms. For different cases, such as in spinal muscular 
atrophy (SMA), where a mutation causes haploinsuffiency, AAV-mediated replacement 
therapy of the SMN gene has rapidly advanced to human clinical trials with 
groundbreaking results [126]. However, some diseases may require a combination of both 
silencing and replacement therapy to rescue normal cell function [48, 49] , such as in the 
case of hereditary sensory neuropathy (HSAN1), for which we have designed a therapeutic 










A C9ORF72 BAC mouse model recapitulates key epigenetic 
 perturbations of ALS/FTD 
Introduction 
A pathological GGGGCC hexanucleotide repeat expansion mutation located within the 
non-coding portion of the C9ORF72 gene has been identified as the cause of chromosome 
9p21-linked ALS and frontotemporal dementia (FTD),[127, 128]. The C9ORF72 HRE is 
hypothesized to confer cytotoxicity, in part, via RNA gain of function whereby sense and 
antisense transcripts harboring the repeat sequester RNA binding proteins resulting in 
ribonucleoprotein foci [119, 129], preventing the proteins from carrying out their normal 
function. In addition, expanded RNAs and dipeptide-repeat proteins (DPRs) that arise from 
aberrant translation of mutant RNAs disrupt nucleocytoplasmic transport [24, 130, 131]. 
Given that mutant RNAs and the DPRs derived from them are the primary source of 
pathology in C9-ALS and epigenetic mechanisms regulate their production, it follows that 
epigenetic regulation of expanded C9ORF72 alleles is of particular significance. 
Epigenetic alterations occur in many repeat expansion disorders and there is now definitive 
evidence that epigenetic perturbations associated with the C9ORF72 HRE contribute to 
C9-ALS pathophysiology [132-134]. Expanded C9ORF72 alleles have reduced 
transcription rates, are depleted of active histone marks with concomitant enrichment of 
repressive epigenetic marks, including DNA hypermethylation in some cases. Specifically, 
the levels of all three C9ORF72 transcript variants are reduced in C9-ALS, including 
variant 2 which does not contain the repeat sequence due to alternative transcription start 
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site (TSS) utilization [119, 127, 135]. Enriched repressive epigenetic marks include tri-
methylation of histone 3 at lysine positions 9 and 27 (H3K9me3, H3K27me3) and histone 
4 lysine 20 (H4K20me3) [135]. In addition, DNA methylation of cytosine residues within 
CpG islands near the C9ORF72 promoter occurs in approximately 30% of patients [136-
138]. Notably, promoter hypermethylation is theorized to be protective due to decreased 
production of toxic products in patient cells [139] leading to reduced neuronal loss in the 
brain [140]. Mechanistically, DNA hypermethylation is counteracted by active DNA 
demethylation [141] while repeat instability is conferred by highly stable GC-rich RNA-
DNA duplex formation across the HRE [142]. In addition to repeat instability, RNA-DNA 
hybrid structures, or R-loops, may also contribute to C9ORF72 hypermethylation. Indeed, 
R-loops are known to regulate DNA methylation at CpG islands of gene promoters 
including those affected by repeat expansion mutations [143, 144]. Taken together, these 
observations indicate that the C9ORF72 HRE alters the local epigenetic environment such 
that the rate of transcription, DNA methylation, histone modification and R-loop formation 
are all perturbed by the expansion mutation. 
Two independent groups were first to develop transgenic mouse models of C9-ALS 
carrying the pathogenic C9ORF72 HRE [121, 145]. The human repeat expansion sequence 
was introduced into the mouse genome using a bacterial artificial chromosome (BAC). The 
C9-BAC mice displayed typical histopathological gain-off-function features of C9-ALS 
including RNA foci and DPR aggregates, yet no motor or cognitive phenotypes were 
observed. Subsequently, two additional groups generated C9-BAC mice that exhibit 
reduced survival, motor deficits and cognitive dysfunction [120, 122]. While these 
previous reports focused on the production of toxic HRE products, none have described 
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epigenetic features of the C9ORF72 transgene. Notably, the number of toxic mRNA foci 
and DPR abundance in C9-BAC mice was observed to significantly decline as a function 
of age [121]. This is somewhat counter-intuitive since ALS/FTD are age-related disorders. 
Therefore, we hypothesized that partial epigenetic repression of the C9ORF72 transgene 
could potentially attenuate the severity of phenotypes in C9-BAC mice, limiting their 
applicability to human disease. Herein, we performed a post-natal developmental study 
using transgenic BAC mice reported by Peters et al. [121] to systematically investigate 
whether characteristic epigenetic features of the HRE in C9-ALS are recapitulated in this 
mouse model system. 
Results 
Expression of the human C9ORF72 transgene decreases while H3K9 tri-methylation 
increases in C9-BAC mice during the first post-natal weeks  
Tissue samples from mice of 7 different age groups were assessed in this study: post-natal 
week 0 (n=5), 2 (n=4), 7 (n=5), 17 (n=4), 30 (n=9), 36 (n=4) and 93 (n=9). The activity 
and epigenetic status of the human C9ORF72 transgene was assessed by quantifying levels 
of mRNAs and histone methylation within the promoter of the human gene. First, we 
measured human C9ORF72 mRNA levels in the neocortex of C9-BAC mice across all age 
groups using quantitative real-time (qPCR). Three primer sets were used to amplify 
different human C9ORF72 mRNA transcript variants (V1, V2, and V3) as well as three 
endogenous controls (beta-actin, GAPDH and 18S). Due to the observed variability in beta-
actin expression levels across age groups (Figure A1.1A), we used the average values of 
GAPDH and 18S for normalization. We found that levels of all three C9ORF72 transcript 
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variants are significantly reduced, starting within the first post-natal weeks of age (Figure 
A1.1B, C, D). To confirm our findings, we performed digital droplet quantitative PCR 
(ddPCR) for absolute quantification of the human C9ORF72 levels and observed a similar 
trend (Figure A1.1F). This observation suggests that partial epigenetic repression of the 
transgene in the brain of post-natal C9-BAC mice is age-dependent. Next, we utilized 
chromatin immunoprecipitation (ChIP) to isolate H3K9me3-bound DNA fragments from 
brain samples of 0 and 7 weeks-old C9-BAC mice. H3K9me3 is a repressive epigenetic 
mark that negatively correlates with transcription rates and is enriched within the promoter 
region of expanded C9ORF72 alleles as compared to unexpended alleles [135, 146, 147]. 
Using two different primer sets (C9.A and C9.B), we found that H3K9me3 levels within 
the promoter of the human C9ORF72 transgene were significantly increased in the brain 
of C9-BAC mice by week 7 (Figure A1.1E). Increased H3K9me3 indicates partial 





















Figure A1.1 C9ORF72 transcription decreases while a repressive histone methylation 
mark increases in the brain of C9-BAC mice during the first post-natal weeks 
Relative quantification (RQ) values of mouse beta-actin, GAPDH and 18S endogenous 
controls in C9-BAC mouse cortex across different age groups are shown (A) Values of 
human C9ORF72 in the BAC mouse cortex, normalized to the average of GAPDH and 
18S, are shown for primers amplifying transcript variants V1, V2, V3 (B); V1, V3 (C) and 
V2 (D). Age groups are indicated on the x-axis in weeks (wks.). Mean and standard error 
of the mean (SEM) are indicated by long and short bars respectively. For each primer set, 
a one-way analysis of variance was performed (p<0.001). Bonferroni’s multiple 
comparison test was performed between neonatal (0wks) and the rest of the age groups, 
significance is indicated by p<0.05 * and p<0.01 **. H3K9me3 levels were assessed by 
chromatin immunoprecipitation in brain tissues from 0 and 7-week-old C9-BAC mice 
(n=5). Two different primer sets were used: C9.A and C9.B amplifying regions within the 
human C9ORF72 promoter. Relative enrichment of H3K9me3 was calculated by real-time 
PCR amplification of immunoprecipitants (IP) relative to inputs and an IgG negative 
control IP, p<0.01 ** (E). Absolute copy number of human C9ORF72 transcripts per 
microliter in C9-BAC mice as determined by digital droplet PCR (F), one-way ANOVA 
(p<0.001) and Bonferroni’s multiple comparison test was performed between neonatal 
(0wks) and the remaining age groups, significance is indicated by p<0.05 * and p<0.01 **. 
  
DNA hypermethylation within the promoter of the human C9ORF72 transgene 
occurs in a subset of C9-BAC mice, similar to the human C9-ALS patient population  
In about 30% of all C9-ALS cases, methylated CpG dinucleotides within the C9ORF72 




with a modestly attenuated phenotype indicating that epigenetic repression is clinically 
relevant [139, 140]. To assess levels of DNA methylation within the promoter of the 
C9ORF72 transgene, we extracted DNA from the cortex of C9-BAC mice and performed 
methylation-sensitive PCR as previously reported [147]. Interestingly, we found that in 
three adult mice, the C9ORF72 promoter was hypermethylated, similar to what occurs in 
a subset of human C9-ALS patients (Figure A1.2A). Similar to C9-ALS patients, 
C9ORF72 promoter hypermethylation in C9-BAC mice was stable across different brain 
regions (cortex and cerebellum) and somatic tissues (blood and tail clippings) (Figure 
A1.2B). To confirm these findings, we utilized a secondary method to assess DNA 
methylation. Using bisulfite pyrosequencing, we measured DNA methylation across 8 
different CpG dinucleotides located both upstream and downstream of the transcription 
start site (TSS) of the human C9ORF72 promoter (Figure A1.2C). Furthermore, we have 
eliminated the possibility that increased methylation levels are due to the abnormal copy 
number of the human C9ORF72 transgene by CNV analysis (Figure A1.2E). Our data 
demonstrate that adult mice from the same age group can have differential DNA 
methylation levels within the C9ORF72 promoter, mirroring a phenomenon observed in 
C9-ALS patients. To determine whether promoter hypermethylation affects the production 
of toxic DPRs, we next measured levels of glycine-proline (GP) repeat proteins in the 




Figure A1.2 DNA hypermethylation at the expanded C9ORF72 promoter appears in 
a fraction of adult mice 
A) Site-specific DNA methylation sensitive PCR assessment of the human C9ORF72 
promoter in the cortex of C9-BAC mice at seven time points, indicated in weeks (wks) of 
age. Two HhaI restriction sites located at -215 and -109 base pairs from the transcriptional 
start site were interrogated; three hypermethylated animals are indicated by open shapes 
(17wks square, 30wks triangle and 36wks circle). Assay controls (grey circles on right) 
include DNA isolated from post mortem brain tissues of ALS patients with the 
hexanucleotide repeat expansion (C9+) with (me+) or without (me-) promoter 
hypermethylation, an unaffected healthy control (C9-) individual, and synthetic DNA 
enriched (CTL Me 100%) or depleted of 5mC (CTL Me 0%). Values are plotted relative 
to the synthetic high control, which is set to 100%. (B) C9ORF72 promoter methylation 
assessment from brain cortex, cerebellum, blood and tail clippings of a 30-week-old 
hypermethylated mouse using HhaI methylation sensitive PCR. (C) Bisulfite 
pyrosequencing of brain cortex from 17, 30 and 36 weeks old C9-BAC mice (n=2 per age 
group) across 8 CpG dinucleotides within the human C9ORF72 promoter, positions 
relative to TSS are shown on the x-axis. Filled symbols indicate samples from 
hypermethylated (me+) animals, open symbols are samples from unmethylated (me-) 
animals (D) Glycine-Proline DPR assessment of whole brain tissue samples from 3 
hypermethylated animals (open symbols) and representative unmethylated samples (filled 
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symbols) from 17, 30 and 36-week-old C9-BAC mice (n=3 per age group). (E) Copy 
number variation analysis for human C9ORF72 transgene in C9-BAC mouse brain cortex 
with hypermethylated (me+), unmethylated (me-) promoter and wild-type mouse (WT). 
 
 
Our data indicate that there is a trend towards decreased GP levels in hypermethylated 
mice. Nevertheless, further studies with more animals are required to fully investigate the 
effect of DNA hypermethylation at the C9ORF72 promoter on DPR production in these 
mice. Notably, GP levels in hypermethylated mice negatively correlated with the DNA 
methylation percentile as determined by bisulfite pyrosequencing analysis of 8 CpG 
dinucleotides (Figure A1.3). The goodness of fit (R2) was similar for each of the 8 CpGs 




Figure A1.3 GP levels in hypermethylated mice negatively correlated with the DNA 
methylation 
A) Linear regression analysis of the mean C9ORF72 promoter methylation percentile (as 
determined by bisulfite pyrosequencing) and glycine-proline dipeptide abundance (B) R 
square and p values for individual CpG dinucleotides. (C) Quantitative PCR assessment of 
C9ORF72 expression in hypermethylated C9-BAC mice indicated by open shapes (17wks 
square, 30wks triangle, 36wks circle) and their age group counterparts, error bars represent 
SEM 
 
Methylation of GGGGCC repeat expansion mutation increases with age in C9-BAC 
mice 
 Previously, Xi et al. reported that the HRE itself is methylated in every C9-ALS patient 
with the pathogenic repeat number [148], indicating a protective cellular response. 
Interestingly, the authors argue that the origin of DNA hypermethylation initiates within 
the HRE, but in some individuals, methylation spreads upstream to the promoter region. 
Therefore, we sought to determine if HRE hypermethylation is recapitulated in a C9-BAC 
mouse model of ALS. To quantitatively assess DNA methylation levels at the HRE in C9-
BAC mice, we developed a novel assay that combines the HpaII methylation-sensitive 
restriction digest, which recognizes CCGG sequence, with repeat-primed PCR and 
capillary electrophoresis (Figure A1.4A). Given our finding that expression of the human 
C9ORF72 transgene decreases within the first weeks of life (Figure A1.1), we quantified 
DNA methylation of the HRE at 0, 2 and 7 weeks of age (Figure A1.4B). We observed 
that HRE methylation was present in all three age groups but increased with age, reaching 
significance between 0 and 7 weeks. Representative graphs from one animal per group are 
shown in Figure A1.4C. These findings suggest that methylation of cytosine residues 





Figure A1.4 Hexanucleotide (GGGGCC) repeat methylation increases with age in C9-
BAC mice  
A) An illustration of the HRE methylation assessment method. For each sample, two 
repeat-primed PCR reactions are performed, one using DNA subjected to HpaII digest and 
one using uncut control (UC). DNA methylation percentage is calculated based on the area 
under the curve values following capillary fragment analysis of HpaII digested samples 
normalized to the uncut control sample. (B) HRE methylation levels were assessed at 0 
(n=5), 2 (n=4) and 7 (n=5) weeks of age, significance is indicated by *p<0.05. (C) 
Representative electropherograms from 0 and 7-week-old C9-BAC mouse brain cortex 




Hydroxymethylcytosine is observed at the expanded C9ORF72 promoter in the brain 
of C9-BAC mice 
We previously reported that 5-hydroxymethylcytosine (5hmC), a stable intermediate of the 
DNA demethylation pathway, is a novel epigenetic feature of repeat expansions mutations 
in Fragile X Syndrome and C9-ALS [141, 149]. Here, we sought to determine whether 
5hmC is present at the C9ORF72 promoter of hypermethylated BAC mice as well. We 
performed DNA hydroxymethylation assessment as previously described [141, 149]. We 
found that similar to C9-ALS patients, hypermethylated C9-BAC mice show elevated 
levels of 5hmC at the C9ORF72 promoter sites both upstream and downstream of the TSS 
in the cortex (Figure A1.5A, B). Furthermore, we assessed peripheral tissues from the 30-
week-old hypermethylated mouse. We found that 5hmC enrichment was unique to brain 
tissues (Figure A1.5C, D). This indicates more pronounced DNA demethylation in the 
brain of hypermethylated C9-BAC mice which is consistent with the highest abundance of 
the global 5hmC levels occurring in the central nervous system as compared to other tissue 









Figure A1.5 DNA demethylation is observed at the expanded C9ORF72 promoter 
distinctively in the brain 
A, B) Two CpG dinucleotides located within MspI/HpaII restriction sites at positions − 
313 and + 104 base pairs from the C9ORF72 transcriptional start site were interrogated by 
5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) sensitive PCR. The y-axis 
indicates percent 5hmC (black) and 5mC (grey) from brain cortex samples for a subset of 
C9-BAC mice, error bars represent standard deviation, experiments were performed in 
duplicates. Assessment of 5hmC enrichment at two restriction sites across tissue types of 
a 30-week-old hypermethylated mouse are illustrated in C and D. Student’s t-test was 
performed to determine significance, indicated by p<0.05 * 
 
DNA hypermethylation is acquired independently of RNA-DNA hybrid formation at 
the C9ORF72 locus  
We next sought to investigate one possible mechanism of DNA methylation acquisition at 
the C9ORF72 promoter of ALS patients. By analogy to other repeat expansion disorders, 
such as Fragile X Syndrome and Freidriech’s Ataxia [144, 152], we hypothesized that 
DNA-RNA hybrids or R-loops formed by an expanded C9ORF72 transcript lead to 
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epigenetic silencing. In our previous report, we demonstrated that iPSC lines from a 
hypermethylated ALS patient can be used as a tool to investigate the acquisition of DNA 
methylation at the C9ORF72 promoter [141]. In particular, we showed that DNA 
methylation at the C9ORF72 promoter is erased during iPSC generation and then re-
acquired during neuronal differentiation. To determine whether C9ORF72 promoter DNA 
hypermethylation occurs via DNA-RNA hybrid formation, we created a stable iPSC line 
from a hypermethylated ALS patient expressing a small hairpin RNA targeting all three 
C9ORF72 transcript variants (shC9) or a scrambled control (shCTL). We reasoned that 
disrupting R-loop formation by depleting C9ORF72 mRNAs in iPSCs would prevent DNA 
hypermethylation upon neuronal differentiation, similar to what was previously shown in 
Fragile X Syndrome [152]. We generated stable iPSC cell lines expressing either the shC9 
or shCTL constructs then differentiated the cells into motor neurons using our previously 
published protocols [141]. We confirmed efficient depletion of C9ORF72 in shC9 iPSC 
lines using qPCR (Figure A1.6A). We then confirmed efficient disruption of R-loop 
formation at the C9ORF72 locus in shC9 motor neurons using DNA-RNA 
immunoprecipitation (DRIP) followed by qPCR with primers to amplify regions upstream 
and downstream the HRE (Figure A1.6B, C). Finally, DNA methylation at the C9ORF72 
promoter in motor neurons was assessed across 16 individual CpG dinucleotides using 
bisulfite pyrosequencing (Figure A1.6D). Patient-derived motor neurons from an 
individual with the Fragile X Syndrome that does not harbor C9ORF72 repeat expansion 
were used as a negative control. Despite efficient knockdown of C9ORF72 RNAs and 
disruption of R-loops, we did not observe significant differences in DNA methylation 
levels at the C9ORF72 promoter between shC9 and shCTL motor neurons. These results 
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suggest that R-loops may not be required for the acquisition of DNA hypermethylation 


















Figure A1.6 DNA methylation is acquired independently of RNA-DNA hybrid 
formation at the C9ORF72 locus  
A) Relative quantification of all three C9ORF72 transcript variants in iPSC-derived motor 
neurons stably expressing a C9ORF72-specifc shRNA (shC9) or a scrambled CTL 
(shCTL) (A). DNA-RNA immunoprecipitation at the C9ORF72 promoter of shC9 and 
shCTL motor neurons, relative quantification was measured using two sets of primers, 
designed upstream (B) and downstream (C) of the repeat expansion, RNase H treatment 
was performed prior to pull-down as a negative control. (D) DNA methylation levels at the 
C9ORF72 promoter were assessed using bisulfite pyrosequencing across 16 CpG 
dinucleotides; positions relative to the transcription start site are indicated on the x-axis. 
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Fragile X patient-derived iPSC-neurons (FXS) were used as a negative control. 
Significance is indicated by p<0.05 * and p<0.01 **. 
 
Discussion 
Here we report that C9-BAC mice from Peters and Toro et al. [121] recapitulate epigenetic 
perturbations seen in C9ORF72-associated ALS and FTD patients. We observed 
enrichment of the repressive epigenetic mark H3K9me3 in the promoter of the human 
transgene, which corresponded to decreased transcription rates. We also observed DNA 
methylation within the HRE repeat sequence itself for all mice tested and in 3 mice, this 
methylation had spread to the promoter region. Our data show that HRE-mediated 
epigenetic repression occurs during the first few weeks after birth in C9-BAC mice and 
likely occurs at about the time of birth in humans (2 weeks in the mouse), although the 
unavailability of human tissues makes this difficult to assess. It will be important to 
determine whether epigenetic features of the HRE are shared among different C9-BAC 
lines. Of particular interest will be to determine whether phenotypic severity is associated 
with levels of epigenetic repression, in cases where a phenotype is observed, and whether 
the epigenetic repression is lost (even relatively) as animals continue to age and develop a 
clinical phenotype. 
Our findings demonstrate that epigenetic features of the HRE in humans are mirrored in 
the C9-BAC mouse, and in some cases, appear at a similar levels and frequencies. For 
example, DNA hypermethylation of the HRE itself in C9 ALS/FTD patients occurs at a 
rate of 97% [148]. Using a quantitative assay to assess HRE methylation, we found that all 
C9-BAC mice assessed exhibit hypermethylation of the repeat sequence. This HRE 
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methylation increases with age, although P0 mice also show elevated levels of methylation 
within the repeat. These observations support the hypothesis that increased levels of DNA 
methylation within the repeat precede promoter hypermethylation and is a common feature 
of the HRE that serves a protective role to impede transcription across the mutation [139, 
140, 148, 153]. The C9ORF72 promoter hypermethylation on the other hand, is less 
common in C9-ALS patients, and is only observed in a fraction (~30%) of individuals with 
a pathogenic repeat number [136, 138]. Interestingly, we found that to be true for C9-BAC 
mice as well, where only a small fraction of the adults show DNA hypermethylation at the 
C9ORF72 promoter, across different tissues. This is particularly poignant given the 
neuroprotective effect of the C9ORF72 promoter hypermethylation in vivo [140]. Hence, 
we suggest that it may be important to stratify C9-BAC mice based on their epigenetic 
status while conducting phenotypic assessments and performing pre-clinical testing of 
experimental therapeutics.  
Despite increased levels of repressive histone and DNA methylation marks, expanded 
C9ORF72 alleles sustain sufficient transcriptional activity to produce toxic levels of mutant 
RNAs and DPRs. We have recently identified enrichment of 5hmC, an active DNA 
demethylation intermediate, as a novel epigenetic alteration common to at least two repeat 
expansion disorders: Fragile X Syndrome and C9-ALS [141, 149]. Given the high 
abundance of 5hmC at the C9ORF72 promoter of hypermethylated patients and C9-BAC 
mice, we postulate that active DNA demethylation counteracts the protective 
hypermethylation of the promoter. Active DNA demethylation is a process facilitated by 
the ten-eleven translocation (TET) family proteins and acts as a switch between 
transcriptionally inactive and active gene states [154]. Our data demonstrate that active 
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DNA demethylation is most pronounced in the brain of C9-BAC mice, in concordance 
with the literature indicating that TET activity and global 5hmC levels are highest in 
neurons [150, 155]. Future studies are warranted to investigate the possibility of leveraging 
epigenetic equilibrium, perhaps by using small molecules, in such way that it favors DNA 
hypermethylation to more completely repress the expanded locus. This would be 
hypothesized to reduce the production of toxic products in C9-BAC mice.  
The mechanism by which DNA hypermethylation is established at the C9ORF72 promoter 
has been studied by our group and others [141, 146, 156]. These studies suggest that RNA-
DNA hybrids or R-loops are key mediators of epigenetic repression [157]. Recent 
discoveries in other repeat expansion disorders, including Fragile X Syndrome and 
Freidriech’s Ataxia support this reasoning [144, 152]. Here we investigated this possibility 
using iPSC-derived motor neurons, a method that we have successfully utilized in our 
previous report to model the acquisition of DNA hypermethylation in C9-ALS [141]. We 
show that despite their presence at the C9ORF72 promoter of C9-ALS patient derived cells, 
reducing R-loop formation by depleting HRE RNAs is not sufficient to prevent the 
acquisition of DNA hypermethylation. Future studies could investigate alternative 
mechanisms leading to the epigenetic repression of HRE promoters. Though we did not 
address this issue here, it would also be interesting to see whether C9ORF72 knockdown 
in C9-BAC mice will have any effect on the levels of DNA methylation associated with 
the expanded locus. 
In conclusion, we have determined that epigenetic perturbations seen in C9-ALS patients 
are also observed in C9-BAC mice and that R-loops are unlikely to be initiators of DNA 
methylation at the expanded C9ORF72 locus. Since many repeat expansion mutations, 
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including C9-ALS, have an epigenetic component that is directly linked to pathology, our 
observations are of significant importance for understanding the mechanism of disease and 
are of consequence for therapeutic development efforts utilizing C9-BAC mouse models. 
Methods 
C9-BAC mice 
 Animals used in the present study have previously been described [121]. Briefly, a BAC 
containing human sequence from a C9-ALS patient, spanning the gene promoter to exon 
6, was inserted into the mouse genome using standard transgenic methods. All 
experimental procedures involving transgenic mice were performed in accordance with the 
guidelines of Institutional Animal Care and Use Committee of the University of 
Massachusetts Medical School. 
DNA and RNA extraction 
Genomic DNA and total RNA extractions were performed from 30mg of mouse brain 
tissues using a kit (AllPrep DNA/RNA Mini Kit®, Qiagen #80204) as per manufacturers' 
instructions. 
Quantitative PCR (qPCR) 
Reactions were performed using TaqMan® assays that amplify C9ORF72 transcript 
variants V1, V2, V3 (Hs00376619_m1), C9ORF72 V1, V3 (Hs00331877_m1), C9ORF72 
V2 (NM_018325.3, L/R/Probe: 5’CGGTGGCGAGTGGATATCTC / 
5’TGGGCAAAGAGTCGACATCA/ 5’TAATGTGACAGTTGGAATGC), mouse 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Mm99999915_g1), beta-actin 
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(Mm00607939_s1), eukaryotic 18S ribosomal RNA (Hs99999901_s1) and human 
GAPDH (Hs02758991_g1). Relative quantification values were calculated using a 
standard curve method, normalized to the average of GAPDH and 18S endogenous control 
genes. 
Digital droplet PCR (ddPCR) 
For gene expression, 500ng of total RNA was used in a 20µl reaction to generate 
complementary DNA (cDNA) using random hexamer primers and MultiScribe reverse 
transcriptase (High capacity RNA-to-cDNA Kit, Life Technologies). After diluting the 
cDNA 1:1.25, 2µl were loaded into a 20µl reaction containing ddPCR Supermix for Probes 
(nodUTP) (Bio-Rad, Gladesville, NSW, Australia), and 1µl of primers amplifying all three 
C9ORF72 transcripts (Hs00376619_m1, Life Technologies). The 20µl sample, along with 
70µl of ddPCR-oil was loaded into a DG8 cartridge and covered with a gasket according 
to manufacturer’s instructions; the cartridge was then placed in a QX100 droplet generator. 
40µl of sample were then transferred to a 96-well PCR plate and put in a normal PCR 
thermocycler (Eppendorf, North Ryde, NSW, Australia). The plate was then placed in the 
QX100 ddPCR reader (Bio-Rad, Gladesville, NSW, Australia) for absolute quantification.  
Methylation-sensitive quantitative PCR 
DNA methylation at the C9ORF72 promoter was assessed using previously reported 
methods [147]. Briefly, 100ng of genomic DNA was used for methylation-sensitive 
restriction digest with 4 units of HhaI endonuclease. Two sets of primers were used for 
subsequent quantitative PCR: C9me (L/R: 5’CGGTAAAAACAAAATTTCATCCA / 
5’GGGCAACTTGTCCTGTTCTT) spans two HhaI restriction sites within the C9ORF72 
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promoter, and C9ec (L/R: 5’AGGAAAGAGAGGTGCGTCAA / 
5’TCCTAAACCCACACCTGCTC) was used as an endogenous control. 
Bisulfite pyrosequencing 
Genomic DNA (2µg) was treated with bisulfite and analyzed by pyrosequencing 
(EpigenDx Inc.) as previously reported [141]. The DNA methylation assessment was 
performed using the PSQTM96HS system and custom assays developed by EpigenDx 
(ADS3232-FS1 and ADS3232-FS2). The assay covers 16 cytosine residues within the 
C9ORF72 promoter from −55 to +125 base pairs relative to the C9ORF72 transcriptional 
start site. 
Copy Number Variation (CNV) analysis 
C9ORF72 mouse brains were fresh frozen and cut in a sagittal section to extract DNA. The 
tissue was lysed overnight at 55°C, RNAse treated and eluted following manufacturer’s 
instructions (Gentra Puregene Tissue Kit, Qiagen). The DNA was diluted to 20ng/µl and 
2µl were added to the ddPCR master mix along with 1µl of each primer/probe. Primer and 
probe sequences used for human genomic C9ORF72 (L/R/Probe: 
5’AAGGCACAGAGAGAATGGAAG / 5’AGGCTTATTCGTATGTCTCCAAG / 
5’AGGTTGATGGCTACATTTGTCAAGGC) and for mouse EIF2C1 diploid genome 
(L/R/Probe: 5’CCTGCCATGTGGAAGATGAT / 5’GAGTGTGGTGGCTGGATTTA / 
5’TGGGGAGAGCTGGAGCCAG) quantification are indicated. Droplets were generated 





Poly (GP) immunoassay 
C9-BAC whole brain tissues were lyzed in buffer containing 50 mM Tris–HCl, pH 7.4, 
300 mM NaCl, 1% Triton X-100, 2% sodium dodecyl sulfate, 5 mM EDTA, as well as 
protease (EMD Millipore) and phosphatase inhibitors (Sigma-Aldrich). After sonication, 
samples were centrifuged at 16,000 x g for 20 min at 4°C and supernatants collected. The 
protein concentration of lysates was determined by BCA assay (Thermo Scientific). Poly 
(GP) levels in lysates were measured using a previously described sandwich immunoassay 
that utilizes Meso Scale Discovery (MSD) electrochemiluminescence detection technology 
[158]. Lysates were diluted in Tris-buffered saline (TBS) and tested using 43 µg of protein 
per well in duplicate wells. Serial dilutions of recombinant (GP)8 in TBS were used to 
prepare the standard curve. Response values corresponding to the intensity of emitted light 
upon electrochemical stimulation of the assay plate using the MSD QUICKPLEX SQ120 
were acquired for interpolation of poly (GP) levels using the standard curve.  
Generation of C9ORF72 depleted induced pluripotent stem cell lines 
 Previously, we generated several patient-derived iPSC lines from C9ORF72 ALS patients 
[141]. One of these lines was transduced with a lentiviral vector (Sigma-Aldrich, SHCLNV-
NM-018325, clone TRCN0000148881) expressing a puromycin resistance gene and a 
small hairpin RNA (shRNA) targeting all three C9ORF72 transcript variants. Transduction 
of iPSCs (MOI=3) was carried out in the absence of polybrene. Selection was performed 
in the presence of puromycin (1µg/ml) for 10 days; surviving colonies were expanded and 




Motor neuron differentiation 
 Motor neuronal differentiation was performed according to our previously published 
protocol [147]. Briefly, neural precursor spheres were differentiated from iPSC colonies 
using neural induction medium and cultured in ultra-low attachment flasks. Afterwards, 
spheres were seeded onto poly-L-ornithine and laminin-coated plates with neuronal 
induction medium and cultured for four weeks to obtain terminally differentiated motor 
neurons. 
DNA-RNA immunoprecipitation (DRIP) 
The DRIP protocol was adapted from Loomis et al. [159] with some modifications. Here, 
5x106 cells were lysed with 0.5% SDS and treated with 400 units of proteinase K at 37°C 
overnight. The next day, DNA extraction was performed using standard 
phenol/chloroform/isopropanol precipitation. Fifty micrograms of DNA were digested 
with EcoR1, HindIII, BsrGI, and XbaI (20 units each) at 37°C for 1 hour. Next, samples 
were incubated in the presence of the S9.6 antibody (Kerafast ENH001) for 2 hours at 4°C 
with inversion. As a control, samples were treated with 25 units of RNase H (ThermoFisher 
Scientific #EN0201) for 6 hours at 37°C. Following DRIP, DNA was precipitated with 
isopropanol and used for quantitative PCR with primers amplifying a region upstream 
(L/R: 5’AAGAGCAGGTGTGGGTTTAG / 5’GAGTACTGTGAGAGCAAGTAGTG) 
and downstream (L/R: 5’CTCAGAGCTCGACGCATTT / 





C9ORF72 GGGGCC repeat methylation assessment 
 To measure C9ORF72 HRE methylation, we combined HpaII methylation-sensitive 
restriction digest with the repeat-primed PCR assay in the presence of 5% dimethyl 
sulfoxide and complete substitution of 7-deaza-2-deoxy GTP for dGTP as previously 
described [141]. PCR fragments were analyzed using the ABI3730 DNA Analyzer and 
GeneMapper software. The area under the curve (AUC) values were calculated for peaks 
higher than 150 base pairs. The AUC of digested samples were normalized to AUC of 
uncut controls to calculate the percent DNA methylation of the HRE sequence. 
DNA hydroxymethylation assessment 
 To quantify 5hmC and 5mC levels at the C9ORF72 promoter, we utilized the EpiMark® 
5-hmC and 5-mC Analysis Kit (New England Biolabs E3317), according to the 
manufacturer’s protocol as previously reported [141]. Briefly, 2µg of genomic DNA was 
subjected to glycosylation by T4 β-glucosyltransferase, converting 5hmC to 5ghmC 
residues. Glucosylated DNA was then digested with MspI or HpaII endonucleases for 6 
hours at 37°C and subsequently amplified by quantitative PCR using the -313bp primer set 
(L/R: 5’AGGAAAGAGAGGTGCGTCAA / 5’TCCTAAACCCACACCTGCTC) and 
+104bp primer set (L/R: 5’AAATTGCGATGACTTTGCAG / 
5’ACTGCAAACCCTGGTAGG), each of which spans one CCGG MspI/HpaII restriction 
site. 
Chromatin immunoprecipitation (ChIP)  
Immunoprecipitation of H3K9me3 was performed as we previously reported [147]. 
Briefly, 50mg of brain tissue was sliced into small pieces and crosslinked in 1% 
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formaldehyde for 10 minutes and quenched with 0.125 M glycine for 5 minutes at room 
temperature. Sonication was performed for 5 minutes using the Bioruptor UCD200 
sonication system set to the high setting. Lysates were then transferred to a tube containing 
Protein G Dynabeads prepared with an anti-H3K9me3 antibody (Abcam ab8898), or 
control rabbit IgG, and incubated overnight at 4°C with rotation. The following day, 
stringency washes were performed, and samples were re-suspended in 150 μL elution 
buffer consisting of 1% SDS, 0.1M NaHCO3, 0.2M NaCl and incubated at 65°C overnight. 
The next day, samples were de-crosslinked by treatment with 50μL proteinase K and 
incubated at 42°C for 2 hours. De-crosslinked genomic DNA was isolated using the 
QiaQuick PCR purification kit (Qiagen #28104) according to the manufacturer’s 
instructions. Quantitative PCR was performed using two primer sets: C9.A (L/R: 
5’ACTCGCTGAGGGTGAACAAG / 5’TCCTGAGTTCCAGAGCTTGC) and C9.B 




Appendix II  
RNAi gene therapy for hereditary sensory neuropathy 1 (HSAN1) 
Introduction 
Hereditary sensory autonomic neuropathy 1 (HSAN1) is a rare subtype of sensory 
neuropathy with a low prevalence of <200,000 individuals in the US population [160]. This 
autosomal dominant disease is associated with missense mutations in the serine 
palmitoyltransferase (SPT), long chain base subunit 1 (SPTLC1) gene. Mutations in the 
SPTLC1 gene lead to progressive degeneration of dorsal root ganglion (DG) and motor 
neurons. Studies have shown demyelination of said neurons causes loss of sensory and 
temperature sensation in hands and feet along with muscle atrophy and weakness. Due to 
loss of sensation patients commonly present ulcers which can become infected and result 
in amputation[160, 161].  
SPT is the main enzyme involved in sphingolipid biosynthesis, it drives the conversion of 
L-serine and palmitoyl CoA to 3-oxosphinganine. It is a major component in the formation 
of lipid rafts in cell membranes that enable signal transduction [162]. Mutations in this 
gene alter the substrate specificity allowing the formation of 2 atypical deoxy-sphingoid 
bases (DSB). 1-deoxy-sphinganine (doxSA) and 1-deoxymethyl-sphinganine 
(doxmethSA), both lack a C (1) hydroxyl group of sphinganine, making them unsuitable 
for conversion to complex sphingolipids or degradation. Hence, they accumulate in the 
cells, becoming neurotoxic[161, 162] 
Eichler et al., 2009 showed that overexpression of the wild type SPT1 subunit can lower 
(DSB) levels and rescue the HSAN1 phenotype in mice [162]. Henceforth, recent research 
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in mice and humans showed that an oral supplementation of L-serine could decrease 
neurotoxic DSBs and could be used as a temporary initial treatment for this disease [163]. 
Human clinical trials to evaluate the safety and efficacy of l-serine supplementation to 
HSAN1 patients revealed a slowed progression of the disease [164]. Although 
encouraging, oral supplementation L-serine is not a permanent solution. Given that this 
disease results from a gain- of- function mutation in SPTLC1, a silencing approach would 
be the best therapeutic strategy. By using AAV mediated artificial microRNAs to silence 
the SPTLC1 gene we can target the mRNA and consequently reduce the production of the 
toxic DSB.  
Prior to designing the microRNAs, we sought to find existing mouse models that could aid 
us in testing the efficacy of our therapeutic in vivo. The only available model to date is a 
transgenic mouse which has the Chinese hamster SPTLC1 gene carrying the C133W 
mutation [165]. Since our end goal is to design microRNAs that will target either human 
and/or hamster SPTLC1 we verified that the gene sequence was conserved across these 
different species. [165]. In order to screen for human targeting microRNAs, we used human 
embryonic kidney cells (HEK293T), to screen for hamster targeting we used Chinese 
hamster ovary cells (CHO) and to verify the specificity of the microRNAs in targeting 
human and hamster but not mouse we screened in a neuroblastoma mouse cell line (N2A). 
We began by testing multiple primers and probes for SPTLC1 and HPRT cross-reactivity 











In Figure A2.1 ddPCR mRNA data of the assay specificity screen shows we can accurately 











FigureA2.1: Probe specificity screen 
TaqMan and ddPCR probes were used to test the cross reactivity in human (HEK293T), 
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run using ddPCR and HPRT as an endogenous control. Ratios to HPRT are graphed for 




We have designed microRNAs that target human, hamster or both SPTLC1 simultaneously 
(Table A2.2), all microRNAs were cloned into the same entry plasmid containing Flanking 
ITRs for AAV packaging and a strong (Polymerase III) H1 promoter driving the 
microRNA, followed by Chicken Beta Actin (CB) driving the expression of enhanced 
green fluorescent protein (eGFP) (Figure A2.2A). An example of the microRNA with its 
2-8 nucleotide seed is depicted (Figure A2.2B) and an illustration of an artificial 




















Figure A2.2: microRNA plasmid construct, illustration and sample sequence for 
amiR519  
(A) Plasmid construct containing flanking ITRs, followed by an H1 promoter driving 
expression of microRNAs and a Chicken beta- actin (CB) promote driving GFP expression 
ending with a polyA tail. (B) Example of an artificial microRNA sequence with the 2-8 
nucleotide seed highlighted in red. (C) amiR519 shown here targets both human and 









Artificial microRNAS silence SPTLC1 in vitro  
Human microRNAs were screened using HEK293T (Figure A2.3) cells, and hamster 
microRNAS were screened in a CHO cell line (Figure A2.4), RNA was extracted, and 
mRNA was quantified through digital PCR (ddPCR). Here we show in three independent 
biological replicates that we can significantly silence human and hamster SPTLC1, 48 







Figure A2.3: human microRNA screening in HEK293T cell line 
HEK293T cells were transfected with 3 different artificial microRNAs cloned into the 
plasmid construct shown in (Figure A2.2). ddPCR analysis of expression of human 
SPTLC1 was normalized to Human HPRT and in reference to miR control. In addition, 
H1- amiRC9 a microRNA targeting the C9ORF72 human gene was used as a microRNA 
control. miR603 and miR520 are human targeting and show significant mRNA silencing 
of~ 80%. miR 519 targets hamster and has a slight non-significant decrease of SPTLC1 
(mean ±SEM, n=3, biological replicates, Student-T test (p ≥0.05 not significant; p* 0.01-
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Figure A2.4: human microRNA screening in CHO cell line 
CHO cells were transfected with 3 different artificial microRNAs cloned into the plasmid 
construct shown in (Figure A2.2). ddPCR analysis of expression of human SPTLC1 was 
normalized to Hamster HPRT and in reference to miR control. In addition, H1- amiRC9 a 
microRNA targeting the C9ORF72-ALS human gene was used as a microRNA control. 
miR603 and miR520 are human targeting and show slight mRNA silencing of~ 30%. miR 
519 targets hamster and silences SPTLC1 by 80% (mean ±SEM, n=3, biological replicates, 
Student-T test (p ≥0.05 not significant; p* 0.01-0.05; p** 0.001-0.01; p*** 0.0001-0.001; 
p****<0.0001). 
 
Although these microRNAS are designed to target human and hamster specifically we first 
sought to verify that the microRNAS would not silence mouse SPTLC1 as well. Keeping 
in mind that future in vivo experiments would involve using the hamster transgenic mouse 
model and miss-targeting due to sequence similarity between hamster and mouse could 
lead to misleading data. To this end we used a mouse neuroblastoma cell line (N2A) and 
transfected the plasmids containing the microRNAs. ddPCR analysis in (Figure A2.4) 
illustrated only miR519 could slightly silence mouse SPTLC1 by 20%. All other 
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Figure A2.5: microRNA screening in N2A cell line 
N2Acells were transfected with 3 different artificial microRNAs cloned into the plasmid 
construct shown in (Figure A2.2). ddPCR analysis of expression of human SPTLC1 was 
normalized to mouse HPRT and in reference to miR control. In addition, H1- amiRC9 a 
microRNA targeting the C9ORF72-ALS human gene was used as a microRNA control. 
miR 519 targets hamster and shows a slight silencing trend of 25% of mouse SPTLC1 




Although HSAN1 is not a fatal disease, as a sensory neuropathy it does affect a patient’s 
quality of life. Some patients, in addition to suffering from ulcers, infections and limb 
weakness, also experience hearing loss or are unable to walk due to pain. The need for a 
therapy that would permanently prevent mutant SPTLC1 from forming DSBs would be 
optimal. Knowing that an AAV mediated microRNA approach would silence both mutant 
and healthy alleles, a silence and replace approach is a more reasonable option. To this end 
both, a microRNA silencing SPTLC1 and the healthy SPTLC1 cDNA would be delivered 






































































microRNA targeting by having 2-3 mismatches while coding for the same amino acid 
protein.  
Moving forward, these microRNAs will be packaged into AAVs for in vivo delivery to the 
CNS. An early intervention may be the best approach in patients, to prevent further 
demyelination of neuronal fibers. However, preliminary in vivo screening in mice would 
most likely entail either a direct intrathecal injection to the CSF in adult mice, or a systemic 
intravenous (IV) injection in neonate mice as a surrogate for a peripheral delivery in 
patients.   
Future studies using a BAC transgenic mouse with the human SPTLC1 or a knock-In 
mouse would be a useful tool to validate the efficiency of this approach. Based on this 
preliminary data we hypothesize that decreasing the amount of SPTLC1 by 80% should be 
sufficient to delay disease onset at 10 months of age in the HSAN1 mouse model [165] and 
decrease peripheral axonal demyelination. This work remains to be done and we believe it 




MicroRNA design and cloning  
A 22-nucleotide artificial miRNA against human exons 6-7 and hamster SPTLC1 gene was 
designed and cloned into the miR-155 backbone [166]. Each microRNA in Table A2.2 
was cloned into an entry plasmid construct containing ITRs flanking a human H1 promoter 
driving the expression of the microRNA, followed by a CMV enhancer and a Chicken beta 
actin (CB) promoter driving the expression of eGFP (Figure A2.2A)  
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Table A.2.2: MicroRNA list  
 
In vitro plasmid screening in HEK293T, CHO cells and N2A cells  
HEK293T and CHO cells were seeded (1.2 E5 cell/ml) in a 24 well plate, maintained with 
DMEM media (11995-073; Gibco), 10% Fetal Bovine Serum FBS (F-0926 Sigma-
Aldrich) and 1% Penicillin- Streptomycin (30-001-CI; Corning). The plated cells were 
transfected using jetPRIME reagent (Polyplus) following the manufactures instructions 
and 1µg of each microRNA plasmid DNA (Table A2.2). Forty-eight hours post-
transfection, GFP expression was visually assessed; cells were rinsed with PBS and 
collected using Trizol Reagent (Gibco BRL, Life Technologies, NY, and USA) for RNA 
isolation. Complementary DNA (cDNA) was generated using (High capacity RNA-to-
cDNA Kit, Life Technologies). cDNA was diluted to 20ng/µl and a master mix was 
prepared for ddPCR. 
Droplet Digital PCR (ddPCR) was run as a 20µl reaction containing ddPCR Supermix for 
Probes (no dUTP) (Bio-Rad, Gladesville, NSW, Australia), 1µl of diluted cDNA, 1µl of 
each primer/probe (20x), HPRT with a HEX label was used as an endogenous control, and 
miR-520 
(Human exon 6) 
Top  5'- TGCTGTTTAGAGTAAGCAGGAATAGCGTTTTGGCCACTGACTGACGCTATTCCCTTACTCTAAA -3' 
Bottom  5'- CCTGTTTAGAGTAAGGGAATAGCGTCAGTCAGTGGCCAAAACGCTATTCCTGCTTACTCTAAAC -3' 
miR-603 
(Human exon 7) 
Top  5'- TGCTGAACTTAATGTCACTACGGGATGTTTTGGCCACTGACTGACATCCCGTAGACATTAAGTT -3' 
Bottom  5'- CCTGAACTTAATGTCTACGGGATGTCAGTCAGTGGCCAAAACATCCCGTAGTGACATTAAGTTC -3' 
miR-519 
(Hamster) 
Top  5'- TGCTGTTTAGAGTACGCAGGAATCGCGTTTTGGCCACTGACTGACGCGATTCCCGTACTCTAAA -3' 
Bottom  5'- CCTGTTTAGAGTACGGGAATCGCGTCAGTCAGTGGCCAAAACGCGATTCCTGCGTACTCTAAAC -3' 
143 
 
SPTLC1 assays with FAM labels (Table A2.3). The 20µl sample, along with 70µl of 
ddPCR-oil were loaded into a DG8 cartridge and covered with a gasket according to 
manufacturer’s instructions; the cartridge was then placed in a QX100 droplet generator. 
Into a 96 well PCR plate 40µl of sample were transferred and then placed in a PCR 
thermocycler (Eppendorf, North Ryde, NSW, and Australia). The plate was then placed in 
the QX100 ddPCR reader (Bio-Rad, Gladesville, NSW, Australia) for absolute 
quantification. Ratios were obtained by dividing absolute SPTLC1 values to the absolute 
endogenous HPRT values. Samples were normalized in respect to miR controls. GraphPad 
Prism Program was used to graph and run statistical Student- T tests for three biological 
replicates. 
Table A2.3: Primer and Probes  
 Gene Expression Assay 
ID 
SPTLC1 Hamster GEX: Cg04422833_g1 
SPTLC1 Mouse  GEX: Mm00447350_m1 
SPTLC1 Human GEX: Hs01116903_m1 
HPRT Human  GEX: qHsaCIP0030549 
HPRT hum: Bio-Rad GEX: qHsaCIP0030549 









1. Chio, A., et al., Global epidemiology of amyotrophic lateral sclerosis: a 
systematic review of the published literature. Neuroepidemiology, 2013. 41(2): p. 
118-30. 
2. Flotte, T.R., S.A. Afione, and P.L. Zeitlin, Adeno-associated virus vector gene 
expression occurs in nondividing cells in the absence of vector DNA integration. 
Am J Respir Cell Mol Biol, 1994. 11(5): p. 517-21. 
3. Arthur, K.C., et al., Projected increase in amyotrophic lateral sclerosis from 2015 
to 2040. Nature Communications, 2016. 7: p. 12408. 
4. Murros, K. and R. Fogelholm, Amyotrophic lateral sclerosis in Middle-Finland: 
an epidemiological study. Acta Neurologica Scandinavica, 1983. 67(1): p. 41-47. 
5. Byrne, S., et al., Rate of familial amyotrophic lateral sclerosis: a systematic 
review and meta-analysis. Journal of neurology, neurosurgery, and psychiatry, 
2011. 82(6): p. 623-627. 
6. Kiernan, M.C., et al., Amyotrophic lateral sclerosis. Lancet, 2011. 377(9769): p. 
942-955. 
7. Siddique, T. and S. Ajroud-Driss, Familial amyotrophic lateral sclerosis, a 
historical perspective. Acta myologica : myopathies and cardiomyopathies : 
official journal of the Mediterranean Society of Myology / edited by the Gaetano 
Conte Academy for the study of striated muscle diseases, 2011. 30(2): p. 117-120. 
8. Renton, A.E., et al., A hexanucleotide repeat expansion in C9ORF72 is the cause 
of chromosome 9p21-linked ALS-FTD. Neuron, 2011. 72(2): p. 257-268. 
9. DeJesus-Hernandez, M., et al., Expanded GGGGCC hexanucleotide repeat in 
noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. 
Neuron, 2011. 72(2): p. 245-256. 
10. Gijselinck, I., et al., A C9orf72 promoter repeat expansion in a Flanders-Belgian 
cohort with disorders of the frontotemporal lobar degeneration-amyotrophic 
lateral sclerosis spectrum: a gene identification study. Lancet Neurol, 2012. 
11(1): p. 54-65. 
11. Boeynaems, S., et al., Inside out: the role of nucleocytoplasmic transport in ALS 
and FTLD. Acta Neuropathol, 2016. 132(2): p. 159-73. 
12. Zhang, K., et al., Nucleocytoplasmic transport in C9orf72-mediated ALS/FTD. 
Nucleus, 2016. 7(2): p. 132-7. 
13. Zhang, Y.J., et al., Heterochromatin anomalies and double-stranded RNA 
accumulation underlie C9orf72 poly(PR) toxicity. Science, 2019. 363(6428). 
14. Boeynaems, S., et al., Drosophila screen connects nuclear transport genes to 
DPR pathology in c9ALS/FTD. Sci Rep, 2016. 6: p. 20877. 
15. Shi, Y., et al., Haploinsufficiency leads to neurodegeneration in C9ORF72 
ALS/FTD human induced motor neurons. Nat Med, 2018. 24(3): p. 313-325. 
16. Morris, H.R., et al., Recent advances in the genetics of the ALS-FTLD complex. 
Current neurology and neuroscience reports, 2012. 12(3): p. 243-250. 
17. Ciura, S., et al., Loss of function of C9orf72 causes motor deficits in a zebrafish 
model of Amyotrophic Lateral Sclerosis. Annals of Neurology, 2013. 
145 
 
18. Mackenzie, I.R., P. Frick, and M. Neumann, The neuropathology associated with 
repeat expansions in the C9ORF72 gene. Acta Neuropathol, 2014. 127(3): p. 347-
57. 
19. Gao, F.B., S. Almeida, and R. Lopez-Gonzalez, Dysregulated molecular 
pathways in amyotrophic lateral sclerosis-frontotemporal dementia spectrum 
disorder. Embo j, 2017. 36(20): p. 2931-2950. 
20. Mori, K., et al., Bidirectional transcripts of the expanded C9orf72 hexanucleotide 
repeat are translated into aggregating dipeptide repeat proteins. Acta 
Neuropathol, 2013. 126(6): p. 881-93. 
21. Mori, K., et al., The C9orf72 GGGGCC repeat is translated into aggregating 
dipeptide-repeat proteins in FTLD/ALS. Science (New York, N.Y.), 2013. 
339(6125): p. 1335-1338. 
22. Ash, P.E., et al., Unconventional translation of C9ORF72 GGGGCC expansion 
generates insoluble polypeptides specific to c9FTD/ALS. Neuron, 2013. 77(4): p. 
639-646. 
23. Martier, R., et al., Artificial MicroRNAs Targeting C9orf72 Can Reduce 
Accumulation of Intra-nuclear Transcripts in ALS and FTD Patients. Mol Ther 
Nucleic Acids, 2019. 14: p. 593-608. 
24. Jovicic, A., et al., Modifiers of C9orf72 dipeptide repeat toxicity connect 
nucleocytoplasmic transport defects to FTD/ALS. Nat Neurosci, 2015. 18(9): p. 
1226-9. 
25. Miller, R.G., et al., Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron 
disease (MND). Cochrane Database Syst Rev, 2002(2): p. Cd001447. 
26. Takei, K., et al., Post-hoc analysis of randomised, placebo-controlled, double-
blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral 
sclerosis. Amyotroph Lateral Scler Frontotemporal Degener, 2017. 18(sup1): p. 
49-54. 
27. Cruz, M.P., Edaravone (Radicava): A Novel Neuroprotective Agent for the 
Treatment of Amyotrophic Lateral Sclerosis. P t, 2018. 43(1): p. 25-28. 
28. Hester, M.E., et al., AAV as a gene transfer vector for the treatment of 
neurological disorders: novel treatment thoughts for ALS. Current gene therapy, 
2009. 9(5): p. 428-433. 
29. Schoch, K.M. and T.M. Miller, Antisense Oligonucleotides: Translation from 
Mouse Models to Human Neurodegenerative Diseases. Neuron, 2017. 94(6): p. 
1056-1070. 
30. Fields, B.N., D.M. Knipe, and P.M. Howley, Fields virology. 2007, Philadelphia: 
Wolters Kluwer Health/Lippincott Williams & Wilkins. 
31. De Jong, W.H. and P.J. Borm, Drug delivery and nanoparticles:applications and 
hazards. Int J Nanomedicine, 2008. 3(2): p. 133-49. 
32. Afione, S.A., et al., In vivo model of adeno-associated virus vector persistence 
and rescue. J Virol, 1996. 70(5): p. 3235-41. 
33. Berns, K.I., The Gordon Wilson Lecture. From basic virology to human gene 
therapy. Trans Am Clin Climatol Assoc, 1999. 110: p. 75-85. 
34. Berns, K.I. and N. Muzyczka, AAV: An Overview of Unanswered Questions. Hum 
Gene Ther, 2017. 28(4): p. 308-313. 
146 
 
35. Flotte, T.R. and K.I. Berns, Adeno-associated virus: a ubiquitous commensal of 
mammals. Human Gene Therapy, 2005. 16(4): p. 401-407. 
36. Gruntman, A.M., et al., Gene transfer in skeletal and cardiac muscle using 
recombinant adeno-associated virus. Current protocols in microbiology, 2013. 
Chapter 14: p. Unit 14D.3. 
37. McCarty, D.M., P.E. Monahan, and R.J. Samulski, Self-complementary 
recombinant adeno-associated virus (scAAV) vectors promote efficient 
transduction independently of DNA synthesis. Gene Ther, 2001. 8(16): p. 1248-
54. 
38. Yan, Z., et al., Trans-splicing vectors expand the utility of adeno-associated virus 
for gene therapy. Proc Natl Acad Sci U S A, 2000. 97(12): p. 6716-21. 
39. Duque, S., et al., Intravenous administration of self-complementary AAV9 enables 
transgene delivery to adult motor neurons. Molecular therapy : the journal of the 
American Society of Gene Therapy, 2009. 17(7): p. 1187-1196. 
40. Foust, K.D., et al., Intravascular AAV9 preferentially targets neonatal neurons 
and adult astrocytes. Nat Biotechnol, 2009. 27(1): p. 59-65. 
41. Fu, H., et al., Correction of neurological disease of mucopolysaccharidosis IIIB in 
adult mice by rAAV9 trans-blood-brain barrier gene delivery. Molecular therapy : 
the journal of the American Society of Gene Therapy, 2011. 19(6): p. 1025-1033. 
42. Gray, S.J., et al., Preclinical differences of intravascular AAV9 delivery to 
neurons and glia: a comparative study of adult mice and nonhuman primates. 
Molecular therapy : the journal of the American Society of Gene Therapy, 2011. 
19(6): p. 1058-1069. 
43. McLean, J.R., et al., Widespread neuron-specific transgene expression in brain 
and spinal cord following synapsin promoter-driven AAV9 neonatal 
intracerebroventricular injection. Neurosci Lett, 2014. 576: p. 73-8. 
44. Samaranch, L., et al., Adeno-associated virus serotype 9 transduction in the 
central nervous system of nonhuman primates. Human Gene Therapy, 2012. 
23(4): p. 382-389. 
45. Schuster, D.J., et al., Biodistribution of adeno-associated virus serotype 9 (AAV9) 
vector after intrathecal and intravenous delivery in mouse. Front Neuroanat, 
2014. 8: p. 42. 
46. Stoica, L., et al., Adeno-associated virus-delivered artificial microRNA extends 
survival and delays paralysis in an amyotrophic lateral sclerosis mouse model. 
Ann Neurol, 2016. 79(4): p. 687-700. 
47. Xie, J., et al., MicroRNA-regulated, systemically delivered rAAV9: a step closer 
to CNS-restricted transgene expression. Mol Ther, 2011. 19(3): p. 526-35. 
48. Mueller, C., et al., Sustained miRNA-mediated knockdown of mutant AAT with 
simultaneous augmentation of wild-type AAT has minimal effect on global liver 
miRNA profiles. Molecular therapy : the journal of the American Society of Gene 
Therapy, 2012. 20(3): p. 590-600. 
49. Mueller, C., et al., 5 Year Expression and Neutrophil Defect Repair after Gene 
Therapy in Alpha-1 Antitrypsin Deficiency. Mol Ther, 2017. 25(6): p. 1387-1394. 
50. Wang, D., et al., Adeno-Associated Virus Neutralizing Antibodies in Large 
Animals and Their Impact on Brain Intraparenchymal Gene Transfer. Mol Ther 
Methods Clin Dev, 2018. 11: p. 65-72. 
147 
 
51. Sathasivam, S., Motor neurone disease: clinical features, diagnosis, diagnostic 
pitfalls and prognostic markers. Singapore medical journal, 2010. 51(5): p. 367-
72; quiz 373. 
52. Nowakowski, R.S., Stable neuron numbers from cradle to grave. Proc Natl Acad 
Sci U S A, 2006. 103(33): p. 12219-20. 
53. Harvey, R.J., M. Skelton-Robinson, and M.N. Rossor, The prevalence and causes 
of dementia in people under the age of 65 years. Journal of neurology, 
neurosurgery, and psychiatry, 2003. 74(9): p. 1206-1209. 
54. Mercy, L., et al., Incidence of early-onset dementias in Cambridgeshire, United 
Kingdom. Neurology, 2008. 71(19): p. 1496-1499. 
55. Ratnavalli, E., et al., The prevalence of frontotemporal dementia. Neurology, 
2002. 58(11): p. 1615-1621. 
56. Williams, D.B., D.A. Floate, and J. Leicester, Familial motor neuron disease: 
differing penetrance in large pedigrees. Journal of the neurological sciences, 
1988. 86(2-3): p. 215-230. 
57. Ferri, C.P., et al., Global prevalence of dementia: a Delphi consensus study. The 
Lancet, 2005. 366(9503): p. 2112-2117. 
58. de Lau, L.M. and M.M. Breteler, Epidemiology of Parkinson's disease. Lancet 
Neurol, 2006. 5(6): p. 525-35. 
59. Borel, F., M.A. Kay, and C. Mueller, Recombinant AAV as a Platform for 
Translating the Therapeutic Potential of RNA Interference. Mol Ther, 2013. 
60. Davidson Bl Fau - McCray, P.B., Jr. and P.B. McCray, Jr., Current prospects for 
RNA interference-based therapies. (1471-0064 (Electronic)). 
61. Napoli, C., C. Lemieux, and R. Jorgensen, Introduction of a Chimeric Chalcone 
Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous 
Genes in trans. Plant Cell, 1990. 2(4): p. 279-289. 
62. van der Krol, A.R., et al., Flavonoid genes in petunia: addition of a limited 
number of gene copies may lead to a suppression of gene expression. Plant Cell, 
1990. 2(4): p. 291-9. 
63. Fire, A., et al., Potent and specific genetic interference by double-stranded RNA 
in Caenorhabditis elegans. Nature, 1998. 391(6669): p. 806-11. 
64. Vannini, A. and P. Cramer, Conservation between the RNA polymerase I, II, and 
III transcription initiation machineries. Mol Cell, 2012. 45(4): p. 439-46. 
65. Zamore, S.L.A.x.P.D., Diversifying microRNA sequence and function. Nature  
Reviews Molecular Cell Biology, 2013. 14: p. 475-488. 
66. Macrae, I.J., et al., Structural basis for double-stranded RNA processing by Dicer. 
Science, 2006. 311(5758): p. 195-8. 
67. Park, J.E., et al., Dicer recognizes the 5' end of RNA for efficient and accurate 
processing. Nature, 2011. 475(7355): p. 201-5. 
68. Zeng, Y., R. Yi, and B.R. Cullen, Recognition and cleavage of primary microRNA 
precursors by the nuclear processing enzyme Drosha. Embo j, 2005. 24(1): p. 
138-48. 
69. Pan, Q., et al., A dynamic perspective of RNAi library development. Trends 
Biotechnol, 2012. 30(4): p. 206-15. 
70. Birmingham, A., et al., 3' UTR seed matches, but not overall identity, are 
associated with RNAi off-targets. Nat Methods, 2006. 3(3): p. 199-204. 
148 
 
71. Ossowski Stephan, F.J., Schwab Rebecca, Riester Markus and Weigel Detlef, 
personal communication. WMD3 and AmiRNA. 2005; Available from: 
http://wmd3.weigelworld.org/cgi-bin/webapp.cgi?page=About. 
72. Grimm, D., The dose can make the poison: lessons learned from adverse in vivo 
toxicities caused by RNAi overexpression. Silence, 2011. 2: p. 8. 
73. Maczuga, P., et al., Optimization and comparison of knockdown efficacy between 
polymerase II expressed shRNA and artificial miRNA targeting luciferase and 
Apolipoprotein B100. BMC Biotechnol, 2012. 12: p. 42. 
74. Lorenz, R., et al., ViennaRNA Package 2.0. Algorithms Mol Biol, 2011. 6: p. 26. 
75. Auyeung, V.C., et al., Beyond secondary structure: primary-sequence 
determinants license pri-miRNA hairpins for processing. Cell, 2013. 152(4): p. 
844-58. 
76. Han, J., et al., The Drosha-DGCR8 complex in primary microRNA processing. 
Genes Dev, 2004. 18(24): p. 3016-27. 
77. Zeng, Y. and B.R. Cullen, Structural requirements for pre-microRNA binding and 
nuclear export by Exportin 5. Nucleic Acids Res, 2004. 32(16): p. 4776-85. 
78. Chen, C.Z., et al., MicroRNAs modulate hematopoietic lineage differentiation. 
Science, 2004. 303(5654): p. 83-6. 
79. Gu, S., et al., The loop position of shRNAs and pre-miRNAs is critical for the 
accuracy of dicer processing in vivo. Cell, 2012. 151(4): p. 900-11. 
80. Lewis, B.P., et al., Prediction of mammalian microRNA targets. Cell, 2003. 
115(7): p. 787-98. 
81. Siolas, D., et al., Synthetic shRNAs as potent RNAi triggers. Nat Biotechnol, 2005. 
23(2): p. 227-31. 
82. Boudreau, R.L., A.M. Monteys, and B.L. Davidson, Minimizing variables among 
hairpin-based RNAi vectors reveals the potency of shRNAs. Rna, 2008. 14(9): p. 
1834-44. 
83. Livak, K.J. and T.D. Schmittgen, Analysis of relative gene expression data using 
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (San 
Diego, Calif.), 2001. 25(4): p. 402-408. 
84. Mizielinska, S. and A.M. Isaacs, C9orf72 amyotrophic lateral sclerosis and 
frontotemporal dementia: gain or loss of function? Curr Opin Neurol, 2014. 
27(5): p. 515-23. 
85. Therrien, M., et al., Deletion of C9ORF72 results in motor neuron degeneration 
and stress sensitivity in C. elegans. PLoS One, 2013. 8(12): p. e83450. 
86. Ciura, S., et al., Loss of function of C9orf72 causes motor deficits in a zebrafish 
model of Amyotrophic Lateral Sclerosis. Ann Neurol, 2013. 
87. Almeida, S., et al., Modeling key pathological features of frontotemporal 
dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. Acta 
Neuropathol, 2013. 126(3): p. 385-99. 
88. Donnelly, C.J., et al., RNA toxicity from the ALS/FTD C9ORF72 expansion is 
mitigated by antisense intervention. Neuron, 2013. 80(2): p. 415-28. 
89. Lagier-Tourenne, C., et al., Targeted degradation of sense and antisense C9orf72 
RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad 
Sci U S A, 2013. 110(47): p. E4530-9. 
149 
 
90. Sareen, D., et al., Targeting RNA foci in iPSC-derived motor neurons from ALS 
patients with a C9ORF72 repeat expansion. Sci Transl Med, 2013. 5(208): p. 
208ra149. 
91. Janssens, J. and C. Van Broeckhoven, Pathological mechanisms underlying TDP-
43 driven neurodegeneration in FTLD-ALS spectrum disorders. Hum Mol Genet, 
2013. 22(R1): p. R77-87. 
92. Rohrer, J.D., et al., C9orf72 expansions in frontotemporal dementia and 
amyotrophic lateral sclerosis. Lancet Neurol, 2015. 
93. Geevasinga, N., et al., Cortical Function in Asymptomatic Carriers and Patients 
With C9orf72 Amyotrophic Lateral Sclerosis. JAMA Neurol, 2015: p. 1-7. 
94. Alfieri, J.A., N.S. Pino, and L.M. Igaz, Reversible behavioral phenotypes in a 
conditional mouse model of TDP-43 proteinopathies. J Neurosci, 2014. 34(46): p. 
15244-59. 
95. Filiano, A.J., et al., Dissociation of frontotemporal dementia-related deficits and 
neuroinflammation in progranulin haploinsufficient mice. J Neurosci, 2013. 
33(12): p. 5352-61. 
96. Prudencio, M., et al., Distinct brain transcriptome profiles in C9orf72-associated 
and sporadic ALS. Nat Neurosci, 2015. 18(8): p. 1175-82. 
97. Mizielinska, S., et al., C9orf72 frontotemporal lobar degeneration is 
characterised by frequent neuronal sense and antisense RNA foci. Acta 
Neuropathol, 2013. 126(6): p. 845-57. 
98. Esanov, R., et al., A C9ORF72 BAC mouse model recapitulates key epigenetic 
perturbations of ALS/FTD. Mol Neurodegener, 2017. 12(1): p. 46. 
99. O'Rourke, J.G., et al., C9orf72 BAC Transgenic Mice Display Typical Pathologic 
Features of ALS/FTD. Neuron, 2015. 88(5): p. 892-901. 
100. Pfister, E.L., et al., Safe and Efficient Silencing with a Pol II, but Not a Pol lII, 
Promoter Expressing an Artificial miRNA Targeting Human Huntingtin. Mol 
Ther Nucleic Acids, 2017. 7: p. 324-334. 
101. Batra, R. and C.W. Lee, Mouse Models of C9orf72 Hexanucleotide Repeat 
Expansion in Amyotrophic Lateral Sclerosis/ Frontotemporal Dementia. Front 
Cell Neurosci, 2017. 11: p. 196. 
102. Peters, O.M., et al., Human C9ORF72 Hexanucleotide Expansion Reproduces 
RNA Foci and Dipeptide Repeat Proteins but Not Neurodegeneration in BAC 
Transgenic Mice. Neuron, 2015. 88(5): p. 902-909. 
103. Bak, M., et al., MicroRNA expression in the adult mouse central nervous system. 
Rna, 2008. 14(3): p. 432-44. 
104. Adlakha, Y.K. and N. Saini, Brain microRNAs and insights into biological 
functions and therapeutic potential of brain enriched miRNA-128. Mol Cancer, 
2014. 13: p. 33. 
105. Bartel, D.P., MicroRNAs: genomics, biogenesis, mechanism, and function. (0092-
8674 (Print)). 
106. Ambros, V., The evolution of our thinking about microRNAs. Nat Med, 2008. 
14(10): p. 1036-40. 
107. Hoffer, P., et al., Posttranscriptional gene silencing in nuclei. Proceedings of the 




108. Huang, V. and L.C. Li, miRNA goes nuclear. RNA biology, 2012. 9(3): p. 269-
273. 
109. Nishi, K., et al., Human TNRC6A is an Argonaute-navigator protein for 
microRNA-mediated gene silencing in the nucleus. RNA (New York, N.Y.), 2013. 
19(1): p. 17-35. 
110. Jiang, J., et al., Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in 
C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-
Containing RNAs. Neuron, 2016. 90(3): p. 535-50. 
111. Borel, F., et al., Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult 
SOD1(G93A) Mice and Nonhuman Primates. Hum Gene Ther, 2016. 27(1): p. 19-
31. 
112. Borel, F., et al., Safe and effective superoxide dismutase 1 silencing using 
artificial microRNA in macaques. Sci Transl Med, 2018. 10(465). 
113. Pfister, E.L., et al., Artificial miRNAs Reduce Human Mutant Huntingtin 
Throughout the Striatum in a Transgenic Sheep Model of Huntington's Disease. 
Hum Gene Ther, 2018. 29(6): p. 663-673. 
114. Niblock, M., et al., Retention of hexanucleotide repeat-containing intron in 
C9orf72 mRNA: implications for the pathogenesis of ALS/FTD. Acta Neuropathol 
Commun, 2016. 4: p. 18. 
115. Sznajder, L.J., et al., Intron retention induced by microsatellite expansions as a 
disease biomarker. Proc Natl Acad Sci U S A, 2018. 115(16): p. 4234-4239. 
116. Tabet, R., et al., CUG initiation and frameshifting enable production of dipeptide 
repeat proteins from ALS/FTD C9ORF72 transcripts. Nat Commun, 2018. 9(1): 
p. 152. 
117. Zhang, Y.J., et al., Poly(GR) impairs protein translation and stress granule 
dynamics in C9orf72-associated frontotemporal dementia and amyotrophic 
lateral sclerosis. Nat Med, 2018. 24(8): p. 1136-1142. 
118. Martier, R., et al., Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD 
by RNAi-Based Gene Therapy. Molecular Therapy - Nucleic Acids, 2019. 16: p. 
26-37. 
119. Donnelly, C.J., et al., RNA toxicity from the ALS/FTD C9ORF72 expansion is 
mitigated by antisense intervention. Neuron, 2013. 80(2): p. 415-28. 
120. Jiang, J., et al., Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in 
C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-
Containing RNAs. Neuron, 2016. 90(3): p. 535-550. 
121. Peters, O.M., et al., Human C9ORF72 Hexanucleotide Expansion Reproduces 
RNA Foci and Dipeptide Repeat Proteins but Not Neurodegeneration in BAC 
Transgenic Mice. Neuron, 2015. 88(5): p. 902-909. 
122. Liu, Y.J., et al., C9orf72 BAC Mouse Model with Motor Deficits and 
Neurodegenerative Features of ALS/FTD. Neuron, 2016. 90(3): p. 521-534. 
123. Evers, M.M., L.J.A. Toonen, and W.M.C. van Roon-Mom, Antisense 
oligonucleotides in therapy for neurodegenerative disorders. Advanced Drug 
Delivery Reviews, 2015. 87: p. 90-103. 
124. Flotte, T.R., et al., Phase 2 clinical trial of a recombinant adeno-associated viral 
vector expressing alpha1-antitrypsin: interim results. Hum Gene Ther, 2011. 
22(10): p. 1239-47. 
151 
 
125. Loring, H.S. and T.R. Flotte, Current status of gene therapy for alpha-1 
antitrypsin deficiency. Expert Opin Biol Ther, 2015. 15(3): p. 329-36. 
126. Mendell, J.R., et al., Single-Dose Gene-Replacement Therapy for Spinal Muscular 
Atrophy. New England Journal of Medicine, 2017. 377(18): p. 1713-1722. 
127. DeJesus-Hernandez, M., et al., Expanded GGGGCC hexanucleotide repeat in 
noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. 
Neuron, 2011. 72(2): p. 245-56. 
128. Renton, A.E., et al., A hexanucleotide repeat expansion in C9ORF72 is the cause 
of chromosome 9p21-linked ALS-FTD. Neuron, 2011. 72(2): p. 257-68. 
129. Zu, T., et al., RAN proteins and RNA foci from antisense transcripts in C9ORF72 
ALS and frontotemporal dementia. Proc Natl Acad Sci U S A, 2013. 110(51): p. 
E4968-77. 
130. Freibaum, B.D., et al., GGGGCC repeat expansion in C9orf72 compromises 
nucleocytoplasmic transport. Nature, 2015. 525(7567): p. 129-33. 
131. Zhang, K., et al., The C9orf72 repeat expansion disrupts nucleocytoplasmic 
transport. Nature, 2015. 525(7567): p. 56-61. 
132. Belzil, V.V., R.B. Katzman, and L. Petrucelli, ALS and FTD: an epigenetic 
perspective. Acta Neuropathologica, 2016. 132(4): p. 487-502. 
133. Evans-Galea, M.V., et al., Epigenetic modifications in trinucleotide repeat 
diseases. Trends in Molecular Medicine, 2013. 19(11): p. 655-663. 
134. Yandim, C., T. Natisvili, and R. Festenstein, Gene regulation and epigenetics in 
Friedreich's ataxia. Journal of Neurochemistry, 2013. 126: p. 21-42. 
135. Belzil, V.V., et al., Reduced C9orf72 gene expression in c9FTD/ALS is caused by 
histone trimethylation, an epigenetic event detectable in blood. Acta Neuropathol, 
2013. 126(6): p. 895-905. 
136. Belzil, V.V., et al., Characterization of DNA hypermethylation in the cerebellum 
of c9FTD/ALS patients. Brain Res, 2014. 1584: p. 15-21. 
137. Xi, Z., et al., Hypermethylation of the CpG-island near the C9orf72 G(4)C(2)-
repeat expansion in FTLD patients. Hum Mol Genet, 2014. 23(21): p. 5630-7. 
138. Xi, Z., et al., Hypermethylation of the CpG island near the G4C2 repeat in ALS 
with a C9orf72 expansion. Am J Hum Genet, 2013. 92(6): p. 981-9. 
139. Liu, E.Y., et al., C9orf72 hypermethylation protects against repeat expansion-
associated pathology in ALS/FTD. Acta Neuropathol, 2014. 128(4): p. 525-41. 
140. McMillan, C.T., et al., C9orf72 promoter hypermethylation is neuroprotective: 
Neuroimaging and neuropathologic evidence. Neurology, 2015. 84(16): p. 1622-
30. 
141. Esanov, R., et al., C9orf72 promoter hypermethylation is reduced while 
hydroxymethylation is acquired during reprogramming of ALS patient cells. Exp 
Neurol, 2016. 277: p. 171-7. 
142. Reddy, K., et al., Processing of double-R-loops in (CAG).(CTG) and C9orf72 
(GGGGCC).(GGCCCC) repeats causes instability. Nucleic Acids Res, 2014. 
42(16): p. 10473-87. 
143. Ginno, P.A., et al., R-loop formation is a distinctive characteristic of 
unmethylated human CpG island promoters. Mol Cell, 2012. 45(6): p. 814-25. 
152 
 
144. Groh, M., et al., R-loops associated with triplet repeat expansions promote gene 
silencing in Friedreich ataxia and fragile X syndrome. PLoS Genet, 2014. 10(5): 
p. e1004318. 
145. O'rourke, J.G., et al., C9orf72 BAC Transgenic Mice Display Typical Pathologic 
Features of ALS/FTD. Neuron, 2015. 88(5): p. 892-901. 
146. Cohen-Hadad, Y., et al., Marked Differences in C9orf72 Methylation Status and 
Isoform Expression between C9/ALS Human Embryonic and Induced Pluripotent 
Stem Cells. Stem Cell Reports, 2016. 7(5): p. 927-940. 
147. Zeier, Z., et al., Bromodomain inhibitors regulate the C9ORF72 locus in ALS. 
Exp Neurol, 2015. 
148. Xi, Z., et al., The C9orf72 repeat expansion itself is methylated in ALS and FTLD 
patients. Acta Neuropathol, 2015. 129(5): p. 715-27. 
149. Esanov, R., et al., The FMR1 promoter is selectively hydroxymethylated in 
primary neurons of fragile X syndrome patients. Human Molecular Genetics, 
2016. 
150. Globisch, D., et al., Tissue distribution of 5-hydroxymethylcytosine and search for 
active demethylation intermediates. PLoS One, 2010. 5(12): p. e15367. 
151. Kinney, S.M., et al., Tissue-specific distribution and dynamic changes of 5-
hydroxymethylcytosine in mammalian genomes. J Biol Chem, 2011. 286(28): p. 
24685-93. 
152. Colak, D., et al., Promoter-bound trinucleotide repeat mRNA drives epigenetic 
silencing in fragile X syndrome. Science, 2014. 343(6174): p. 1002-5. 
153. Bauer, P.O., Methylation of C9orf72 expansion reduces RNA foci formation and 
dipeptide-repeat proteins expression in cells. Neuroscience Letters, 2016. 612: p. 
204-209. 
154. Kaas, G.A., et al., TET1 controls CNS 5-methylcytosine hydroxylation, active 
DNA demethylation, gene transcription, and memory formation. Neuron, 2013. 
79(6): p. 1086-93. 
155. Kriaucionis, S. and N. Heintz, The nuclear DNA base 5-hydroxymethylcytosine is 
present in Purkinje neurons and the brain. Science, 2009. 324(5929): p. 929-30. 
156. Zamiri, B., et al., Quadruplex formation by both G-rich and C-rich DNA strands 
of the C9orf72 (GGGGCC)8‚Ä¢(GGCCCC)8 repeat: effect of CpG methylation. 
Nucleic Acids Research, 2015. 43(20): p. 10055-10064. 
157. Wang, J., A.R. Haeusler, and E.A. Simko, Emerging role of RNA center dot DNA 
hybrids in C9orf72-linked neurodegeneration. Cell Cycle, 2015. 14(4): p. 526-
532. 
158. Su, Z., et al., Discovery of a biomarker and lead small molecules to target 
r(GGGGCC)-associated defects in c9FTD/ALS. Neuron, 2014. 83(5): p. 1043-50. 
159. Loomis, E.W., et al., Transcription-Associated R-Loop Formation across the 
Human FMR1 CGG-Repeat Region. Plos Genetics, 2014. 10(4). 
160. Bejaoui, K., et al., SPTLC1 is mutated in hereditary sensory neuropathy, type 1. 
Nat Genet, 2001. 27(3): p. 261-2. 
161. Penno, A., et al., Hereditary sensory neuropathy type 1 is caused by the 




162. Eichler, F.S., et al., Overexpression of the wild-type SPT1 subunit lowers 
desoxysphingolipid levels and rescues the phenotype of HSAN1. J Neurosci, 2009. 
29(46): p. 14646-51. 
163. Garofalo, K., et al., Oral L-serine supplementation reduces production of 
neurotoxic deoxysphingolipids in mice and humans with hereditary sensory 
autonomic neuropathy type 1. J Clin Invest, 2011. 121(12): p. 4735-45. 
164. Fridman, V., et al., Randomized trial of l-serine in patients with hereditary 
sensory and autonomic neuropathy type 1. Neurology, 2019. 92(4): p. e359-e370. 
165. McCampbell, A., et al., Mutant SPTLC1 dominantly inhibits serine 
palmitoyltransferase activity in vivo and confers an age-dependent neuropathy. 
Hum Mol Genet, 2005. 14(22): p. 3507-21. 
166. Toro Cabrera, G. and C. Mueller, Design of shRNA and miRNA for Delivery to the 
CNS. Methods Mol Biol, 2016. 1382: p. 67-80. 
 
